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Introduction to the thesis 
 
 In the early 1960s, the US National Cancer Institute started a program aimed at the 
discovery of new anticancer drugs by releasing protocols for widespread screening of 
substances and extracts from various origins for antineoplastic activity. Of the more 
than 100,000 compounds from 35,000 plant species tested between 1960 and 1981, 
paclitaxel, a complex diterpene isolated from the Pacific Yew tree (Taxus brevifolia), 
proved one of the most interesting and active agents. Extensive studies on the 
synthesis of paclitaxel analogues and the development of structure-activity 
relationships have been carried out over the last few decades, and led in 1986 to the 
development of docetaxel, a semisynthetic taxane derivative prepared from a 
noncytotoxic precursor isolated from the European Yew tree (Taxus baccata). 
Following an extensive clinical evaluation program that started in 1990, docetaxel has 
currently been recognized as one of the most widely active agents available, and it has 
been approved in most countries for the treatment of advanced breast cancer and non-
small cell lung cancer. 
 
 Although pharmacokinetic investigations were a principal component of the early 
clinical development of docetaxel during phase I and phase II trials, it was recognized 
in the late 1990s that various aspects of docetaxel pharmacology required further 
investigation in order to improve treatment outcome. Specifically, docetaxel treatment 
in patients with cancer, despite the use of standard premedication, is often associated 
with a significant incidence of very severe toxic side effects, including neutropenic 
fever, that is a direct consequence of unusually high systemic exposure to docetaxel. 
 
 Against this background, it was the aim of the work described in this thesis to 
systematically unravel factors influencing the pharmacokinetic variability of docetaxel 
in patients with cancer (summarized in Chapter 2), and to lay the foundation for the 
development of improved future treatment strategies with this agent. Many of the 
described investigations have been made possible by the development of selective 
analytical methodologies to simultaneously monitor total concentrations of the parent 
drug and its formulation vehicle polysorbate 80 in plasma (Chapter 7), as well as to 
determine the extent of vascular binding of docetaxel (Chapter 8). 
 
 Although the prescribed dose of docetaxel is calculated using body-surface area 
(BSA) as the only independent variable, it has been shown that this approach still 
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results in a large interpatient variability in drug exposure (Chapters 3 and 4). This 
suggests that alternate dosing strategies that consider factors other than standard body-
size measures are needed. Candidate factors include commonly available 
characteristics like measures of organ dysfunction, sex, and patient age (Chapter 10), 
but also the comcomitant use other drugs that might interfere with the elimination 
pathways of docetaxel, the total amount of drug administered (Chapter 4), as well as 
the frequency of administration and the rate of drug infusion (Chapter 9).  
 
 One of the principal candidates for consideration in future dosing strategies for 
docetaxel is phenotypic expression of the cytochrome P-450 isozymes of the 3A 
subfamily (CYP3A). These enzymes are responsible for the metabolic breakdown of 
docetaxel into several pharmacologically inactive compounds, and the activity of 
CYP3A is now known to vary up to 14-fold in cancer patients (Chapter 5). Clearly this 
degree of interindividual variation might have important ramification for treatment of 
patients with docetaxel, and has instigated the use of various noninvasive in vivo 
probes, such as the erythromycin breath test, for evaluating CYP3A activity, as well as 
to identify demographic, physiologic, and inheritable factors that influence the activity 
of this group of enzymes (Chapter 5). 
 
 A further complication with the clinical use of docetaxel is the presence of the 
polyoxyethylated surfactant polysorbate 80 in the currently used pharmaceutical 
formulation (Taxotere). Over the last few years, evidence has accumulated that the use 
of polysorbate 80 might be associated with some of the side effects observed with 
docetaxel treatment. Furthermore, polysorbate 80 has the potential to modulate the 
pharmacokinetic behavior of docetaxel by altering the availability of the fraction 
unbound drug in the circulation (Chapter 6), and consequently influence a patient’s 
susceptibility to severe docetaxel-mediated hematologic toxicity (Chapter 11). 
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Abstract 
 
 Docetaxel belongs to the class of taxane antineoplastic agents, and acts through 
inhibition of tubulin polymerization. The drug has shown a broad spectrum of 
antitumor activity in preclinical models as well as clinically, with responses observed 
in various disease types including advanced breast cancer and non-small cell lung 
cancer. The pharmacokinetics and metabolism of docetaxel are extremely complex, 
and have been the subject of intensive investigation in recent years. Docetaxel is 
subject to extensive metabolic conversion by the cytochrome P450 (CYP) 3A 
isozymes, which forms several pharmacologically inactive oxidation products. 
Elimination routes of docetaxel are also depending on the presence of drug-
transporting proteins, notably P-glycoprotein, present on the bile canalicular 
membrane. The various processes mediating drug elimination, either through 
metabolic breakdown or excretion, impact substantially on interindividual variability 
in drug handling. Strategies to individualize docetaxel administration schedules based 
on phenotypic or genotype-dependent differences in CYP3A expression are underway, 
and may ultimately lead to more selective chemotherapeutic use of this agent. 
 
Introduction 
 
 The antineoplastic agent docetaxel acts by disrupting the microtubular network, 
and has activity against numerous cancers including breast, lung, head and neck, 
ovarian, and prostate. Docetaxel is currently approved to treat patients with locally-
advanced or metastatic breast cancer after failure of prior chemotherapy, and patients 
with unresectable locally-advanced or metastatic non-small cell lung cancer (NSCLC) 
in combination with cisplatin, who have not received prior chemotherapy. It is also 
approved for patients with unresectable locally-advanced or metastatic NSCLC after 
failure of prior platinum-based chemotherapy and for use in combination with 
prednisone as a treatment for androgen-independent (hormone-refractory) metastatic 
prostate cancer. An application for the use of docetaxel in treating women with early-
stage operable breast cancer with involved axillary lymph nodes is under consideration 
in the U.S. and Europe. The docetaxel dose used for treating cancer patients ranges 
from 60 to 100 mg/m2 as a 1-hour intravenous infusion given once every 3 weeks (3-
weekly). In this regimen, neutropenia occurs in virtually all patients, and grade 4 
neutropenia occurs in 75% of patients given 100 mg/m2 (N = 2045; febrile neutropenia 
incidence, 12%); grade 3/4 neutropenia occurs in 65% of patients given 75 mg/m2 
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(n=176; febrile neutropenia incidence, 6.3%), and grade 4 neutropenia occurs in 75% 
of patients given 60 mg/m2 (n=174; febrile neutropenia incidence, 0%) (see: 
http://www.taxotere.com/ - last accessed July 13, 2004). Other side effects with the 3-
weekly regimen include alopecia, asthenia, dermatologic reactions, fluid retention, 
hypersensitivity reactions, stomatitis and diarrhea. There has been a recent trend 
toward administration of docetaxel at lower doses (25 to 40 mg/m2) on weekly 
schedules. Weekly schedules are associated with comparable response rates as 3-
weekly schedules, but with reduced myelosuppression [3-5]. However, severe fatigue 
and asthenia have become dose-limiting with weekly schedules and many physicians 
are reverting back to administering docetaxel once every 21 days. 
 Since the last comprehensive review on the clinical pharmacokinetics of docetaxel 
by Clarke and Rivory [6], numerous studies have further characterized the clinical 
pharmacokinetics of docetaxel. Recent developments on predictors of docetaxel 
disposition and pharmacokinetic-pharmacodynamic relationships are herein reviewed. 
 
Analytical Methods 
 
 Several reversed-phase high-performance liquid chromatographic (HPLC) 
methods using solid-phase extraction (SPE) for sample clean-up were developed 
during early Phase I investigations with docetaxel, permitting the pharmacokinetic 
behavior of the agent in both brief and prolonged schedules of administration. In 
general these methods, which were mostly based on the method described by Vergniol 
et al (7), are not very sensitive (i.e., lower limit of quantitation of 5 to 10 ng/mL) due 
to the presence of endogenous interferences as well as the limited UV absorption 
characteristics of the taxane moiety and the low wavelengths required to quantitate the 
drug. More sensitive and specific reversed-phase HPLC methods capable of detecting 
docetaxel concentrations in human plasma as low as 0.4 ng/mL have been developed 
recently by the utilization of liquid chromatography coupled with tandem mass 
spectrometry (MS/MS) (Table 1). As such, these methods may have potential for 
clinical monitoring in studies utilizing very low doses that result in plasma 
concentrations that approach or are below the sensitivity limits for the HPLC-UV 
assays, and can be used to allow determination of the drug in samples obtained more 
than 2 days after drug administration. It is of importance to indicate here that the lower 
limit of quantitation reported in the various publications can be somewhat misleading 
when it is reported simply in terms of sample concentration rather then the innate 
sensitivity. This is because it does not give an indication of the sample size required or 
Chapter 2_____________________________________________________________ 
 14
the proportion of the analyte in the sample actually injected for analysis. For example, 
the method reported by Hou et al. has a lower limit of quantitation of only ~20 ng/mL 
but it requires only 40 microliters of plasma [8], which might be advantageous when 
serial analyses are being planned on the same material collected from laboratory 
animals or patients. 
 In addition to analytical methods available for the determination of total drug 
concentrations in human plasma, assays have been developed for measuring the 
unbound fraction of docetaxel in patient plasma samples. These procedures are based 
on either ultrafiltration [9] or equilibrium dialysis [10,11]. The latter procedure uses 
only 200-microliters of sample in a 96-well dialysis plate, which makes the assay more 
cost-efficient and less time-consuming than the other currently available assays, and 
likely introduces less bias and random error. 
 
Table 1. Analytical methods for quantitation of docetaxel in human plasma 
Sample 
Pretreatment 
I.S. 
Sample 
Volume 
LLOQ 
(ng/mL) 
ULOQ 
(ng/mL) 
Detection Reference 
LLE paclitaxel 50 µL 5 1000 MS/MS [112]  
SPE paclitaxel 1 mL 0.21 800 MS/MS [113]  
LLE paclitaxel 1 mL 25 1000 227 nm [114]  
LLE paclitaxel 1 mL 10 20,000 230 nm [115]  
LLE paclitaxel 1 mL 0.40 80 MS/MS [116]  
SPE Paclitaxel 1 mL 0.25 800 MS [117]  
SPE paclitaxel 1 mL 5 1000 227 nm [118]  
SPE 
2’-methyl 
paclitaxel 
1 mL 10 1000 227 nm [119]  
SPE paclitaxel 1 mL 5 1000 227 nm [120]  
SPE paclitaxel 1 mL 10 2500 227 nm [7]  
SPE + 
column 
switching 
paclitaxel 900 µL 2.5 2000 227 nm [121]  
PP paclitaxel 40 µL 20 2000 MS/MS [8]  
 
Abbreviations: LLE, liquid-liquid extraction; SPE, solid phase extraction; PP, protein 
precipitation; MS, mass spectrometry; MS/MS, tandem mass spectrometry; LLOQ, lower 
limit of quantitation; ULOQ, upper limit of quantitation. 
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Protein Binding 
 
 In vitro studies have demonstrated that docetaxel is extensively bound to albumin 
and alpha1-acid glycoprotein (orosomucoid; ORM; AAG), and that the latter is the 
main determinant of variability in docetaxel serum binding [9]. In cancer patients, 
AAG concentrations vary approximately 7-fold between patients [12], which may 
contribute to differences in protein binding and systemic drug clearance. From a 
population pharmacokinetic model involving 547 patients, AAG was identified as a 
significant predictor of docetaxel total clearance, where an AAG concentration of 260 
mg/dL (95% quantile) was associated with a 19% decrease in docetaxel clearance [13]. 
However, low concentrations of AAG have been shown to be an independent predictor 
of the severity of neutropenia [14] and improved survival in patients with non-small 
cell lung cancer [15]. Regarding the latter observation, high AAG concentrations are 
associated with inflammation in cancer patients and may be a marker for advanced 
disease and worse prognosis [16,17]. 
 Unbound docetaxel pharmacokinetic parameters are summarized in Table 2. In 
several studies, mean unbound clearance values were 315 and 565 mL/min and varied 
up to 8.5-fold [11,18]. The pre-treatment unbound fraction expressed as a percentage 
was 4.7% (range, 1.2 – 8.65); however, docetaxel unbound fraction calculated as the 
ratio of AUCunbound/AUCtotal (expressed as a percentage) was 5.7%, representing a 20% 
increase in fraction unbound compared to that measured in pre-treatment samples [18]. 
Consistent with this observation, complete concordance was not observed between 
pre-treatment fu and AUCunbound/AUCtotal by linear regression (R2 = 0.4593) [18], 
indicating that accurate assessment of unbound docetaxel exposure cannot be 
determined from pre-treatment unbound fraction only.  
 The discordance between docetaxel pre-treatment unbound fraction and 
AUCunbound/AUCtotal suggests a time-dependent change in unbound fraction after the 
start of the infusion, which may be due to the formulation vehicle, polysorbate 80. In 
vitro, increasing concentrations of polysorbate 80 from 0 to 0.5 µL/mL resulted in a 
13% increase in docetaxel unbound fraction [11]. When assessed in cancer patients 
treated with docetaxel, the unbound fraction of docetaxel increased during the 
docetaxel infusion and declined post-infusion to values close to baseline unbound 
fraction at 3 to 7 hours post-infusion [18]. The mechanistic basis for the influence of 
polysorbate 80 on docetaxel fraction unbound during the infusion is unknown, but it is 
possible that polysorbate 80 or its metabolites (e.g., oleic acid) interfere with the 
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binding of docetaxel to albumin and AAG and lead to temporary increase in the 
unbound fraction. 
Similar to docetaxel unbound fraction, polysorbate 80 concentrations increased during 
the docetaxel infusion, and declined post-infusion with concentrations below the assay 
limit of detection at 3 to 7 hours post-infusion (Figure 1). The parallel time profile for 
docetaxel unbound fraction and polysorbate 80 concentrations suggests a causative 
relationship similar to that observed from in vitro studies [11]. Polysorbate 80 
pharmacokinetic parameters are summarized in Table 3. Measures of exposure to 
polysorbate 80 increased in near proportion with an increase in dose over the range of 
650 to 1950 mg/m2. Polysorbate 80 clearance was independent of administered dose 
and infusion duration (1-h versus 30-min), although most subjects received a 1-h 
infusion providing limited data to assess the effect of infusion duration on polysorbate 
80 clearance. The disappearance of polysorbate 80 from plasma is characterized by a 
short terminal half-life of approximately 30 min. The volume of distribution at steady 
state for polysorbate 80 is approximately 5 to 6 L, indicating limited distribution of 
this excipient outside the blood volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Concentration-time profiles of polysorbate 80 after dose adjustments to 1000 mg 
absolute dose. Data are from reference [1]. 
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 AAG concentration has been shown to be significantly correlated with pre-
treatment docetaxel unbound (free) fraction both in vitro [9] and in vivo [11,18], with 
higher free fraction values in the presence of lower AAG concentrations. Based on 
these findings, and the observation of an association between low concentrations of 
AAG and the incidence of the severity of neutropenia [14], it has been postulated that 
low AAG concentrations will result in higher exposure to unbound docetaxel. 
However, in a recent analysis of 40 cancer patients receiving docetaxel 75 mg/m2, 
where AAG concentrations ranged from 60 to 257 mg/dL (mean, 141 mg/dL) and 
unbound docetaxel AUC ranged from 96.4 to 584 µg/mL×h (mean, 321 µg/mL×h), no 
relationship was observed between AAG and unbound docetaxel AUC by linear 
regression analysis (R2 = .028, P = .2994) (data from reference [18]). This is not 
unexpected because unbound drug clearance is used to examine factors other than 
protein-binding that influence clearance (e.g., drug metabolizing enzyme activity) by 
eliminating the confounding affects of binding to proteins or other macromolecules in 
the systemic circulation. In addition, because total docetaxel clearance decreases with 
increasing AAG concentrations, but free fraction also decreases with increasing AAG 
concentrations, clearance of unbound drug and AUC of free drug, may be unaffected 
by varying AAG concentrations, as was shown [18]. A multiple linear regression 
analysis was performed to determine the influence of other factors including age, liver 
function, and polysorbate 80 exposure on unbound docetaxel clearance. Only 
polysorbate 80 AUC and liver impairment, defined as concurrent elevations in liver 
transaminases ≥ 1.5 times the upper limit of institutional normal (× ULN) and alkaline 
phosphatase ≥ 2.5 × ULN or elevated total bilirubin ≥ 1.5 × ULN, were retained in the 
final model and explained 32% of the variation in unbound clearance among patients. 
In this analysis, higher polysorbate 80 AUC values were associated with lower 
unbound clearance values. One possible explanation for this observation is that 
polysorbate 80 or its metabolites (e.g., oleic acid) inhibit cytochrome P-450 3A [19,20] 
and/or P-glycoprotein [21] mediated elimination of docetaxel. 
 
Elimination pathways 
  
Pharmacogenetics of metabolism and transport 
 Based on catalytic potential, CYP3A4 and CYP3A5 are the most important among 
the four members of the CYP3A subfamily (CYP3A4, CYP3A5, CYP3A7, CYP3A43) 
involved in docetaxel metabolism and elimination [22]. The major docetaxel 
metabolites and less than 10% of the parent drug are excreted into the feces, whereas 
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total urinary excretion is less than 10% [6]. The metabolites demonstrate substantially 
reduced cytotoxic activity as compared to the parent drug, making biotransformation 
by CYP3A a major route of inactivation [23]. 
 CYP3A4 is considered the major isoform expressed in adult livers and intestine in 
all racial/ethnic populations studied [24]. Over 30 single nucleotide polymorphisms 
(SNPs) in CYP3A4 have been published, most of which are very rare and unlikely to 
impact on CYP3A activity in vivo [25]. The best-characterized polymorphism, a 
promoter variant with an A to G transition at nucleotide -392 (CYP3A4*1B), was 
initially shown in vitro to have increased transcriptional activity [26]. This variant was 
not detected in 25 cancer patients of Asian descent receiving docetaxel therapy, 
precluding genotype-pharmacokinetic correlation analysis [27]. However, a recent 
report indicates no association between the CYP3A4*1B variant and CYP3A activity 
using the phenotypic probes midazolam clearance and the erythromycin breath test, 
under constitutive and induced (by pretreatment with rifampin) conditions in 57 
healthy subjects including 23 Caucasian- and 34 African-Americans [28]. In line with 
this data, no association was observed between this variant and the erythromycin 
breath test in 118 patients with advanced cancer (n=106, wild type; n=12, 
heterozygous variant), which were predominantly of Caucasian descent [12].  
 In contrast to CYP3A4, CYP3A5 is polymorphically expressed in some adults, 
which varies by race/ethnicity. To date, 13 allelic variants involving both coding and 
intronic sequences have been identified [24]. A splice variant in intron 3 of CYP3A5 
at nucleotide position 6986 (6986A>G, CYP3A5*3C) is the most common variant 
across all racial/ethnic populations, which results in the absence of functional CP3A5 
protein [24,29,30]. Only individuals with at least one wild type allele at nucleotide 
position 6986 (CYP3A5*1) express large amounts of CYP3A5 protein [30]. The allele 
frequency of the CYP3A5*3C variant is 71 - 75% in East Asians, 55-65% in South 
Asians, 29-35% in Blacks, 89 - 94% in Caucasians, and 60 - 66% in Hispanics [24]. 
Goh et al. examined the association between the CYP3A5*3C variant and docetaxel 
and midazolam clearance in cancer patients of Asian descent [27]. No relationship was 
observed in this population, where 3, 13, and 9 patients had the wildtype (*1/*1), 
heterozygous variant (*1/*3), or homozygous variant (*3/*3) genotype, respectively. 
One recent study involving a predominantly Caucasian population of 67 cancer 
patients observed 1.7 folder higher midazolam clearance in 9 patients with the *1/*3 
genotype compared to 58 patients with the *3/*3 genotype [31]. This data is not 
consistent with another recent study in a larger population of 121 patients with 
advanced cancer (n=2, *1/*1; n=19, *1/*3; and n=100, *3/*3 genotype), where no 
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association was observed between CYP3A5*3C genotype and the erythromycin breath 
test. The discordance in results from these studies assessing genotype-phenotype 
relationships could be explained when the CYP3A probe drug is considered: docetaxel 
and erythromycin are deemed CYP3A4 substrates but poor substrates for CYP3A5, 
whereas midazolam is a substrate for both CYP3A4 and CYP3A5 (32). However, 
studies in healthy subjects involving populations of similar sample size and diverse 
race/ethnicity including African Americans [28], Asians [33] and Caucasians [28,34], 
showed no association between CYP3A5*3C genotype and midazolam clearance. In 
addition, the one study showing an association between CYP3A5*3C genotype and 
midazolam clearance used a limited sampling scheme involving one plasma sample at 
4-h, whereas the other studies utilized intensive sampling schemes for midazolam 
[28,33,34]. Furthermore, CYP3A5 genotype-phenotype relationships are more likely 
to be observed in healthy volunteers compared to cancer patients because interpatient 
variation in CYP3A activity is much lower in the former (4- versus 14-fold) [12,28], 
most likely due to the absence of comorbidities and environmental influences (e.g., 
drug-drug and drug-herb interactions) that would confound genotype-phenotype 
relationships. Another explanation for the lack of CYP3A5 genotype-phenotype 
associations may be due to the administration of drug doses that produce plasma 
concentrations well below the threshold for CYP3A4 enzyme saturation. A recent 
study showed a dose-dependent association between CYP3A5*3C genotype and 
plasma concentrations of the investigational antibiotic ABT-773, where drug exposure 
was higher in CYP3A5 negative individuals (those that were homozygous variant 
[*3/*3 genotype]) only at the highest dose administered (450 mg versus 150 or 300 
mg) [35]. When CYP3A4 drug metabolizing capability becomes saturated, individuals 
that express CYP3A5 (those that are wild type or heterozygous variant with at least 
one *1 allele), may metabolize the compound more quickly because of the additional 
activity of a second major CYP3A enzyme. 
 In addition to CYP3A-mediated elimination, docetaxel is also a substrate for the 
efflux membrane-localized transporter P-glycoprotein, encoded by the ABCB1 gene 
[36]. This protein is expressed on the apical surface of the small-intestinal epithelium 
and the biliary surface of hepatocytes [37]. Preclinical observations in mice lacking 
mouse Abcb1 have indicated that docetaxel AUC following intravenous administration 
was not different in knockout and wildtype mice, indicating that metabolism rather 
than transport is the prominent elimination pathway for docetaxel [38]. However, 
ABCB1-mediated intestinal secretion has been demonstrated to contribute 
significantly to fecal elimination of taxane drugs both in mice lacking Abcb1 [39] and 
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humans [40], without changing plasma concentrations. 
 Recent re-sequencing of the ABCB1 gene has revealed a number of allelic variants 
that affect activity and/or expression of the encoded protein in vivo [37]. In total, 50 
SNPs and 3 insertion/deletion polymorphisms in ABCB1 have been reported [41]. The 
most common ABCB1 variants are a silent mutation at the 3435C>T transition in exon 
26 (ABCB1*6), a nonsynonymous ABCB1 2677G>T/A variant (ABCB1*7) resulting 
in an amino acid change in exon 21 (Ala893Ser/Thr), and a silent ABCB1 1236 C>T 
variant (ABCB1*8). The homozygous T allele of ABCB1*6 has been associated with 
reduced protein expression in different human tissues, including duodenum biopsies 
and CD56+ natural killer cells, although an association with higher protein expression 
has been observed and this relationship is somewhat controversial [37]. The frequency 
of this allele varies extensively with race/ethnicity as follows: 37 - 66% in Asians, 10 - 
27% in Blacks, and 46 - 59% in Caucasians [37]. No association was observed 
between ABCB1*6 genotype and docetaxel and midazolam clearance in 25 cancer 
patients of Asian descent [27], consistent with similar findings in healthy subjects 
receiving intravenous midazolam [28,34] and the erythromycin breath test [28]. Close 
linkage of the ABCB1*6, ABCB1*7, and ABCB1*8 polymorphisms has been found, 
which makes a variant haplotype termed ABCB1*2 [42]. Recent work indicates that 
the use of the ABCB1*2 haplotype is superior to single SNP analysis to predict 
substrate drug pharmacokinetics [43-45] and this remains to be assessed for docetaxel. 
It is noteworthy that ABCB1 variants may be associated with toxicity and response 
unrelated to the potential influence on docetaxel plasma pharmacokinetics. 
 
CYP3A phenotype-pharmacokinetic relations 
 Several studies have assessed the ability of CYP3A phenotyping probes to predict 
total docetaxel clearance. One study involved the administration of docetaxel 100 
mg/m2 to 21 patients with sarcoma and a pre-treatment CYP3A phenotypic test using 
the erythromycin breath test [46]. A strong linear correlation was observed between 
CYP3A activity, assessed as the log transformation of % 14C dose exhaled during the 
first hour calculated from a 20-min sample and the equation from Wagner [47], and 
docetaxel clearance, expressed in units of L/h/m2 (R2 = .67, P = .0001). However, one 
patient had greatly reduced CYP3A activity and docetaxel clearance. Inclusion of this 
patient increased the range of docetaxel clearance values from 3- to 6-fold in the 
studied population and most likely improved the correlation between CYP3A activity 
and clearance. In another study, urinary 6-beta- hydroxycortisol excretion was used to 
determine the association between CYP3A activity and docetaxel clearance in 29 
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cancer patients with advanced NSCLC from Japan receiving docetaxel 60 mg/m2 [48]. 
In the population studied, a strong linear correlation was observed between CYP3A 
activity and docetaxel clearance (R2 = .73) and values for these parameters varied 
approximately 4.5- and 3.5-fold, respectively. In a third study, CYP3A activity, 
determined by assessment of midazolam clearance after intravenous injection, was 
correlated with docetaxel clearance (R2 = .36, P = .0005) in 31 cancer patients 
receiving docetaxel 75 mg/m2, where CYP3A activity and drug clearance varied 
approximately 4.5- and 3.5-fold, respectively [27]. Finally, a pilot study was recently 
reported suggesting potential usefulness to using dexamethasone as a CYP3A4 
phenotyping probe for docetaxel clearance in a group of 23 cancer patients [49]. 
Regression equations for prediction of docetaxel clearance derived from these studies 
involving a small number of patients may limit the application of these phenotypic 
tests for prediction of docetaxel clearance in larger populations, where docetaxel 
clearance may vary up to 7- to 10-fold [50,51].  
 A population pharmacokinetic approach was recently utilized to identify patient 
covariates that significantly influence the clearance of docetaxel when administered 
weekly at a dose of 40 mg/m2 to 54 patients with advanced cancer [52]. 
Pharmacokinetic studies included sparse sampling (2 to 3 samples) and CYP3A 
activity was phenotyped pre-treatment using the erythromycin breath test. Significant 
relationships were found between docetaxel clearance and the erythromycin breath test 
parameter, 1/Tmax (R2 = .15, P = .0003), and liver function enzymes (alkaline 
phosphatase, R2 = .22, P = .0002; aspartate amino transferase, R2 = .21, P = .0005; 
alanine amino transferase, R2 = .19, P = .001; gamma glutamyl aminotransferase, R2 
= .12, P = .006). Docetaxel clearance was best described by the following equation: 
clearance = 21.51 + 217 (1/Tmax) - 0.13 (ALT). The ability of this equation to a priori 
predict docetaxel clearance and achieve a target AUC will require prospective 
evaluation. 
 
Clinical Pharmacokinetics 
 
Weekly administration schedules 
 Weekly administration of docetaxel has demonstrated comparable efficacy 
together with a distinct toxicity profile with a reduction in acute toxicity and only mild 
myelosuppression [3-5,53]. The pharmacokinetics of weekly docetaxel administered at 
a dose of 35 mg/m2 and on 3-weekly schedules for comparison are summarized in 
Table 4 [2]. Mean ± SD docetaxel clearance values were similar with weekly and 3-
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weekly schedules (overall means, 25 ± 7.7 versus 23.7 ± 7.9 L/h/m2; P = .5467). 
Values for half-life were also similar with both schedule of administration (overall 
means, 16.5 ± 11.2 and 17.6 ± 7.4 h; P = .6990). On average, Cmax values with 
weekly docetaxel 35 mg/m2 over 30 min were comparable to those achieved with 
docetaxel 75 mg/m2 over 1 h, but less than those achieved with 100 mg/m2 over 1h. On 
the other-hand, estimated AUC during 3 weeks of treatment is larger following 35 
mg/m2 weekly (4.44 ± 1.24 µg/mL×h) compared to 60 mg/m2 (2.85 ± 1.40 µg/mL×h) 
and 75 mg/m2 (3.05 ± 0.85 µg/mL×h) administered 3-weekly, but in the range of that 
achieved at 100 mg/m2 (5.62 ± 2.12 µg/mL×h) given 3-weekly. Given the differences 
in the incidence of severe myelosuppresion between the two schedules of 
administration and the exposure-toxicity relationships defined previously for 3-weekly 
regimens (see section Pharmacokinetic-Pharmacodynamic Relationships), pharmaco-
kinetic data showing similar exposure (AUC) over a 3-week period for both weekly 
and 3-weekly regimens suggests exposure-toxicity relationships for 3-weekly 
administration does not apply to weekly regimens. 
 
Extended sampling schemes  
 The pharmacokinetics of docetaxel have been described utilizing extended plasma 
sampling schemes to days 8 to 22 post –treatment and a sensitive analytical method 
based on tandem mass spectrometry (Table 4) [2]. With extended sampling, clearance 
is approximately 18% lower and the terminal half-life is approximately 5-fold longer 
resulting in measurable concentrations for the entire dosing interval (Figure 2). At 35 
mg/m2, the mean ± SD docetaxel concentration on day 8 was 1.1 ± 0.51 nM; at 75 
mg/m2, concentrations on days 8, 15, and 22 were 1.8 ± 0.53 nM, 0.83 ± 0.31 nM, and 
0.58 ± 0.099 nM, respectively [2]. These data demonstrate prolonged circulation of 
low nanomolar concentrations of docetaxel during each dosing interval, which may 
contribute to docetaxel mechanisms of action including suppression of microtubule 
dynamics and tumor angiogenesis [54-56]. 
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Table 4. Comparative total docetaxel pharmacokinetic parameters for weekly and 3-
weekly administration schedules using 24-h and extended sampling schemesa 
   Parameter 
Schedule 
Concurrent 
Drug 
n 
Cmax 
(µg/mL) 
AUC 
(µg/mL×h) 
CL (L/h/m2) t1/2,z (h) 
24-h Sampling       
Weekly       
35 mg/m2 None 8 1.85 ± 0.73 1.32 ± 0.42 29.1 ± 10.2 15.6 ± 12.0 
35 mg/m2 Irinotecan 12 1.99 ± 0.52 1.59 ± 0.40 22.5 ± 4.2 17.1 ± 12.7 
 ALL DATA    25.2 ± 7.7 16.5 ± 11.2 
3-Weekly       
60 mg/m2 Doxorubicin 10 1.55 ± 0.41 2.85 ± 1.40 25.0 ± 9.7 18.0 ± 9.3 
75 mg/m2 None 9 2.18 ± 0.71 3.05 ± 0.85 25.8 ± 6.3 17.5 ± 7.3 
100 mg/m2 None 7 4.15 ± 1.35 5.62 ± 2.12 19.6 ± 5.6 17.2 ± 6.2 
 ALL DATA    16.5 ± 11.2 17.6 ± 7.4 
Extended 
Sampling 
      
Weekly       
35 mg/m2 None 6 N/A 1.63 ± 0.30 22.0 ± 3.8 61.3 ± 12.5 
35 mg/m2 Irinotecan 10 N/A 1.87 ± 0.37 19.4 ± 3.7 60.4 ± 24.6 
3-Weekly       
60 mg/m2 Doxorubicin 5 N/A 3.74 ± 0.77 16.6 ± 3.6 135 ± 21.9 
75 mg/m2 None 9 N/A 3.41 ± 0.98 23.2 ± 5.7 91.7 ± 32.1 
100 mg/m2 None 4 N/A 7.87 ± 2.90 14.4 ± 6.4 120 ± 80.5 
 
a Data represent mean ± standard deviation. Data were obtained from reference [2]. Docetaxel 
administered as a 30-min infusion with weekly schedules and as a 1-h infusion with 3-weekly 
schedules. 
Abbreviations: Mean values ± standard deviation; Cmax, peak plasma concentration; AUC, 
area under the plasma concentration-time curve from time zero to infinity; CL, systemic 
clearance; t1/2,z , half-life of the terminal disposition phase; n, number of patients studied; 
N/A, not applicable. 
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Figure 2. Mean docetaxel total plasma concentrations following administration of docetaxel 
35 mg/m2 (solid line); 75 mg/m2 (dashed line); and 100 mg/m2 (dotted line). The following 
equation converts docetaxel concentrations in units nM to µg/mL: concentration (nM) = 
concentration (µg/mL) × 1237.79. Data are from reference [2]. 
 
 
Elderly 
 The first evaluation to assess the influence of elderly age on the pharmacokinetics 
of docetaxel was from a large (N = 547) population pharmacokinetic analysis of 3-
weekly docetaxel, which showed minimal effect of age on docetaxel clearance; a 71-
year old patient would be expected to have a 6.7% decrease in docetaxel clearance 
[13]. More recently, a population pharmacokinetic analysis of sparse concentration-
time data (2 to 3 samples) following administration of weekly docetaxel 40 mg/m2 to 
54 patients showed no effect of age on docetaxel clearance [52]. The effect of age on 
docetaxel pharmacokinetics has also been prospectively evaluated in 20 patients aged 
≥ 65 years and 20 patients aged < 65 years following administration of 3-weekly 
docetaxel 75 mg/m2 [51]. Docetaxel pharmacokinetic parameters including clearance, 
were similar in the elderly and younger age groups (mean ± SD, 30.1 ± 18.3 L/h 
versus 30.0 ± 14.8 L/h; P = .98). Combined, these results indicate that there is no 
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statistically significant change in the pharmacokinetics of docetaxel in older and 
younger patients. Consistent with the pharmacokinetic data, CYP3A activity assessed 
using the erythromycin test was similar in 34 patients aged ≥ 70 years compared to 82 
patients aged < 70 years [12]. Docetaxel administered in weekly schedules at lower 
doses has been found to be both efficacious and generally well tolerated in elderly 
patients [57-59]. However, there is general reluctance to administer docetaxel 3-
weekly to elderly patients due to the prevalence of neutropenia with docetaxel therapy 
[60], although this has not been adequately evaluated in a clinical trial as weekly 
schedules have.  
  
Organ dysfunction 
 The pharmacokinetic profile of docetaxel has been evaluated in patients with 
varying degrees of hepatic impairment. A population pharmacokinetic analysis of 
patients receiving docetaxel 75 to 100 mg/m2 identified a subset of patients with mild 
hepatic impairment defined as total bilirubin < 1.5 × ULN, elevated transaminases ≥ 
1.5 to ≤ 3.5 × ULN concurrent with increased alkaline phosphatase ≥ 2.5 to ≤ 5 × ULN 
[14]. These patients had a 27% reduction in total docetaxel clearance. Prospective 
evaluation of docetaxel in patients with moderate (total bilirubin ≥ 1.5 × ULN to < 3.0 
× ULN with any transaminase and alkaline phosphatase elevations) and severe (total 
bilirubin ≥ 3.0 × ULN with any transaminase and alkaline phosphatase elevations) 
hepatic impairment has been performed [61,62], resulting in an overall reduction in 
docetaxel clearance of approximately 50% in both groups. As described below (section 
Pharmacokinetic-Pharmacodynamic Relationships), reduced docetaxel clearance is 
associated with an increase in the incidence and severity of side effects. Consequently, 
docetaxel dose reductions are required in patients with liver function impairment. 
 
Extravascular routes of administration 
 
Oral Administration 
 Despite all kinds of dosing schedules tested to date, the total docetaxel dose that 
can be tolerated in any time period is approximately the same. Prolonged infusion 
times might theoretically improve the efficacy of docetaxel, as cytotoxicity of tubulin 
poisons is S-phase specific [63], although the relevance of this principle for docetaxel, 
given its prolonged terminal disposition half-life, is unclear. From in vitro models it 
was known that tumor cells are more responsive to increased exposure duration than to 
further escalation of drug concentrations above a plateau level for taxane drugs [63].  
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 The availability of a suitable oral formulation of a taxane would allow for more 
convenient use of prolonged dosing schedules. In addition, the oral administration of 
drugs is usually considered to be more convenient and practical, drugs can be 
administered on an outpatient basis or at home, increasing convenience and patient 
quality of life, and possibly decreasing the costs by reducing hospital admissions [64]. 
Unfortunately, most taxanes, including docetaxel, have a low (less than 10%) and 
highly variable oral bioavailability [39]. In view of the narrow therapeutic window of 
docetaxel, this variable bioavailability may result in unanticipated toxicity or 
decreased efficacy when therapeutic plasma concentrations are not achieved. There is 
a number of important mechanisms that can explain the variable and/or low oral 
bioavailability, including high affinity for drug transporters in the gastrointestinal tract 
such as P-glycoprotein, which limits absorption, and high extraction of the drug by 
extensive metabolism in the intestine and/or liver (first-pass effect) by CYP3A [65]. 
Other important factors include structural instability and limited solubility of docetaxel 
in the gastrointestinal fluids, as well as increased potential for drug-drug and drug-
food interactions, motility disorders or obstructive disorders, and existence of nausea 
and vomiting [66].  
 The overlap in substrate selectivity for ABCB1 and CYP3A, combined with their 
tissue localization, suggests that these two proteins cooperate and constitute a major 
absorption barrier against toxic xenobiotics such as docetaxel [67]. Cummins et al. 
have confirmed this and showed that ABCB1 can affect intestinal drug metabolism 
(especially by the isoenzyme CYP3A4) by controlling the access of a drug to the 
intracellular metabolizing enzyme system [68]. The proposed interplay between these 
proteins in the intestine and, consequently, the combined activity of CYP3A and 
ABCB1, may be major determinants of limited and/or variable oral bioavailability of 
shared substrate drugs. 
 Because of encouraging results obtained with paclitaxel administered orally in 
combination with ABCB1 inhibitors [69], studies in mice have also been performed 
recently with docetaxel. These studies performed in mice lacking functional ABCB1 
confirmed that this protein plays a role in the low bioavailability of docetaxel. 
Furthermore, the AUC of oral docetaxel increased 9-fold by coadministration with 
cyclosporine, a competitive inhibitor of ABCB1 and CYP3A4 [38]. In addition, the 
coadministration of docetaxel and ritonavir, a very potent modulator of CYP3A4 
function with minor ABCB1 inhibitory properties, was tested in a murine model. In 
this study, co-administration with ritonavir resulted in an increase in the apparent oral 
bioavailability of docetaxel from 4% to 183%, suggesting that extensive first-pass 
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metabolism is the predominant mechanism responsible for poor intestinal absorption 
of oral docetaxel in mice [38]. Based on these findings, it has been proposed that 
simultaneous inhibition of ABCB1 and CYP3A4 function may be a strategy to 
improve the systemic exposure to oral docetaxel. 
 A clinical proof-of-concept study of oral docetaxel was recently carried out in 
patients with solid tumors. Patients received one course of oral docetaxel at 75 mg/m2 
with or without a single oral dose of cyclosporine at 15 mg/kg. Pharmacokinetic 
results showed that coadministration of oral cyclosporine resulted in a 7.3-fold 
increase of the systemic exposure to docetaxel. The apparent bioavailability of oral 
docetaxel increased from 8% to 90% in the absence and presence of cyclosporine, 
respectively [70]. Although it is likely that this increase in systemic exposure can be 
explained by inhibition of both CYP3A4 and ABCB1 by cyclosporine, the 
contribution of each of these proteins is unknown. Interestingly, the effect of 
cyclosporine co-administration on the bioavailability of docetaxel was less pronounced 
in mice [38] compared with humans [70], but the reasons for the rather modest effect 
in mice are not clear. 
 The same investigators also performed a clinical phase II study in patients with 
advanced breast cancer given oral docetaxel in the presence of cyclosporine [71]. 
Cyclosporine 15 mg/kg was given 30 minutes prior to a weekly oral docetaxel dose of 
100 mg, which produced a docetaxel AUC that was equivalent to a weekly intravenous 
dose of 40 mg/m2. In addition, the interpatient and intrapatient variabilities in the AUC 
of docetaxel after oral administration were in the same range as that observed after 
intravenous administration of docetaxel (29 to 53%) [6]. However, the current 
availability of novel highly cytotoxic taxanes that are not substrates for ABCB1 and 
have good oral bioavailability, such as MAC-321 [72], 10-deoxy-10-C-
morpholinoethyl-docetaxel [73], IDN 5390 [74], IDN-5109 [75], BMS-275183 [76], 
as well as other orally-available tubulin-interacting agents, such as epothilone and its 
derivatives [77] suggests that further evaluation of oral docetaxel is not warranted. 
 
Intraperitoneal Administration 
 Intraperitoneal administration of docetaxel has also been studied recently and may 
have some potential advantages over the intravenous route. The major goal of 
intraperitoneal therapeutic strategies is to expose tumors within the peritoneal cavity to 
higher concentrations of antineoplastic agents for longer periods of time than can be 
achieved by systemic drug administration. Treatment with docetaxel given 
intraperitoneally is theoretically particularly attractive in patients with ovarian 
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carcinoma, since the drug has proven single agent activity in this disease [78]. 
 Animal models evaluating the pharmacokinetics and tissue distribution of 
intraperitoneal versus intravenous docetaxel [79,81] have shown promising results and 
have led to the initiation of a number of clinical trials. De Bree et al have evaluated the 
pharmacokinetics and toxicity of docetaxel (75 mg/m2) after continuous hyperthermic 
(41-43°C) peritoneal infusion in patients with gynecological malignancies [82,83]. In 
addition, a phase I trial was recently conducted in patients with peritoneal 
carcinomatosis in order to determine the pharmacokinetic characteristics and potential 
pharmacological advantage of intraperitoneal docetaxel [84]. Across all dose levels the 
mean AUC ratio (AUCintraperitoneal/AUCplasma) was approximately 200 in both studies, 
indicating high local drug concentrations and low systemic drug exposure. It is 
possible, as has been observed with paclitaxel [85], that with this route of drug 
administration, the presence of polysorbate 80 as an integral component of the clinical 
formulation may actually be advantageous as it prolongs exposure to the tumor cells 
and reduces transport across the peritoneal/blood barrier. Further phase II/III trials 
should determine if this favorable exposure ratio translates in an improvement of 
treatment outcome. 
  
Drug interactions 
 Drug interactions may arise as a result of altered pharmacodynamics or 
pharmacokinetics of the drugs involved. In the case of the latter, this is usually due to 
modification of tissue disposition and metabolism of the drugs. These phenomena are of 
particular importance in cancer chemotherapy when cytotoxic agents are used, because of 
the increased risks of severe toxicity. Most of the data currently available to evaluate 
potential drug interactions with docetaxel come from clinical trials of docetaxel given in 
combination with one or more other anticancer agents. Although in most cases only 
limited information is available, some preliminary conclusions can be drawn. 
  Pharmacokinetic interaction studies with docetaxel have been performed with 
cisplatin either given alone or in combination with 5-fluorouracil [86], and indicated 
unaltered disposition profiles of both docetaxel and 5-fluorouracil at any dose level or 
sequence tested [87]. Likewise, no interactions have been reported when docetaxel is 
coadministered with carboplatin [89], epirubicin [90], doxorubicin [91], vinorelbine [92], 
gemcitabine [93], methotrexate [94], 5-fluorouracil [95], capecitabine [96], ifosfamide 
[97], estramustine [98], and irinotecan [2,99]. 
 In contrast to the findings of Itoh et al [91], a recent pharmacokinetic evaluation 
involving a multivariate analysis in a large cohort of cancer patient revealed a 20% 
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decrease in the clearance of docetaxel in the presence of doxorubicin [50]. Although 
the mechanistic basis for this interaction is presently unclear, it is important to note 
that this interaction might be clinically significant in view of the notion that a 25% 
decrease in docetaxel clearance was previously shown to increase the odds for 
development of febrile neutropenia [14]. Furthermore, it provides an explanation for 
the severe hematological toxicity observed in regimens combining doxorubicin with 
docetaxel [50]. 
 It has been suggested that an interaction or sequence-dependent effect is present for 
the combination of topotecan and docetaxel [100]. Administration of topotecan on days 1 
and 4 and docetaxel on day 4 resulted in an approximately 50% decrease in docetaxel 
clearance [101]. As both drugs are metabolized by CYP3A, competition might occur 
when these drugs are given sequentially, and as a result, the clearance of docetaxel might 
be decreased. A similar interaction resulting in decreased clearance of docetaxel has been 
described in patients receiving concomitant administration of pegylated liposomal 
doxorubicin [102,103]. To date, no other cytotoxic drug has been shown to affect the 
pharmacokinetics of docetaxel. 
 Although not evaluated clinically, it is likely that anticonvulsants, phenytoin and 
phenobarbital in particular, will interact with docetaxel through induction of the 
docetaxel metabolic pathway. CYP3A4, in particular, has increased expression when 
patients are treated with these compounds. This type of interaction might be of major 
importance since it suggests that anticonvulsants will greatly reduce the potential 
antitumor effects of docetaxel. Besides potent inhibitors of CYP3A like ketoconazole 
[104], other well established CYP3A-inducing and inhibiting compounds 
(http://medicine.iupui.edu.flockhart/), dietary supplements and food products (e.g., 
grapefruit juice) and herbal preparations (e.g., St. John’s wort and echinacea), harbor 
the potential to induce pharmacokinetic interactions with docetaxel. 
 In line with preclinical data obtained in mice lacking ABCB1 [38], specific 
inhibitors of P-glycoprotein like R101933 [105,106] have been demonstrated not to 
interfere with the plasma pharmacokinetics of docetaxel. It is noteworthy, however 
that certain modulators like GF120918 (elacridar) can increase the accumulation of 
docetaxel in normal brain tissue without simultaneously having significant effects on 
systemic drug exposure [107], suggesting that certain pharmacokinetic processes and 
side effects (e.g., central nervous system toxicity) cannot be predicted based on plasma 
concentration measurements alone. 
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Pharmacokinetic-Pharmacodynamic Relationships 
 
 Docetaxel’s pharmacokinetic profile is characterized by substantial interpatient 
variability. In a population pharmacokinetic study of more than 600 patients receiving 
docetaxel 75 to 100 mg/m2 that used a limited sampling scheme with the last sampling 
time point at 24 hours post-infusion, the median clearance was 36 L/h (5% to 95% 
percentile: 17-59 L/hr), representing approximately 3.5-fold variation in this 
population [14]. In a more recent study where patients received docetaxel 75 mg/m2 
and an extended sampling scheme to day 8 post infusion was utilized, approximately 
10-fold variation in drug clearance was observed when patients with outlier values 
were not excluded from the analysis [51]. The observed large pharmacokinetic 
variability for docetaxel has important clinical consequences. In the aforementioned 
population pharmacokinetic study, decreased docetaxel clearance was associated with 
an increased frequency of grade 4 neutropenia and febrile neutropenia; a 50% decrease 
in docetaxel clearance increased the odds of developing grade 4 neutropenia and 
febrile neutropenia by 430% and 300%, respectively [14]. Even a 25% decrease in 
docetaxel clearance was associated with a 150% increase in the odds of developing 
febrile neutropenia [14]. In a subset of 180 patients with non-small cell lung cancer 
treated with docetaxel 100 mg/m2 in phase II studies, docetaxel plasma AUC was the 
only significant predictor of severe toxicity including febrile neutropenia, infection, 
grade 3/4 mucositis, grade 3/4 diarrhea, and severe asthenia; in 13.9% of patients 
experiencing at least one severe adverse event, a high AUC was associated with 
increased probability of experiencing any of the severe toxicities [15]. Docetaxel 
exposure has also been related to treatment efficacy. AUC was a significant predictor 
of time to tumor progression in non-small cell lung cancer [14], and underdosing (e.g., 
lower docetaxel AUC due to increased clearance) was associated with a worse time to 
progression and time to death [108]. 
 More recently, the association between exposure to unbound docetaxel and 
neutropenia in cancer patients was examined [18]. Docetaxel was administered once 
every 3 weeks at a dose of 75 mg/m2 to 49 patients with normal liver function (N = 40) 
or mild elevations in liver function tests (N=9), or at 50 mg/m2 to patients with 
moderate elevations in liver function tests (N=6). Patients with moderate liver 
impairment received a reduced dose of docetaxel to achieve AUC values similar to 
those with normal liver function or mild elevations in liver parameters receiving 
docetaxel 75 mg/m2; as such, unbound and total AUC values were similar in the three 
groups and AUC values at the different dose levels were combined to assess the 
Chapter 2_____________________________________________________________ 
 32
relation between docetaxel unbound and total exposure and neutropenia. From this 
analysis, unbound docetaxel AUC was better correlated than total AUC with both 
percentage decrements in absolute neutrophil count (P=.002 versus P=.029) and worst 
grade of neutropenia (P=.013 versus P = .220), where higher exposure was associated 
with worse hematological toxicity. It was concluded that exposure to unbound 
docetaxel is more closely related to drug-induced hematologic toxicity than total drug 
and should be considered for future pharmacologic investigations. 
 
Conclusion 
 
 Docetaxel, because of its broad spectrum of antitumor activity, is clearly one of 
the most important new anticancer drugs developed in the last few decades. The 
clinical pharmacokinetic behavior of docetaxel has been explored extensively in recent 
years, and the generated information has been of fundamental importance in the 
understanding of the clinical effects of this agent. In addition, a wealth of information 
has become available that has yielded valuable insight into the mechanism of action, 
the mechanisms of tumor resistance, toxicities, and considerations of dosage and 
schedule and route of drug administration. Many of these studies have been made 
possible by the development of selective analytical methodologies to specifically 
monitor the parent drug, with sufficient sensitivity to detect the compounds at 
concentrations achieved after therapeutic dosing. However, only through further 
investigations that may allow better definition of the biochemistry and 
pharmacokinetics of docetaxel can the rational optimization of therapy involving this 
agent be achieved. This need has become even more important in light of the current 
clinical use of docetaxel in combination with other antineoplastic drugs or agents 
specifically administered to modify docetaxel-induced toxicity profiles. In this respect, 
the use of mathematical models to predict systemic exposure measures for docetaxel 
by application of limited-sampling strategies or population pharmacokinetic models, 
coupled with continued investigations into the role of individual enzyme-expression 
levels and detection of enzyme and transporter polymorphisms, will allow more 
rational and selective chemotherapy with this agent. 
 Finally, the drawbacks presented by the presence of polysorbate 80 in the 
clinically used formulation of docetaxel have instigated extensive research to develop 
alternative delivery forms, and currently, several strategies are in progress to develop a 
surfactant-free formulation of docetaxel [109]. For example, a recent dose-finding 
study with a new submicronic polysorbate 80-free dispersion formulation of docetaxel 
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has shown a lower incidence and severity of hematological and non-hematological 
toxicity (fluid retention) at equimolar doses compared to the current formulation of 
docetaxel that contains polysorbate 80 [110]. Likewise, the absence of the 
pharmaceutical excipient Cremophor EL in a novel nanoparticle-based albumin-bound 
formulation of the related agent paclitaxel (i.e., ABI-007; Abrexane) permits drug 
administration without premedication routinely used for the prevention of 
hypersensitivity reactions, as well as increases in the maximum tolerated dose as 
compared to paclitaxel formulated in Cremophor EL [111]. It is suggested that 
continued investigations into the role of pharmaceutical vehicles in taxane-related 
drugs should eventually lead to a more rational and selective chemotherapeutic 
treatment with these agents.  
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 Although the prescribed dose of anticancer agents is most commonly calculated 
using body-surface area as the only independent variable, it has been shown that this 
approach results in a large interpatient variability in drug exposure. We retrospectively 
assessed the pharmacokinetics of 33 investigational agents, which were tested in phase 
I trials between 1991 and 2001, as a function of body-surface area in 1650 adult cancer 
patients. Twelve of the drugs were administered orally, 19 were administered 
intravenously, and two were administered by both routes. Body-surface area-based 
dosing was statistically significantly associated with a reduction in interpatient 
variability in drug clearance for only five of the 33 agents: DHA-paclitaxel, 5-
fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine. These results do 
not support the use of body-surface area in dose calculations and suggest that alternate 
dosing strategies should be evaluated. We conclude that body-surface area should not 
be considered to determine starting doses in future phase I studies of investigational 
agents. 
 
 In clinical oncology, the traditional method by which individualized anticancer 
drug doses are determined uses body-surface area, because use of this measurement is 
thought to reduce the interpatient variability of drug exposure, and hence, drug effects 
[1]. The use of body-surface area measurements arose from the extrapolation of drug 
doses used in experimental animals to those considered safe as starting doses for 
human cancer patients in phase I clinical trials [1]. However, a rigourous scientific 
rationale for body-surface area-based dosing of anticancer drugs in adults is lacking, 
especially when one considers that the difference in size between mice and humans is 
far greater than the difference in size between individual patients. Although the 
primary objective of phase I trials is to evaluate drug toxicity, antitumor activity is 
usually a secondary objective of such trials. Other measures, such as drug clearance, 
have also been used as a surrogate marker of drug effects. However, it has been widely 
recognized that large interpatient variability in drug clearance exists despite the use of 
body-surface area in drug-dose calculations [2]. Indeed, for most drugs that are used in 
clinical practice today, clearance cannot be reliably predicted by body-surface area 
because other factors involved in drug disposition may be more important for 
clearance [1,3-5]. For example, several recent studies have highlighted the importance 
of genetic polymorphisms in drug-metabolizing enzymes and drug transporter proteins 
in explaining inter-individual pharmacokinetic variability [6-9]. As a follow up to a 
preliminary report by Grochow et al. [10], we have assessed the pharmacokinetics of 
33 investigational agents in adult cancer patients as a function of body-surface area in 
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order to provide a pharmacokinetic rationale for the appropriate selection of starting 
doses for phase I evaluation. 
 Data were obtained from 1650 patients who were treated with 33 anticancer drugs 
(involving 21 classes of agents) that were developed in phase I trials over a 10-year 
period at three institutions. Twelve of the drugs were administered orally, 19 were 
administered intravenously, and two were administered by both routes. Detailed 
clinical and pharmacokinetic profiles for these agents have been described elsewhere 
[5,11-68]. All patients were at least 18 years old and had normal organ function, 
except for those enrolled in two studies that involved patients with varying degrees of 
renal and hepatic impairment [65,66]. Drug clearance was calculated by using either 
non-compartmental or compartmental analysis [69], and was expressed either as liters 
per hour (L/h) or as L/h normalized to body-surface area in meters squared (L/h/m2). 
Interpatient variation in drug clearance was calculated by dividing the standard 
deviation by the mean and expressed as a percentage (i.e., the coefficient of variation 
[CV]). We used the following arbitrarily-defined criteria to determine if body-surface 
area-based dosing was statistically significantly associated with a reduction in 
interpatient variation in clearance: (i) a linear regression coefficient (R) ≥ .50; (ii) P < 
.01; and (iii) a relative reduction in the variability of clearance ≥ 15%, which was 
calculated as according to the following formula: {[CV for clearance (L/h) - CV for 
clearance (L/h/m2)] / [CV for clearance (L/h)]} × 100. All three criteria had to be met 
for the reduction to be considered statistically significant. 
 The median body-surface area for the entire patient population was 1.86 m2 
(interquartile range = 1.68 - 2.00 m2) and the mean body-surface area was 1.86 m2 
(range = 1.25 - 3.06 m2). The CV for clearance, the correlation between body-surface 
area and clearance, and relative reduction in variability for clearance for each of the 
agents are listed in Tables 1 and 2. For all but five agents (i.e., DHA-paclitaxel, 5-
fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine), body-surface 
area-based dosing was not associated with a statistically significant reduction in the 
interpatient variability in drug clearance. 
 In the case of drugs for which renal function plays a principal role in drug 
elimination, BSA-based dosing may decrease variability in drug clearance between 
patients. For example, troxacitabine, an L-nucleoside analogue, and 5-fluorouracil co-
administered orally with the dihydropyrimidine-dehydrogenase inactivator eniluracil, 
are primarily excreted in the urine as unchanged drugs (~60% unchanged and 75% 
unchanged, respectively).  
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 Normalization of drug dose to body-surface area was associated with 22% 
reduction in the interpatient variation in troxacitabine clearance and a 15% reduction 
in the interpatient variation in 5-fluorouracil/eniluracil clearance [17,67]. Body-surface 
area-based dosing of MTA, a novel multi-targeted antifolate that is also mainly 
excreted in urine as unchanged drug (>70% unchanged), was also associated with a 
16% reduction in interpatient variation in drug clearance [70]. The known association 
between body-surface area and glomerular filtration rate [71] may explain the 
observed relationship between body-surface area and clearance of renally-excreted 
agents. However, differences in body-surface area among patients account for only a 
small percentage of the total variability in drug clearance (i.e., ≤ 22%), which is 
consistent with results from a recent study that reported that body-surface area was 
poorly correlated with glomerular filtration rate (R < .22) [72]. Therefore, for agents 
that are excreted principally by the kidneys, dosing strategies that are based on the 
accurate assessment of glomerular filtration rate and not on body-surface area should 
be associated with decreased interpatient variability in clearance [73]. 
 Body-surface area-based dosing may also be a preferred dosing strategy for drugs 
that are confined to blood volume because of the known relationship between body 
size and blood volume [74,75]. For example, we found that body-surface area was 
highly correlated with temozolomide clearance (R = .88, P<.001) and was associated 
with 35% of the variation in temozolomide clearance between patients. Temozolomide 
is an alkylating agent that undergoes pH-dependent breakdown to the active moiety 5-
(3-methyltriazen-1-yl)imidazole-4-carboxamide immediately following drug 
administration and is virtually isolated to the central compartment. Interpatient 
variability in DHA-paclitaxel clearance was reduced by 26% when the dose of that 
agent was normalized to body-surface area. DHA-paclitaxel has a low clearance (~ 
0.11 L/h) and a small volume of distribution (~ 4 L), and is extensively (>99.6%), but 
non-specifically, bound to alpha1-acid glycoprotein and albumin [76]. These 
characteristics indicate that DHA-paclitaxel is principally confined to blood volume, 
and that protein binding for this agent may dictate systemic exposure to total drug. By 
contrast, drugs that bind a single protein with high affinity but low capacity (e.g., as 
UCN-01 binds alpha1-acid glycoprotein [77]) are more likely than DHA-paclitaxel to 
show wide variations in unbound (pharmacologically active) drug concentrations 
among patients. For agents with disposition characteristics like UCN-01, measurement 
of total drug concentrations in plasma is a poor surrogate for unbound drug [78], and 
accurate assessment of the relationship between body-surface area and clearance will 
require measurement of unbound drug concentrations. Thus, the protein-binding 
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characteristics of investigational agents across species should be characterized before 
those agents are evaluated in phase I trials. 
 Normalizing doses to body-surface area may also provide an advantage for drugs, 
such as paclitaxel, which are formulated in vehicle substances known to affect drug 
disposition. For example, previous work has shown that the distribution of paclitaxel 
in the blood depends on the duration of drug infusion and the dose of its formulation 
vehicle (Cremophor) [51], which is likely due to the preferential affinity of paclitaxel 
for Cremophor in the circulation [79]. It has been demonstrated that this vehicle has a 
distribution volume that approximates the blood volume, and that body-surface area is 
a statistically significant covariate for Cremophor clearance [80]. Thus the impact of 
body-surface area on the variability in paclitaxel pharmacokinetics is most likely 
associated with the affinity of paclitaxel for its vehicle in the circulation [81], the 
distribution of which is linked to total blood volume, and thus to body-surface area 
[75]. 
 We found that body-surface area-based dosing did not decrease interpatient 
variability in clearance to a statistically significant extent for the majority of the 
anticancer agents we examined that underwent development in adult patients from 
1991 through 2001. For the few agents for which clearance was statistically 
significantly associated with body-surface area, the relative reduction in variability for 
clearance was between 15% and 35%, which suggests that only up to one third of the 
total variability can be explained by body-surface area. These results, therefore, do not 
support the use of body-surface area-based dosing for most anticancer agents, and 
suggest that alternate dosing strategies should be considered for phase I evaluation of 
anticancer agents in adult humans. A non-body-surface area-based dosing strategy 
(e.g., one based on a fixed dose) was successfully implemented in the development of 
five of the orally-administered agents examined in the present study (i.e., 
phenylbutyrate [20], PKI166 [21], R115777 [32], SCH66336 [23], and ZD9331), 
demonstrating that administration of a fixed total dose is feasible for the development 
of both cytotoxic and non-cytotoxic anticancer agents. We therefore recommend that 
the practice of calculating starting drug doses on the basis of body-surface area in 
phase I trials should be abandoned and that future early clinical trials should instead 
evaluate the administration of fixed drug doses that are calculated on the basis of an 
average body-surface area of 1.86 m2. For novel non-cytotoxic agents, dose refinement 
should be based on the achievement of an exposure that produces a biologic or 
molecular effect on a drug target that is associated with a desired therapeutic outcome 
or avoidance of a toxicologic outcome. For cytotoxic agents that have a narrow 
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therapeutic window, efforts should continue to focus on defining individual doses that 
are based on patient characteristics that are known to effect drug clearance (e.g., age, 
sex, renal function, use of concomitant medications). A combination of these strategies 
should yield more rational dosing schemes that can be implemented in oncology 
practice. 
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Abstract  
 
 Current dosing strategies for anticancer drugs result in wide interindividual 
pharmacokinetic variability. Here, we explored the influence of age, body size, 
concomitant drugs, dose, infusion duration, and sex on the clearance for doxorubicin 
and docetaxel in 243 individual patients. Patients received doxorubicin (n=110) or 
docetaxel (n=152) as monotherapy or in combination chemotherapy regimens. The 
mean (±SD) clearance was 63.6±22.7 L/h for doxorubicin and 42.8±14.9 L/h for 
docetaxel. Normalization for body surface area (BSA) reduced the interindividual 
variability by only <1.7%. Doxorubicin clearance was significantly reduced when 
administered at doses >50 mg/m2 or in combination with cyclophosphamide. Upper 
extremes of body size were associated with increased clearance for both drugs, 
whereas no consistent effect of age on clearance was discerned. Overall, tJGUGHKPFKPIU
UWIIGUV VJCV KPEQTRQTCVKQP QH XCTKCDNGU KP CFFKVKQP VQ $5# UJQWNF DG EQPUKFGTGF KP
TQWVKPGFQUKPIUVTCVGIKGUHQTFQZQTWDKEKPCPFFQEGVCZGN
 
Introduction  
 
 There is often a marked variability in drug handling between individual patients, 
which may contribute to variability in the pharmacodynamic effects of a given drug 
dose. Hence, an identical drug dose may result in a therapeutic response with 
acceptable toxicity in one patient, and unacceptable and possibly life-threatening 
toxicity in another. A combination of physiological, genetic, and environmental factors 
is known to alter the relationship between the absolute dose and a drug’s 
concentration-time profile. Over the last few decades, numerous studies have 
established relationships between systemic exposure to anticancer drugs and drug-
induced toxicity or response. These relationships have subsequently been used to 
individualize chemotherapy regimens either a priori or a posteriori, for example as in 
case of carboplatin and methotrexate, respectively [1,2]. A variety of strategies is now 
being evaluated to improve the therapeutic index of other anticancer drugs, some of 
which include implementation of geno- or phenotyping individual patients for drug 
metabolizing enzymes, the use of biomodulating agents and/or modification of drug 
scheduling. 
 Docetaxel and doxorubicin are commonly used for the treatment of a variety of 
cancers. Although drug-induced toxicity is dose-dependent for both of these agents, 
the individual susceptibility to side effects varies considerably. As for most other 
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anticancer agents, the administered dose of docetaxel and doxorubicin is normalized 
by a patient’s body surface area (BSA). However, for most anticancer agents clearance 
is poorly correlated to body-size measures and hence, the routine use of BSA as the 
only independent variable considered in drug dosing is questionable [3-12]. Previous 
studies have revealed significant relationships between interindividual variation in 
docetaxel and doxorubicin clearance and the likelihood of tumour response and/or 
toxicity [3]. However, the factors contributing to pharmacokinetic variability for these 
agents are largely unknown and unstudied. In an attempt to further optimize use of 
these agents, we characterized the pharmacokinetics of doxorubicin and docetaxel in a 
broad patient population under general clinical conditions, and explored demographic 
subpopulations or drug conditions for which dose adjustment may be needed. 
 
Patients and methods 
 
Patient selection and treatment 
 All patients studied had a malignant solid tumour and were treated on trials with 
doxorubicin monotherapy [13], doxorubicin-based combination therapy (with either 
cyclophosphamide [14], docetaxel [15], or paclitaxel [16], docetaxel monotherapy 
[17,18] [19-21], or docetaxel-based combination therapy (with either capecitabine 
[18], cisplatin [17], doxorubicin [15], doxorubicin with or without marimastat [22], 
methotrexate [19], or R101933 [20,21]). Doxorubicin was administered as a bolus (5 
minutes), a short infusion (15 to 20 minutes), or as a 1- to 3-hour infusion at doses 
ranging from 40-75 mg/m2, and docetaxel as a 1-hour infusion at doses 55-100 mg/m2. 
For the purpose of this study, the drug administration schedule assigned for each agent 
was based on the co-administered drug and infusion duration (Table 1). Patients were 
included on these trials if they were over 18 years old and had adequate haematologic, 
hepatic, and renal function. Written informed consent was obtained from each patient 
according to institutional guidelines. 
 
Pharmacokinetic sampling and analysis 
 Pharmacokinetic sampling schema and analytical methods employed have been 
previously described for total drug concentrations [13-24]. All sampling schema 
involved intensive serial plasma sampling for up to 24-48 hours post infusion. 
Pharmacokinetic studies were performed during one cycle of therapy (cycle 1 or 2).  
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Clearance values for doxorubicin and docetaxel were estimated for individual patients 
by the method of weighted least-squares regression using either a 2-compartment or 3-
compartment linear model as implemented in ADAPT II [25], WinNonlin (Pharsight 
Corp., Mountain View, CA, USA), or Siphar (InnaPhase, Philadelphia, PA, USA). 
Previous investigations evaluating drug exposure-effect relationships for doxorubicin 
and docetaxel have shown that area under the total plasma concentration curve (AUC) 
is more closely correlated with the principal toxicity neutropenia than other 
pharmacokinetic parameters [26,27]. AUC is a function of both the drug dose and 
clearance by the equation clearance=dose/AUC; therefore, drug clearance was selected 
as the parameter for evaluation of pharmacokinetic variability. 
 Body-size measures including BSA, lean body mass (LBM), ideal body weight 
(IBW), adjusted ideal body weight (AIBW), and body mass index (BMI) were 
calculated as described previously [28-30]. For statistical and graphical analysis, 
values for BSA were grouped as: lower quartile (25% quantile), interquartile range, 
and upper quartile (75% quantile). Values for BMI were grouped as: ≤25 (normal), 25-
29 (overweight), 30-34 (obese), and ≥35 (morbidly obese). The four BMI groups were 
used to graphically display individual clearance values; due to the small numbers in 
the BMI 30-34 and ≥35 groups, the data were combined for these two groups for 
ANOVA. Values for age were grouped as: <65 years old, 65-69 years old (borderline 
elderly), and ≥70 years old (elderly). 
  
Statistical analysis 
 Interindividual differences in clearance values were evaluated by the coefficient of 
variation (CV). The relative reduction in variability (RIV) for clearance was calculated 
as described previously [9]. Univariate linear regression analysis was used to assess 
the relationship between body size indices, age, and drug clearance. One-way analysis 
of variance (ANOVA) was used to compare the differences in clearance as a function 
of drug administration schedule (a combination of concomitant drug and infusion 
duration), categorical age, categorical BSA, categorical BMI, and sex followed by a 
Tukey-Kramer’s multiple comparison test. Univariate linear least-squares regression 
analysis and ANOVA were performed using JMP Statistical Discovery Software, 
version 4.0.4 (SAS Institute, Cary, NC, USA). 
 Due to the study design, it was necessary to account for potential confounding 
variables and the correlation between individuals from the same protocol. Random 
effects multiple linear regression models were used to assess the influence of dose, 
concomitant drugs, infusion duration, age, sex, and BSA (predictor variables) on drug 
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clearance (outcome) where a random effect was included to account for correlation 
between individuals within an administration schedule. This approach assumes 
independence between individuals from different protocols, but assumes that outcomes 
from individuals in the same protocols are correlated. First, the associations between 
predictor variables were assessed to detect possible multi-colinearity in regression 
models: categorical variables were compared using Fisher’s exact test, continuous 
variables were compared using Pearson and Spearman correlation, categorical were 
compared to continuous using ANOVA. This analysis was exploratory in nature and 
necessary due to the observational nature of the dataset. Random effects models were 
then fit to the data iteratively and interactions between predictors were also 
considered. Regression coefficients, standard errors of the coefficients, and the 
associated P-values were determined. The coefficients represent the expected 
difference in clearance for a one-unit difference in a predictor, adjusted for the other 
predictors in the linear regression model. Multiple linear regression modelling was 
performed using the software STATA, version 7.0 (Stata Corporation, Cary, NC, 
USA). The a priori level of significance was set at P <0.05. 
 
Results 
 
Patient demographics are summarized in Table 2.  
 
Doxorubicin pharmacokinetics  
 The mean plasma clearance of doxorubicin in the entire group was 63.6±22.6 L/h 
(range, 16.6-125 L/h) with a CV of 35.5% (Table 3), similar to previous findings.(31) 
Compared to the other drug administration schedules, doxorubicin clearance was 
reduced by approximately 30% when co-administered with cyclophosphamide 
(47.9±25.6 L/h versus 66.9±20.6 L/h; P=0.0007) (Figure 1A); consequently, these 
nineteen patients were excluded from subsequent analysis. A positive association was 
observed between BSA and doxorubicin clearance (r=0.34; P=0.0015); a separate 
analysis in males and females revealed a stronger correlation in males (r=0.64; 
P=0.0002) than females (r=0.01; P=0.95). However, when normalized to BSA, the 
RIV for clearance was 0.8%. Consequently, only for males did normalization of 
clearance to BSA result in a substantial reduction in variability of clearance (RIV 
18.7%). A trend for increasing doxorubicin clearance as BSA values increased from 
the lower quartile to the upper quartile was observed; clearance was 20% higher in 
patients with BSA values in the upper quartile (BSA>1.97 m2) (63.1±22.6 L/h versus 
64.7±17.3 L/h versus 76.6±24.2 L/h; P=0.061) (Figure 2A).  
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Table 2. Patient demographics 
Patient Characteristics Doxorubicin Therapy Docetaxel Therapy 
Total Number of Patients 110d 152d 
Age [years (range)] 52.5a (27-78) 53.1a (21-75) 
     < 65 94b 128b 
     65 – 69 9b 16b 
     ≥ 70 7b 8b 
Sex (male:female) 34:76 69:83 
Height [cm (range)] 165.9a,c (140-193) 170.9a (149-193) 
Weight [kg (range)] 74.1a,c (38-117) 73.3a (39.3-109.2) 
BSA [m2 (range)] 1.83a,c (1.26-2.42) 1.86a (1.28-2.38) 
     25% Quantile 1.67 1.71 
     Median 1.78 1.84 
     75% Quantile 1.97 2.00 
LBM [kg (range)] 53.9a,c (34.1-72.3) 54.2a (31.8-78.8) 
IBW [kg (range)] 59.1a,c (34.1-87.3) 64.5a (42.3-87.3) 
AIBW [kg (range)] 62.6a,c (41.9-86.6) 66.7a (41.5-90.6) 
BMI (range) 26.6a,c (15.5-43.6) 25.1a (16.4-40.5) 
     < 25 40b 80b 
     25 – 29 37b 50b 
     30 – 34  15b 18b 
    ≥ 35 7b 3b 
Clearance (L/h) 63.6a (16.6-124.5) 42.8a (13.8-84.4) 
Infusion Duration  0.47 (0.07-3) 1.05a (0.92-1.50) 
     Bolus 57b   
     Short Infusion 43b   
     Long Infusion 10b   
aResults expressed as mean value.  bData are the number of patients.  cHeight, BSA, LBM, 
IBW, AIBW, and BMI were available for 99 of 110 patients; weight was available for 104 of 
110 patients. dNineteen patients received both doxorubicin and docetaxel in combination 
therapy and are represented in both data sets; the total number of individual patients studies 
were 243. 
 
 Similarly, clearance was 22% higher in patients with BMI values ≥30 kg/m2 
(63.6±19.9 L/h versus 65.7±17.1 L/h versus 78.9±27.3 L/h; P=0.045) (Figure 3A). 
Although doxorubicin clearance was reduced by 13% in females compared to males 
(63.3±19.2 L/h versus 73.0±22.2 L/h; P=0.032), no sex differences were noted when 
clearance was normalized to BSA (37.0±12.4 L/h/m2 versus 37.3±9.37 L/h/m2; 
P=0.90). Age was not associated with reductions in doxorubicin clearance (P=0.88) 
(Figure 4A); however, the number of patients in the studied population that were aged 
65-69 years (n=4) or ≥70 years (n=6) may not be adequate to detect a difference if one 
exists. 
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Table 3. Mean (± standard deviation) clearance of doxorubicin and docetaxel as a 
function of body-size measures 
Doxorubicin1 Docetaxel 
Body-size measure 
% CV Clearance2 % CV Clearance2 
None (L/h) 30.8 66.9 ± 20.6 34.8 42.8 ± 14.9 
BSA (L/h/m2) 30.6 37.1 ± 11.3 34.2 23.0 ± 7.9  
LBM (L/h/kg) 32.0 1.3 ± 0.4 35.0 0.8 ± 0.3  
IBW (L/h/kg) 33.9 1.2 ± 0.4 35.8 0.7 ± 0.2  
AIBW (L/h/kg) 32.4 1.1 ± 0.4 35.4 0.7 ± 0.2 
BMI (kg/m2) 33.3 2.6 ± 0.9 36.8 1.7 ± 0.6 
Height (L/h/cm) 30.0 0.4 ± 0.1 36.0 0.3 ± 0.1  
Weight (L/h/kg) 35.1 0.9 ± 0.3 36.7 0.6 ± 0.2 
 
1Excludes patients enrolled to drug administration schedule #1. n=91 for none, n = 86 for 
weight, n = 82 for all others. 2mean ± SD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Clearance as a function of drug administration schedule for (A) doxorubicin and 
(B) docetaxel. The solid line represents the mean, while the dashed line represents the 
median. 
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Figure 2. Clearance as a function of body surface area (BSA) for (A) doxorubicin and (B) 
docetaxel. The solid line represents the mean, while the dashed line represents the median. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Clearance as a function of body mass index (BMI) for (A) doxorubicin and (B) 
docetaxel, where { is < 25, z is ≥ 25-29 years,  is 30-34, and J is ≥ 35. The solid line 
represents the mean, while the dashed line represents the median. 
 
 
 Multiple linear regressions helped to determine that concomitant medication and 
sex, and concomitant medication and infusion duration were strongly confounded. 
Therefore, concomitant medication was not included in the final multiple linear 
regression model. In addition, preliminary modelling indicated that infusion duration 
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was not significantly associated from clearance so it was not included in the final 
model. Interactions were found between sex and BSA, and sex and dose. As a result, 
the associations between predictor variables and doxorubicin clearance were stratified 
by sex and summarized in Table 4. At doxorubicin doses greater than 50 mg/m2, there 
was a trend for decreased clearance, although this did not reach a level of significance 
(coefficient=-10.63; P=0.056). Assuming an average clearance of 63 L/h, this would 
represent a 17% decrease in clearance when doxorubicin is administered at doses >50 
mg/m2. BSA was positively associated with clearance in males (coefficient=66.42; 
P<0.001) but not in females (coefficient=-7.46; P=0.61), and age was not associated 
with altered drug clearance (coefficient=-0.05; P=0.82). 
 
Table 4. Multiple regression model for doxorubicin clearance 
 Coefficient Standard Error P value 
Males (n = 29):    
Intercept -50.03 26.80 0.11 
High dose1 -10.63 4.49 0.056 
BSA 66.42 9.72 <0.001 
Age -0.05 0.21 0.82 
Females (n = 69): 
Intercept 83.15 31.15 0.04 
High dose -10.63 4.49 0.056 
BSA -7.46 13.84 0.61 
Age -0.05 0.21 0.82 
 
1High dose is binary with a dose greater than 50 mg/m2 coded as 1, and less than or equal to 
50 coded as 0. 
 
 
Docetaxel pharmacokinetics 
 The mean plasma clearance of docetaxel was 42.8±14.9 L/h (range, 13.8-84.4 L/h) 
with a CV of 34.8% (Table 3), and was similar among the different drug 
administration schedules (P=0.34) (Figure 1B). A positive correlation was noted 
between BSA and docetaxel clearance (r=0.30; P=0.0002); a separate analysis 
revealed a stronger correlation in males (r=0.35; P=0.0032) than in females (r=0.18; 
P=0.11). After normalization of clearance for BSA, the mean value was 23.0±7.87 
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L/h/m2 with an associated CV of 34.2%, indicating a negligible RIV for clearance of 
1.7%. However, the mean clearance increased as BSA values increased from the lower 
to the upper quartile, and was significantly higher by 33% in patients with BSA values 
>2.0 m2 (36.8±15.9 L/h versus 42.6±14.4 L/h versus 49.0±13.0 L/h; P=0.0029) (Figure 
2B). Clearance was not higher in patients with BMI ≥30 kg/m2 (40.9±15.0 L/h versus 
46.1±15.2 L/h versus 42.3±13.3 L/h; P=0.15) (Figure 3B). Docetaxel clearance was 
reduced on average by 11% in females compared to males (40.6±14.7 L/h versus 
45.6±14.8 L/h; P=0.040), although no sex differences were noted when clearance was 
normalized to BSA (22.9±8.44 L/h/m2 versus 23.2±7.19 L/h/m2; P=0.88). Advanced 
age was not associated with reduced docetaxel clearance in 16 patients between the 
ages of 65-69 and 8 patients aged ≥70 years (P=0.45) (Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Clearance as a function of categorical age for (A) doxorubicin (data from drug 
administration schedule 1 is not included) and (B) docetaxel, where { is < 65 years old, z is 
≥ 65 and < 70 years old, and  is ≥ 70 years old. The solid line represents the mean, while 
the dashed line represents the median.  
 
 
 Using multiple linear regression analysis, an interaction between sex and BSA was 
observed, and therefore results are stratified for males and females. The association 
between predictor variables and docetaxel clearance is summarized in Table 5. BSA 
was associated with docetaxel clearance in males only (coefficient=28.11; P=0.039). 
Concomitant treatment with doxorubicin and capecitabine was associated with 
decreased and increased docetaxel clearance, respectively (for doxorubicin, 
coefficient=-8.57; P=0.014; for capecitabine, coefficient=1.48; P=0.010). Assuming an 
%CVGIQTKECN#IG
[T [T [T
&Q
EG
VCZ
GN
%N
GC
TCP
EG

.
J









_________
_________ _________
     
_ _ _ _ _ _
_ _ _ _ _ _
2$
 
Chapter 4_____________________________________________________________ 
 68
average docetaxel clearance of 42.8 L/h, the coefficient of –8.57 indicates that co-
treatment with doxorubicin results in a 20% decrease in clearance. No association was 
observed between age and docetaxel clearance (P=0.67). 
 
Discussion 
 
 The traditional method of individualizing anticancer drug dosage in adult patients 
is by using BSA [3-12,32,33]. The usefulness of normalizing anticancer drug doses to 
BSA has been questioned, since it has been shown that for some agents there is no 
relationship between BSA and anticancer drug clearance [3-12,32,33]. In these cases, 
the use of BSA-adjusted dosing results in the administration of a standard dose 
multiplied by an arbitrary number (i.e., the ratio of the patient’s BSA to an average 
BSA). These considerations have led to a desire for better tools to individualize 
chemotherapy, and to new ways of evaluating and treating patients. In the present 
study, exploratory relationships were assessed between disposition characteristics of 
doxorubicin and docetaxel and a number of common patient and drug-related 
variables. 
 Doxorubicin clearance was decreased by approximately 17% at doses >50 mg/m2, 
consistent with a previous report suggesting nonlinear disposition [34]. In contrast, 
some investigators have observed the absence of dose- and time-dependency, possibly 
on the basis of sparsity of data sets [35]. It was also observed that doxorubicin 
clearance was reduced (30%) when co-administered with cyclophosphamide, which is 
in line with a previous report [36]. This interaction has been attributed to reduced 
formation of the doxorubicin 7-deoxyaglycone metabolite, and, hence, decreased 
elimination of the parent drug [37]. The administration of doxorubicin doses >50 
mg/m2 when combined with cyclophosphamide could result in greatly reduced 
doxorubicin clearance. These observations provide mechanistic support for recent 
observations in an ongoing adjuvant breast cancer clinical trial (NSABP B-30, see: 
www.nsabp.pitt.edu), where excessive toxicity, including the occurrence of toxic 
deaths, was noted in the original TAC regimen combining doses of doxorubicin 60 
mg/m2, docetaxel 60 mg/m2, and cyclophosphamide 600 mg/m2. However, similar 
events were not observed in another breast cancer adjuvant trial that used TAC doses 
of 50, 50, 500 mg/m2, respectively [38]. In contrast to cyclophosphamide, taxanes in 
the tested schedules had no apparent effect on the clearance of doxorubicin by 
univariate analysis but could not be tested in multiple linear regression analysis 
because of confounding predictor variables. We could therefore not confirm previous 
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observations describing effects of docetaxel or paclitaxel on doxorubicin 
pharmacokinetics [15,16].  
 Similar to most other chemotherapeutic agents, in the entire population studied, 
dose calculations based on BSA did not significantly reduce interpatient variability in 
doxorubicin clearance. However, doxorubicin clearance was approximately 20% 
higher in patients with BSA >1.97 m2 (P=0.061) and BMI ≥30 kg/m2 (P=0.045). It is 
noteworthy in this context that a previous study involving 21 patients indicated that 
drug clearance was reduced by almost 50% in 7 obese females, where obesity was 
defined as greater than 130% of IBW [39]. This observation was not confirmed in the 
present investigation both for females and males in a broader patient population. 
Doxorubicin clearance was unaltered in 10 elderly patients, consistent with previous 
findings in 9 elderly patients [40]. However, another study involving 56 patients, 7 of 
whom were aged ≥70 years, showed a linear association between age and clearance, 
although complete overlap in clearance values was observed in patients between the 
ages of 40-80 years [41].  
 In the case of docetaxel, a multiple regression analysis revealed a 20% decrease in 
clearance in the presence of doxorubicin. Although the mechanistic basis for this 
interaction is unknown, it may be clinically significant considering the notion that a 
25% decrease in docetaxel clearance significantly increases the odds for development 
of febrile neutropenia [42,43]. It provides a further explanation for the severe 
haematological toxicity observed in regimens combining doxorubicin with docetaxel. 
 Similar to doxorubicin, normalization of docetaxel clearance to BSA resulted in 
negligible reduction in variability in clearance. However, also similar to doxorubicin, 
docetaxel clearance was increased by approximately 33% in patients with BSA >2.0 
m2 (P=0.0029); this association was not observed, however in obese patients with BMI 
values ≥30 kg/m2 (P=0.15) despite 15 of 21 patients being identical in the 2 
subcategories. It thus remains unclear if docetaxel clearance is altered in obese 
patients. It is still debatable whether the interpatient variability of docetaxel clearance 
has a clinically meaningful relationship with BSA. Although Bruno and colleagues 
reported that BSA is a significant covariate for docetaxel clearance [43], the only 
clinically relevant variables that impact significantly upon clearance of this drug are 
altered levels of transaminases and alkaline phosphatase [42]. Thus, although 
docetaxel clearance may be weakly related to BSA, this measure does not contribute 
substantially to explaining interindividual pharmacokinetic variability.  
 In the present population, docetaxel clearance does not appear to be significantly 
reduced in elderly patients, which lends further support to a population 
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pharmacokinetic analysis indicating that age is not a significant covariate for clearance 
[42,43]. In contrast, a previous investigation in a group of 226 patients with equal 
histopathologic conditions has shown a significant decline in the content of the main 
docetaxel-metabolizing enzyme (i.e., cytochrome P450 3A) in patients after 70 years 
of age [44]. A confirmatory multi-institutional trial that includes phenotyping for 
cytochrome P450 3A is currently being conducted in patients of different age groups.  
 Although recent investigations have provided evidence against the use of BSA in 
anticancer drug dosing [3-12], there may be some situations, in the absence of more 
accurate and validated dosing strategies, where BSA-based dosing is relevant. For 
example, the present investigation observed an increase in drug clearance at the upper 
extremes of body-size; for the studied agents, under these circumstances, normalizing 
drug dose to BSA could account for some of the variability in clearance. In addition, 
the data does not justify the capping of BSA at 2.0 m2 or using ideal-body weight in 
the formula for BSA when calculating drug dose for obese patients. Alternative weight 
descriptors for dose adjustment of these anticancer agents in obese patients are being 
evaluated as recently described [45].  
 In conclusion, the current analysis confirms a number of findings previously 
described by conventional pharmacological analyses in smaller numbers of patients. 
The current statistical evaluation also has eliminated several candidate covariates from 
further consideration as important determinants of drug disposition. It is difficult to 
make specific recommendations for dosing changes of doxorubicin- or docetaxel-
containing chemotherapeutic regimens on the basis of the current findings. Although 
monitoring of plasma levels and dosage adjustment may be necessary to optimize 
anticancer efficacy in patients, therapeutic drug monitoring is not routinely available 
for these agents. Regardless, the described data continue to increase our knowledge on 
these clinically important drugs, and provide the basis for designing future, 
prospective investigations aimed at evaluating alternative and improved dosing 
regimens.  
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Abstract 
 
 Background: Variable response to cancer chemotherapy is related, in part, to 
interindividual variation in expression of the enzyme cytochrome P-450 3A (CYP3A). 
The aim of this study was to identify the demographic, physiologic, and inheritable 
factors that influence CYP3A activity in a large population of patients with cancer. 
 Methods: A total of 134 patients (62 females; age range, 26 to 83 years) underwent 
the erythromycin breath test as a phenotyping probe of CYP3A. Genomic DNA was 
screened for 6 variants of suspected functional relevance in the CYP3A4 and CYP3A5 
genes.  
 Results: CYP3A activity varied up to 14-fold in this population, and was not 
significantly influenced by age, sex, and body size measures. Likewise, no variants in 
the CYP3A4 and CYP3A5 genes was a significant predictor of CYP3A activity. 
CYP3A activity was reduced by approximately 50% in patients with concurrent 
elevations in liver transaminases and alkaline phosphatase or elevated total bilirubin; 
in a multivariate analysis, liver function combined with the concentration of the acute-
phase reactant, alpha-1 acid glycoprotein, explained approximately 18% of overall 
variation in CYP3A activity.  
 Conclusion: These data suggest that baseline demographic, physiologic and 
genetic factors have only a minor impact on phenotypic CYP3A activity in patients 
with cancer. Consideration of additional factors, including the inflammation marker C-
reactive protein as well as concomitant use of other drugs, food constituents, and 
complementary and alternative medicine with inhibitory and inducible effects on 
CYP3A, is needed to reduce variation in CYP3A and response to chemotherapeutic 
treatment of cancer. 
 
 Cancer chemotherapy is characterized by wide variation in response among 
patients. This is due, in part, to pharmacokinetic variability. The most widely used 
strategy to decrease pharmacokinetic variability is to normalize a drug dose to the 
patient’s body-surface area (BSA). Because BSA-based dosing strategies do not 
reduce interindividual variability in anticancer drug pharmacokinetics [1], other 
measures to predict drug disposition and effects are needed. As cytochrome P-450 3A 
(CYP3A) is involved in the metabolism of approximately 50% of all prescribed drugs 
[2], including many anticancer agents, phenotyping strategies to predict an individual’s 
CYP3A activity prior to cytotoxic chemotherapy treatment is one approach for dose 
individualization. Various noninvasive in vivo probes for evaluating CYP3A activity 
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have been described and several have been shown to correlate with drug clearance [3]. 
The most widely tested and accepted CYP3A probes are midazolam and erythromycin, 
although selection of the ideal CYP3A phenotyping probe remains controversial [4,5]. 
 Little is known regarding factors affecting CYP3A activity in cancer patients. 
Rivory and colleagues noted an association between the inflammatory response and 
CYP3A activity, which was assessed using the erythromycin breath test (ERMBT), in 
40 patients with advanced cancer [6]. CYP3A activity was inversely correlated with 
both inflammatory markers C-reactive protein and α-1 acid glycoprotein (AAG), with 
the former accounting for 44% of interpatient variation. In the current study, the 
influence of patient characteristics, including age, body size, liver function and sex, the 
acute phase reactant AAG, and CYP3A4 and CYP3A5 genotype on CYP3A activity, 
as assessed using the ERMBT, was explored in 134 patients with advanced cancer. 
 
Methods 
 
Patients 
 Patients were enrolled to one of 2 clinical protocols where the ERMBT was 
administered at baseline (see below) prior to initiation of chemotherapy treatment. 
Patients had advanced cancer (histologically or cytologically confirmed malignancy). 
Criteria for inclusion of patients into this study were: 1) age ≥ 18 years; 2) 
performance score (PS) ≤ 3 according to the Eastern Cooperative Oncology Group 
criteria; and 3) creatinine ≤ 2.0 × the institutional upper limit of normal (ULN). 
Patients with varying degrees of liver impairment were included in this study and 
grouped according to the following: liver function group 1, total bilirubin < 1.5 × ULN 
and no elevations in aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) or alkaline phosphatase as described for groups 2, 3A, and 3B; liver function 
group 2, total bilirubin < 1.5 × ULN, elevations in AST and/or ALT > 1.0 × ULN 
concurrent with alkaline phosphatase ≥ 2.5 × ULN, or AST and/or ALT ≥ 1.5 × ULN 
concurrent with alkaline phosphatiase > 1.0 × ULN, or isolated elevations of AST 
and/or ALT or alkaline phosphatase ≥ 5.0 × ULN; liver function group 3A, total 
bilirubin < 1.5 × ULN, concurrent elevations in AST and/or ALT ≥ 1.5 × ULN 
concurrent with alkaline phosphatase ≥ 2.5 × ULN; group 3B, total bilirubin ≥ 1.5 × 
ULN with any elevations in liver transaminases or alkaline phosphatase. 
 Patients were not eligible for the clinical trial conducted in Baltimore, MD, 
Washington D.C., and Rotterdam and Leiden, the Netherlands (study protocol 1) if 
they were concurrently taking phenytoin, carbamazepine, barbiturates, rifampin, 
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phenobarbital, St. John’s wort, and/or ketoconazole. Patients enrolled to the clinical 
trial in Sydney, Australia (study protocol 2) were eligible if they were concurrently 
taking medications that were known to induce or inhibit CYP3A activity. The dose, 
frequency and duration of all concomitant drugs were recorded. The clinical protocols 
were approved by the local institutional review boards (Baltimore, MD, Washington, 
DC, Rotterdam and Leiden, the Netherlands, and Sydney, Australia), and all patients 
provided written informed consent before enrollment. 
 Pretreatment evaluations included in this study were performance status, height 
(HT), weight (WT), and the following serum chemistries: serum creatinine, alkaline 
phosphatase, AST, ALT, total bilirubin, and AAG. Body surface area (BSA) was 
calculated using Mosteller’s formula, BSA = [HT(cm) × WT(kg) ÷ 3600]0.5 [7]. Body 
mass index (BMI) was calculated using the formula, BMI = [WT(kg) / (HT/100)2]. 
 
Erythromycin Breath Test (ERMBT) 
 For study protocol 1, the ERMBT dose and collection balloons were obtained from 
Metabolic Solutions. The dose consisted of 0.04 mg [14C-N-methyl]-erythromycin, 
containing 3 µCi of radioactivity, dissolved in 4.5 mL of 5% dextrose solution. The 
dose was administered as an intravenous injection over approximately 1 min. Breath 
samples were collected in balloons post-injection at 5, 10, 15, 20, 25, 30 and 40 min. 
Samples were shipped to Metabolic Solutions (Nashua, NH) for measurement of 
breath carbon dioxide. The data was reported as the flux of 14CO2, expressed as a 
percentage of dose exhaled per min, at each collection time point assuming a CO2 
output of 5 mmol/min per m2 of BSA [8]. 
 For study protocol 2, ERMBT was performed as described previously [9]. Briefly, 
4 µCi of 14C-erythromycin (N-methyl-14C, 55 mCi/mmol, NEN Life Science Products 
Inc, Boston, MA) was administered as an intravenous injection and breath samples 
were collected into gas-tight balloons (Pytest, Ballard Medical Products, UT) post-
injection at 5, 10, 15, 20, 25, 30 and 40 min. Breath samples were processed by 
bubbling the collected gas through a capture solution consisting of hyamine hydroxide 
10X (Packard, Sydney, NSW, Australia) in 50:50 (v/v) methanol:ethanol to which a 
trace of phenolphthalein was added. After the addition of scintillation solution (Ultima 
Gold, Packard, Sydney, NSW, Australia) and counting, the data was reported as the 
flux of 14CO2, expressed as a percentage of dose exhaled per min, at each collection 
time point assuming a CO2 output of 5 mmol/min per m2 of BSA [8]. 
 The conventional ERMBT parameter, the flux at 20 min (C20min) was the observed 
value. The area under the flux curve from time zero to 40 min (AUC0-40min) was 
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determined using the linear trapezoidal method. The ERMBT parameter, 1/Tmax, was 
determined as described previously [9,10]. A mono-exponential equation was fitted to 
the % dose 14C exhaled/min-time data and the time of the maximum % dose 14C 
exhaled/min (Tmax) was estimated. For some patients, the profiles had not reached a 
maximum and were still increasing at 40 min. In these cases, Tmax was set at 50 min, as 
previously recommended [6]. 
 
Genotyping Procedures 
 DNA was isolated from 3 to 5 mL of whole blood using a QIAamp DNA Blood 
Midikit or from 1 mL plasma using a QIAamp UltraSens Virus Kit (Qiagen, Valencia, 
CA). DNA was amplified using polymerase chain reaction (PCR) based techniques. 
Restriction fragment length polymorphisms (RFLP) analysis was used to identify 
variations in the CYP3A4 (CYP3A4*1B, CYP3A4*6, CYP3A4*17, and CYP3A4*18) 
and CYP3A5 (CYP3A5*3C and CYP3A5*6) genes as previously described [11]. For 
the CYP3A5*6 assay, samples were first analyzed for the CYP3A5*3C variant in 
duplicate. Subsequently, only samples with at least one wild type allele (*1/*1 and 
*1/*3 genotypes) were then analyzed for the CYP3A5*6 variant. Samples with the 
CYP3A5*3C genotype *3/*3 were assigned the wild type genotype for CYP3A5*6.  
 
Statistical Considerations 
 ERMBT parameters were summarized as the mean, 95% confidence level, and 
range. Values for age were grouped as < 70 and ≥ 70 (elderly) years. Values for BSA 
and AAG were grouped as: lower quartile, interquartile range, and upper quartile. 
Values for BMI were grouped as: < 25 (normal weight), 25 – 29.9 (overweight), ≥ 30 
(obese). For continuous variables, nonparametric tests were used to compare mean 
values between different groups. When 3 or more groups were compared, a trend test 
was used [12]. Univariate correlation analysis was performed using the software 
program JMP version 3.2.6 (SAS Institute, Carey, NC). Although this analysis was 
mainly exploratory in intent, an adjustment was used to evaluate the significance of the 
multiple comparisons (5 demographic characteristics, 2 genotypes). Probability values 
(two-sided) of less than 0.007 were regarded as statistically significant, and those less 
than 0.05 were considered a trend. 
 Multiple linear regression models were then used to assess the influence of age, 
body size (BSA, BMI), liver function group, sex, AAG, and CYP3A4 and CYP3A5 
genotype (predictor variables) on ERMBT parameters (outcome variables). Age, body 
size and AAG were included as continuous variables; liver function group, sex, and 
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CYP3A4 and CYP3A5 genotype were included as categorical variables. Regression 
coefficients, 95% confidence intervals, and the associated P-values were determined 
from the multiple linear regression modeling. Stepwise backward elimination was 
performed to systematically exclude the least significant factors until the P-value was 
< .05. Multiple linear regression modeling was performed using the software program 
Stata version 8.2 (Stata Corp., College Station, TX). For this analysis, the a priori 
level of significance was set at P < .05. 
 
Table 1. Patient characteristics 
Characteristics Number of Patients 
Age (years) 61 (26 - 83)a 
< 70 99 
≥ 70 35 
Body surface area (m2) 1.85 (1.39 – 2.52)a 
Body mass index (kg/m2) 25 (17 - 44)a 
< 25 65 
25 – 29.9 49 
≥ 30 20 
Race/ethnicity  
Black 7 
White 127 
Sex  
Females 62 
Males 72 
α-1 acid glycoprotein (x ULN) 1.08 (0.33 – 2.36)a 
Liver function group  
1 102 
2 14 
3A 12 
3B 6 
Primary Tumor  
Lung 34 
Breast 33 
Head and Neck 20 
Genitourinary 17 
Gastrointestinal 10 
Unknown 9 
Melanoma 7 
Angiosarcoma 4 
aData are values for median (range) 
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Results 
 
Patients 
 A total of 134 patients with cancer (62 females and 72 males) was included in this 
study (Table 1). The median age was 61 years (range, 26 to 83 years), and 35 patients 
were 70 years or older. The majority of the population was of European descent and 7 
patients were African American. Twenty patients were obese with a BMI ≥ 30 kg/m2 
and 32 patients had elevated liver function tests as defined for liver function group 2 
(N = 14), liver function group 3A (N = 12) and liver function group 3B (N = 6).  
 
CYP3A Phenotype 
 The ERMBT parameters were similar between the 2 study protocols: C20min, 0.047 
versus 0.048 % dose/min (P = .5615); AUC0-40min, 1.57 versus 1.69 % dose/min (P = 
.3294); and 1/Tmax , 0.062 versus 0.061 min-1 (P = .2036). C20min and AUC0-40min were 
highly correlated (R2 = .9657, P < .0001), whereas C20min and 1/Tmax were less strongly 
correlated (R2 = .2578, P < .0001). In this population of cancer patients, interpatient 
variation in CYP3A activity was 50-fold and 10-fold as determined by values for 
AUC0-40min and 1/Tmax, respectively (Figure 1 and Table 2); this extent of interpatient 
variation was observed in patients with normal liver function as defined for liver 
function group 1. In consideration of patients with ERMBT parameter values at the 
extreme of the population, values for AUC0-40min and 1/Tmax for 95% of the population 
varied 14-fold (0.240 – 3.30 % dose/min) and 5-fold (0.020 - 0.10 min-1), respectively. 
 
CYP3A Genotype 
 Genotype and allele frequencies for 4 variants of CYP3A4 and 2 variants of 
CYP3A5 are summarized in Table 3. All patients were wild type for CYP3A4*6 (n = 
120), CYP3A4*17 (n = 116), and CYP3A4*18 (n = 122). For CYP3A5*6, no patients 
were homozygous variant, 2 were heterozygous variant, and 119 patients were wild 
type; the 2 heterozygotes were African American. Because of the low frequency, 
genotypes for CYP3A4*6, CYP3A*17, CYP3A4*18, and CYP3A5*6 were not 
included for genotype-phenotype association analysis as shown below. For 
CYP3A5*3C, 2 patients was wild type (*1/*1 genotype), 19 patients were 
heterozygous variant (*1/*3 genotype), and 100 patients were homozygous variant 
(*3/*3 genotype); 6 of 6 African Americans and 15 of 115 white subjects carried at 
least one *1 allele, respectively. 
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 For CYP3A4*1B, 106 patients were wild type, 12 patients were heterozygous 
variant, and no patients were homozygous variant; 4 of 6 African Americans were 
heterozygous variant. 
 
Predictors of CYP3A Activity 
 CYP3A activity was reduced by approximately 50% in patients in liver function 
groups 3A and 3B (P < .001 for trend) (Table 2). Consequently, for univariate 
association analysis between patient characteristics, CYP3A4/5 genotype and CYP3A 
activity, patients in liver function groups 3A and 3B were excluded (Table 3). CYP3A 
activity was similar in patients aged 70 years or older compared to those less than 70 
years of age (P > .3726), at the upper extreme of BSA values (P > .092 for trend) and 
in obese patients (P > .162 for trend). CYP3A, as determined from the parameter 
AUC0-40min, was higher in females compared to male patients (1.92 versus 1.56 % 
dose/min, P = .0063); the ERMBT parameters C20min and 1/Tmax showed a trend for 
difference according to sex (P = .0120 and .0491, respectively). Analysis of AAG 
values in the 3 quartile groups showed that only the ERMBT parameter 1/Tmax was 
associated with AAG (lower quartile, mean = 0.077 min-1; interquartile range, mean = 
0.065 min-1; upper quartile, mean = 0.055 min-1; P = .001 for trend). There was a trend 
for lower CYP3A activity in patients with AAG concentrations in the upper quartile 
compared to patients with AAG values below the 75% quantile (C20min, 0.053 versus 
0.042 % dose/min, P = .0481; AUC0-40min, 1.82 versus 1.43 % dose/min, P = .0560; 
1/Tmax, 0.067 versus 0.055 min-1, P = .0057). CYP3A activity was not associated with 
CYP3A5*3C genotype (P > .2954) or CYP3A4*1B genotype (P > .1680). 
 As BSA and BMI were highly correlated (R2 = .3794, P < .0001), only BSA was 
included as a body size indicator in the multivariate models. In addition, because of the 
small number of observations and similar values for CYP3A activity in liver function 
groups 3A and 3B, these 2 groups were combined for multiple linear regression 
analysis. Observations for BSA, sex, liver function group and AAG concentration 
were available for 126 patients. When CYP3A4 and CYP3A5 genotype were added to 
the model, observations were available for 115 individuals; because no association was 
noted between CYP3A4*1B and CYP3A5*3C genotype and ERMBT parameters 
values (P > .2719, Table 4), CYP3A4 and CYP3A5 genotypes were not included in the 
multiple linear regression analysis. After stepwise backward deletion, age, BSA, sex 
and were removed from the final model for the 3 ERMBT outcome variables (C20min, 
AUC0-40min, and 1/Tmax).  
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AAG and liver function group 3A/B were predictors of CYP3A activity, where the 
multivariate model explained approximately 18% of overall variation in CYP3A 
activity (Table 4). Both AAG and liver dysfunction were negatively correlated with 
CYP3A activity. Liver impairment had the most profound effect on CYP3A activity 
(coefficient = -.798; P < .001); assuming an average AUC0-40min value of 1.61 % 
dose/min, this represents a 50% reduction in CYP3A activity, which is consistent with 
that observed from the univariate association analysis (Table 2). 
 
Table 5. Multiple regression models for ERMBT parametersa  
 n Coefficient 95% Confidence Interval P value 
C20min (% dose/min)     
Intercept  .0621 .0512 to .0729 < .001 
α-1 acid glycoprotein (× ULN) 126 -.0107 -.0200 to -.00140 .024 
Liver function group     
1b 99    
2 11 .0134 -.00097 to .0277 .067 
3A & 3B 16 -.0228 -.0349 to -.0107 < .001 
Overall model  R2 = .1765, P < .0001 
AUC0-40min (%dose/min)     
Intercept  2.14 1.75 to 2.53 < .001 
α-1 acid glycoprotein (× ULN) 126 -.385 -.717 to -.0534 .023 
Liver function group     
1b 99    
2 11 .465 -.0471 to .976 .075 
3A & 3B 16 -.798 -1.23 to -.365 < .001 
Overall model  R2 = .1720, P < .0001 
1/Tmax (min-1)     
Intercept  .0833 .0722 to .0944 < .001 
α-1 acid glycoprotein (× ULN) 126 -.0174 -.0269 to -.00786 < .001 
Liver function group     
1b 99    
2 11 .00580 -.00888 to .0205 .436 
3A & 3B 16 -.0192 -.0316 to -.00677 .003 
Overall model  R2 = .1799, P < .0001 
 
Abbreviations: n, number of patients; aERBMT parameter value is lower with a negative 
coefficient value; bIncluded as baseline category. 
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Discussion 
 
 There has been great interest to evaluate genotyping methods as a tool to predict 
CYP3A activity in individuals, as this is generally less cumbersome than phenotyping 
methods and require only one single blood sample. In adults, CYP3A4 and CYP3A5 
are the most important among the four CYP3A subfamily members for CYP3A-
mediated drug metabolism [13-15], and because of the genetic diversity in the genes 
encoding these proteins [16], genotyping for CYP3A4 and CYP3A5 variants may be 
useful for prediction of total hepatic CYP3A activity. The CYP3A5 protein isoform is 
known to be expressed in only 10 to 30% of Caucasians due to a splice variant in 
intron 3 of the CYP3A5 gene at nucleotide position 6986 (CYP3A5*3C) [17,18]. 
Approximately 85 to 95% of the White population and 35 to 45% of the Black 
population are homozygous for CYP3A5*3C and thus deficient in CYP3A5 [17-19]. 
Another splice variant (CYP3A5*6), which is observed in black populations also, 
results in lack of CYP3A5 expression [17,18]. Genetic differences may also explain 
60-90% of the observed variation in CYP3A4-mediated drug metabolizing capacity 
between patients [16]. Over 30 single nucleotide polymorphisms (SNPs) in CYP3A4 
have been published, representing alleles CYP3A4*1 to CYP3A4*19, most of which 
are very rare and unlikely to impact on CYP3A4 activity in vivo. The best 
characterized variant, a promoter variant with an A to G transition at nucleotide -392 
(CYP3A4*1B), was shown in vitro to have increased transcriptional activity [16,20] 
This variant exhibits interethnic variation with allele frequencies of 2-10% in subjects 
of European descent and 35-84% in subjects of African descent [17,20-37]. Three 
other CYP3A4 polymorphisms (CYP3A4*6, CYP3A4*17, and CYP3A4*18) have 
been shown in vitro to result in functional changes in CYP3A activity [38,39].  
 In the present study, no association was noted between the CYP3A5*3C and 
CYP3A4*1B variants and CYP3A activity. This is similar to findings in healthy 
subjects using the CYP3A phenotyping probes midazolam [29,34,40,41], 
erythromycin [34,35], and nifedipine [35,42]. Since the majority of patients studied 
here were of European descent, one cannot rule out that genetic differences in 
CYP3A5 and CYP3A4 may contribute to CYP3A activity in African Americans, 
considering the frequencies of CYP3A5*3C and CYP3A4*1B in this racial/ethnic 
population. This is not supported, however, by one study involving healthy subjects 
that included a population where the majority of subjects were African American (34 
of 57 subjects); no association between CYP3A5*3C and CYP3A4*1B genotype and 
CYP3A activity was observed using the ERMBT and by assessment of midazolam 
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clearance [34]. Due to the lack of CYP3A4*6, CYP3A4*17, and CYP3A4*18 variants 
in the present study, these polymorphisms most likely have no relevance to CYP3A 
activity in Caucasian populations. 
 Even though CYP3A4 variants did not explain variation in CYP3A activity in this 
predominantly Caucasian population, a consensus is building that human variation in 
CYP3A4 activity may be caused by polymorphisms in transcription factors that 
regulate CYP3A4, such as pregnane X receptor (PXR) and constitutive androstane 
receptor (CAR) [43]. Several variants in human PXR gene, NR1I2, have been 
identified with altered transactivation activity [18,44]. However, these variants are 
extremely rare in Black and White populations (0 - 1.6%) and it is unlikely that they 
explain the variation in CYP3A4 expression. 
 In the current study, CYP3A activity was unaltered in patients with mild 
elevations in liver function tests (group 2), but was reduced by approximately 50% in 
patients with moderate to severe liver impairment as defined for liver function groups 
3A and 3B. Interestingly, categorization of liver function tests for group 3A was 
described by Bruno et al for prediction of docetaxel clearance [45,46]; patients with 
total bilirubin < 1.5 × ULN but elevations in liver transaminases (≥ 1.5 × ULN) 
concurrent with elevated alkaline phosphatase (≥ 2.5 × ULN) where shown to have 
reduced docetaxel clearance by 25%. The same categorization of liver function tests to 
describe liver impairment was also associated with reduced CYP3A activity in the 
present study. However, liver function tests are not accurate in prediction of CYP3A 
activity as patients with the lowest CYP3A activity had normal liver function (group 
1). The use of the ERMBT as a phenotypic probe has been questioned as conflicting 
reports on its ability to predict the total body clearance of probe drugs have been 
reported [4,47], although a study in 20 patients with sarcoma showed that the ERMBT 
predicted docetaxel clearance in those with greatly reduced drug clearance [48]. 
Nevertheless, despite the limitations of the ERMBT, results of the present study 
demonstrate that patients with low breath levels of 14CO2 have low CYP3A function 
and are likely to have reduced CYP3A-mediated drug clearance. 
 Because of large variations in concentrations of the acute phase reactant protein 
AAG in cancer patients (7-fold), it has been hypothesized that decreased hepatic 
clearance by CYP3A in some individuals might be a consequence of an inflammatory 
response [49]. In the present study, AAG was associated with CYP3A activity in both 
univariate and multiple regression analysis. However, combined with liver function, 
only 18% of CYP3A variation was explained by these 2 variables. Previously, a better 
correlation was observed between C-reactive protein and CYP3A activity compared to 
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AAG [6]. Assessment of C-reactive protein, a more specific marker of inflammation, 
may have accounted for more of the variation in CYP3A activity in this population of 
cancer patients. 
 In the present study, BSA and BMI were not correlated with CYP3A activity 
providing further support that BSA has no relevance to anticancer drug dosing [1]. 
However, alterations in anticancer drug clearance have been noted in obese patients 
and those at the upper extreme of body size, such as for doxorubicin and docetaxel 
[50]. Other factors in addition to CYP3A activity, such as changes in volume of 
distribution, may contribute to altered drug disposition in obese patients [51]. 
Prospective pharmacokinetic and pharmacodynamic evaluations of anticancer drugs in 
obese patients are required to determine the effect of altered body size and 
composition on drug disposition and determination of alternative doseing strategies. 
 The influence of age on the expression and activity of drug-metabolizing enzymes 
remains controversial with reports describing either a decline in activity or no change 
in activity in elderly patients [52-54]. In the current study, CYP3A activity was shown 
to be similar in patients aged less than 70 years (n = 99) and 70 years or older (n = 35). 
Prior in vitro studies have suggested an age related decline in CYP3A activity [55]. 
However, our results are consistent with an in vivo study that applied the ERMBT as a 
phenotyping probe of CYP3A-mediated drug clearance where no decrease in CYP3A 
activity was observed as a function of age in 39 older hypertensive men [54]. 
 Many drugs that are substrates of CYP3A show higher clearance in women than in 
men [56-58]. In concordance with this observation, previous studies have shown 
approximately 20 to 25% higher CYP3A activity in females than males using the 
ERMBT [8,34,52]. However, it has been suggested that this observation is due to one 
limitation of the ERMBT, the assumption that individuals (both females and males) 
produce 5 mmol of CO2/min per m2 at rest [10]. Reanalysis of previously published 
data evaluating the calculation of CO2 output in different populations revealed an 
approximately 20% lower rate of CO2 production in females, which is consistent with 
the 20 to 25% difference observed in ERMBT results between the two sexes [10]. In 
the present study, females were found to have approximately 15 to 20% higher 
CYP3A activity than males in univariate analysis, but the association was not 
significant in multiple regression analysis. Interestingly, a recent study of 94 surgical 
liver samples found 2-fold higher CYP3A4 protein content and higher expression of 
CYP3A4 messenger RNA transcripts in female compared with male samples [59]. 
Regardless of apparent sex-related differences in CYP3A activity, the same range of 
wide interpatient variation in CYP3A activity was observed in both female and male 
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cancer patients (Table 4), indicating that dosing strategies for drugs cleared by CYP3A 
should focus on the individual and not necessarily sex. 
 One additional factor to consider is the influence of drug-interactions on 
interpatient variation in CYP3A activity. There is considerable motivation for 
understanding adverse drug interactions with anticancer agents because of their narrow 
therapeutic index. Usually, such interactions arise as a result of altered 
pharmacokinetics of the drugs involved. Careful examination of the concomitant drug 
profiles for drugs that are substrates, inhibitors or inducers of CYP3A did not reveal an 
association with results of the ERMBT in the entire population or upon analysis of 
values in the lower and upper quartiles. In addition, many botanical dietary 
supplements contain pharmacologically active phytochemicals, and to date, numerous 
herb-drug interactions have been described in the medical literature [60,61], and are 
most commonly pharmacokinetic in nature. Availability of this type of information is 
particularly relevant to the treatment of cancer patients who are known to take a wide 
variety of complementary and alternative medicine (CAM) concomitantly with their 
chemotherapeutic regimen [62]. However, little information is available from 
prospective evaluation of drug interactions between CAM and anticancer agents to 
help guide the use of CAM in cancer patients receiving chemotherapy [63]. To 
complicate matters further, the current study protocol conducted in the United States 
and the Netherlands included a list of CAM to review with each patient prior to study 
enrollment; however, of 80 patients enrolled on this protocol, no patients were 
documented to be taking CAM. Since various studies have documented the extensive 
use of CAM in cancer patients, and that fewer than 40% of patients disclose their 
herbal supplement usage to health care providers [64], ways to ensure accurate and 
complete documentation of CAM use by patients enrolled to clinical trials is urgently 
needed. 
 In conclusion, the current investigation has identified liver function and AAG 
concentration in plasma as significant predictors of CYP3A activity in patients with 
cancer. However, these two factors combined explained only 18% of overall variation 
in CYP3A activity. Consideration of additional factors, including C-reactive protein as 
well as the concomitant use of other drugs, food constituents, and CAM with 
inhibitory and inducible effects on CYP3A, may account for variation in CYP3A 
activity in cancer patients. Furthermore, the influence of genetic polymorphisms in 
transcription factors that regulate the inhibition and induction of CYP3A expression by 
co-administered agents is currently not known. In light of the present results noting no 
significant genotype-phenotype associations, CYP3A phenotyping strategies should 
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provide the most clinically relevant information reflecting the combined effects of 
genetic, environmental, and endogenous/ physiological factors on drug disposition and 
effects. 
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Abstract 
 
 Objective: Our objectives were to study the extent of docetaxel binding to plasma 
in the presence and absence of its excipient, polysorbate 80 (Tween 80), in vitro and to 
evaluate the pharmacokinetics of unbound docetaxel in vivo. 
 Methods: Equilibrium-dialysis was used for determination of the fraction unbound 
docetaxel (fu), and was applied to study the pharmacokinetic behavior of unbound 
docetaxel in 23 cancer patients receiving an intravenous infusion of the drug 
formulated in polysorbate 80 (Taxotere). 
 Results: Polysorbate 80, added at clinically relevant concentrations (up to 1.0 
µL/mL), increased fu in vitro by 13% (7.84 ± 0.0752% versus 6.95 ± 0.0678%, P < 
0.00001). Similarly, fu calculated on the basis of the observed AUC values [fu(AUC)] in 
vivo was 12% higher than fu in pretreatment samples [fu(pre)] (6.00 ± 1.03% versus 5.49 
± 1.01%, P = 0.38). Of various serum proteins evaluated, only α1-acid glycoprotein 
was significantly related to fu (P < 0.0018), with higher fu in the presence of lower 
protein levels. Total docetaxel clearance was related to α1-acid glycoprotein (R2 = 
0.13, P = 0.58), fu(pre) (R2 = 0.15, P = 0.39) and fu(AUC) (R2 = 0.29, P = 0.0048).  
 Conclusion: This study demonstrates that the plasma binding of docetaxel is 
influenced by both α1-acid glycoprotein and its formulation vehicle. Further 
investigation is required to resolve the potential clinical significance of these 
observations. 
 
Introduction 
 
 The use of nonionic surfactants like Cremophor EL and polysorbate 80 (Tween 
80) as pharmaceutical formulation vehicles has become an area of increasing interest 
in the development of poorly water-soluble agents and has significant implications for 
their pharmacokinetic behavior [1,2]. There are several factors contributing to the 
complexity of the pharmacological handling of drugs delivered by such vehicles after 
intravenous administration, including the fact that the circulating drug is present in 3 
distinguishable forms (i.e., vehicle associated, protein-bound, and protein-unbound) 
and that clearance occurs as a result of various processes with different elimination 
rates (i.e., distribution of vehicle micelles carrying the drug, leaking of drug from the 
micelles, and clearance of unbound drug). Therefore it has been argued that 
pharmacokinetic studies with such agents limited to the analysis of total drug 
concentrations in plasma are not informative enough and may even be misleading, 
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because the pharmacodynamic effects are mainly related to the level of free drug in 
plasma [3]. A very small number of reports have addressed this issue for anticancer 
agents formulated in nonionic surfactants, including the antimicrotubule agent 
paclitaxel (Taxol), which is formulated for clinical use in a mixture of Cremophor EL-
ethanol. These studies have demonstrated that the principal fraction of drug present in 
the circulation remains entrapped within the hydrophobic interior space of the carrier 
system [4,5]. In contrast to paclitaxel, the only other approved taxane, docetaxel 
(Taxotere), is formulated in a vehicle containing polysorbate 80 (Tween 80), and 
clinical data on binding interactions for this agent are essentially lacking [6]. 
Docetaxel was shown previously to bind extensively in vitro to serum proteins, 
including α1-acid glycoprotein (AAG), albumin and lipoproteins, in a concentration-
independent manner [7], with high AAG levels being associated with both a decrease 
in the unbound drug fraction in vitro and a decrease of total docetaxel clearance in 
vivo [7,8]. Although these combined effects were thought not to result in marked 
changes in systemic exposure to unbound docetaxel [9], a restriction of drug 
distribution in patients with high AAG or polysorbate 80 levels cannot be ruled out 
and could explain the decreased hematologic toxicity observed in these patients 
[10,11]. To further clarify the role of polysorbate 80 and serum proteins in docetaxel 
pharmacology, we now describe the development and validation of a novel assay for 
separation of unbound and bound (i.e., polysorbate 80 plus protein-associated) drug in 
plasma, as well as its implementation in a retrospective analysis of clinical samples 
from cancer patients treated with 1-hour docetaxel infusions. 
 
Methods 
 
Chemicals and reagents 
 Reference standards of docetaxel and paclitaxel were kindly supplied by Aventis 
(Vitry-sur-Seine Cedex, France) and Bristol-Meyers Squibb (Woerden, the 
Netherlands), respectively. An aliquot of the docetaxel powder was used to synthesize 
generally-labeled [3H]docetaxel (specific activity, 7.2 Ci/mmol; concentration, 2 mCi 
in 2 mL of ethanol), and was purchased from Moravek Biochemicals Inc. (Brea, Ca). 
The product was found to be radiochemically pure (~96.5%) as determined by 
reversed-phase high-performance liquid chromatography, and did not contain any 
detectable levels of contaminating tritiated water (not shown). Polysorbate 80 was 
obtained from Sigma (St. Louis, Mo), acetonitrile and methanol from Biosolve 
(Valkenswaard, the Netherlands), ammonium acetate and formic acid from Baker 
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(Deventer, the Netherlands), dimethyl sulfoxide, n-butyl chloride and tetrahydrofuran 
from Rathburn (Walkerburn, UK), and absolute ethanol from Merck (Darmstadt, 
Germany). Phosphate-buffered saline, pH 7.4 (PBS) was from Oxoid (Basingstoke, 
UK), and Emulsifier-Safe scintillation cocktail from Packard Biosciences BV 
(Groningen, the Netherlands). Water was filtered and deionized by a Milli-Q-UF 
system delivered by Millipore (Milford, Ma) and used throughout. 
 
Assay methods 
 Analytical measurement of total docetaxel concentrations was performed as 
described previously [12], whereas concentrations of [3H]docetaxel in aqueous 
solutions or biological samples were analyzed for total radioactivity (3H-cpm) by 
liquid-scintillation counting on a 1409 counter (Wallac Oy, Turku, Finland), until a 
preset time of 20 minutes was reached. Determination of the fraction unbound (fu) 
docetaxel in human plasma was performed using a previously published method for 
unbound paclitaxel [13]. In the final optimized method, 260-µL aliquots of plasma 
were dialyzed against an equal volume of PBS containing a [3H]docetaxel tracer (i.e., a 
25,000-fold dilution of the ethanolic stock in PBS) over a membrane with a 12,000-
14,000-dalton molecular weight cut-off (Spectrum Medical, Houston, Tx). Dialysis 
experiments were performed using 2-mL polypropylene Safe-Lock vials (Eppendorf, 
Hamburg, Germany) as dialysis chamber in a humidified atmosphere of 5% CO2 at 
37°C [14]. After the dialysis period, 150 µL of the PBS fraction (containing unbound 
docetaxel) and 25 µL of the plasma fraction (containing both bound and unbound 
drug) were transferred to separate 2-mL vials. To the latter, 125 µL of PBS were 
added, followed by addition of 2 mL of scintillation cocktail to all samples, vigorous 
mixing, and liquid-scintillation counting. The fu, expressed as a percentage, was 
calculated as follows: 
 
fu = [(3H-cpm PBS – 3H-cpm blank) / (3H-cpm plasma – 3H-cpm blank)] × 100 (Eq. 1) 
 
 The equilibrium dialysis method was validated by use of 2 quality-control samples 
prepared from plasma obtained from a healthy volunteer. One quality-control sample 
did not contain docetaxel, and one contained unlabeled docetaxel at a concentration of 
1 µg/mL, which represents a clinically relevant concentration achieved at the end of a 
1-hour docetaxel infusion. The within-run precision and between-run precision were 
calculated after analysis of the samples in quintuplicate on 3 separate occasions, as 
described previously [12]. The recovery of the radiolabel was calculated by comparing 
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the total amount of [3H]docetaxel observed in the plasma and PBS fractions after 
dialysis to those when added to PBS. 
 To eliminate any extent of quenching, a fixed volume of 25 µL of human plasma 
was mixed with 125 µL of PBS before quantitation in all further experiments. The 
time to equilibrium of docetaxel between proteins and plasma water was reached 
within 48 hours after start of incubation. The fu docetaxel was not significantly 
different with or without the addition of unlabeled docetaxel, with mean (± SD) values 
of 6.81 ± 0.312% and 7.01 ± 0.487%, respectively. This suggests that within a 
clinically relevant range the docetaxel concentration has no influence on the unbound 
fraction, which is consistent with previous findings [7]. With the final method, values 
for within-run and between-run precisions were less than <7.04%. It was confirmed 
that the total drug recovery was equal to amount of [3H]docetaxel added to PBS (i.e., 
>97.5% recovery). The effect of polysorbate 80 on docetaxel binding was evaluated in 
triplicate at final polysorbate 80 concentrations in the expected clinically relevant 
range of 0.010 to 1.0 µL/mL. 
 AAG concentrations in plasma samples were measured by use of a turbidimetric 
assay on a Hitachi 911 clinical chemistry analyzer (Roche, Basel, Switzerland). The 
reagents, calibrator standard, and the normal range controls were obtained from 
INstruchemie (Delfzijl, the Netherlands), whereas liquicheck I (Biorad, Veenendaal, 
the Netherlands) was used as low-range control material. The assay showed linearity 
between 0.10 and 3.00 g/L, and the between-run variation coefficients ranged from 2.0 
to 2.8%. 
 
Patient samples 
 Plasma samples were obtained from 23 patients participating in a clinical trial in 
which docetaxel was administered in combination with intravenous methotrexate. The 
eligibility and exclusion criteria and detailed clinical profiles have been documented 
elsewhere [15]. Docetaxel was preceded by an intravenous bolus of methotrexate and 
was given as a 1-hour intravenous infusion (mean, 1.02 ± 0.112 hours; range, 0.73 – 
1.27 hours) on day 1 (n = 4) or day 2 (n = 19) at dose levels of 75 (n = 19) or 85 
mg/m2 (n = 4). Blood samples for pharmacokinetic analysis were drawn from a vein in 
the arm contralateral to that used for drug administration. Samples were obtained at the 
following time points: immediately before docetaxel administration, at 30 minutes 
after the start of infusion, at the end of the infusion (typically at 1 hour), and at 1, 3, 5 
and 23 hours after the end of infusion. Blood was collected in glass tubes containing 
lithium heparin as anticoagulant and was immediately centrifuged to separate plasma, 
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which was stored at –80°C until analysis. A previous analysis has shown that the 
pharmacokinetic profile of docetaxel is unaffected by methotrexate in the dose range 
studied (30-50 mg/m2), and is similar to single agent data [6,15]. The study protocol 
was approved by the Ethics Board of the Erasmus MC (Rotterdam, the Netherlands), 
and written informed consent before study entry was obtained from all patients. 
 
Pharmacokinetic analysis 
 The individual AUC values of total and unbound docetaxel were calculated by 
noncompartmental analysis up to the last measurable time point (Tlast) by use of the 
linear-trapezoidal rule. The AUC values were extrapolated to infinity by dividing Tlast 
by the terminal disposition rate constant (λz), determined from the slope of the 
terminal phase of the concentration-time profile. Clearance was calculated by dividing 
the dose administered (in mg/m2) by the observed AUC, and the unbound fraction on 
the basis of the observed AUC values [fu(AUC)] was calculated as follows:   
 
 fu(AUC) = AUC unbound docetaxel / AUC total docetaxel  (Eq. 2) 
 
 Pharmacokinetic parameters were estimated using the software package Siphar 
v4.0 (InnaPhase, Philadelphia, Pa), and statistical analyses were done with Number 
Cruncher Statistical System 2001 (NCSS, Kaysville, UT). The cut-off level for 
statistical significance was taken at 0.05. 
 
Table 1. Extent of binding of docetaxel to human plasma, as a function of polysorbate 
80 
Polysorbate 80 µl/ml Fraction unbound  
mean ± SD (%) 
Percentage of  
reference value1 
none 6.95 ± 0.0678 100% 
0.010 6.34 ± 0.0241 91% * 
0.025 6.50 ± 0.182 93% * 
0.050 6.32 ± 0.281 91% * 
0.10 6.44 ± 0.198 93% * 
0.25 6.94 ± 0.154 100% 
0.50 7.55 ± 0.189 109% ** 
1.0 7.84 ± 0.0752 113% ** 
1 None is considered as the reference value (i.e., no polysorbate 80 added)  
* Significantly lower than none; ** Significantly higher than none (one-way ANOVA, 
followed by Duncan’s multiple range test); Data are presented as mean values ± SD of 
triplicate observations [except for none, 0.010, and 0.50 µL/mL (duplicate each)]. 
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Table 2. Patient demographic data (n=23) 
Characteristic Median Range 
Baseline screening 
Age (years)  
Sex (male/female)* 
BSA (m2) 
Height (cm) 
Weight (kg)   
WHO performance status 
 
47 
10 / 13 
1.79 
173 
69 
1 
 
27-66 
 
1.50-2.18 
152-192 
53-97 
0-2 
Pre-treatment hematology 
Hemoglobin (mM)  
Hematocrit (%)  
Leukocytes (× 109/L)  
Neutrophils (× 109/L)  
Platelets (× 109/L) 
 
7.2 
35 
8.3 
5.6 
352 
 
5.8-9.8 
31-42 
4.9-22 
2.9-20 
171-545 
Pre-treatment clinical chemistry 
AST (units/L)  
ALT (units/L)  
ALP (units/L)  
GGT (units/L)  
Total bilirubin (µM)  
Serum creatinine (µM)   
AAG (g/L) 
Albumin (g/L) 
High-density lipoprotein (mM) 
Low-density lipoprotein (mM) 
 
21 
15 
93 
41 
6 
86 
1.40 
36 
1.2 
3.2 
 
12-75 
3-76 
37-178 
13-98 
3-12 
66-130 
0.58-2.06 
30-41 
0.8-1.8 
1.7-5.3 
 
Abbreviations: n, total number of patients studied; BSA, body-surface area; WHO, World 
Health Organization; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, 
alkaline phosphatase; GGT, gamma-glutamyltransferase; AAG, α1-acid glycoprotein. 
* Data indicate number of patients. 
 
Chapter 6_____________________________________________________________ 
 106
Results 
 
In vitro results 
 As predicted by earlier experiments [7], docetaxel was found to bind extensively 
to human plasma in vitro in the absence of polysorbate 80. In the presence of 
polysorbate 80, the fu docetaxel significantly changed in an apparent concentration-
dependent, biphasic manner; at low concentrations of polysorbate 80, a small decrease 
in the fu docetaxel was observed, whereas at higher concentrations, an increase was 
noted (Table 1). The highest fu relative to the reference value was observed at a 
polysorbate 80 concentration of 1.0 µL/mL (Table 1), which caused an increase of 
13% (7.84 ± 0.0752% versus 6.95 ± 0.0678%, P < 0.00001, 1-way ANOVA). 
 
In vivo results 
 Equilibrium-dialysis was applied to plasma samples of 23 patients treated with 
docetaxel given as a 1-hour infusion (Table 2). The concentration-time profile of 
unbound docetaxel followed the same general pattern as that of total docetaxel levels. 
The overall mean value for unbound docetaxel clearance was relatively consistent in 
all patients (Table 3), suggesting a moderate degree of interindividual variability 
(coefficient of variation, 22.7%).  
 
Table 3. Summary of docetaxel pharmacokinetics (n=23)* 
Parameter Median Mean ± SD Range 
CL total (L/h/m2) 17.9 18.9 ± 5.50 10.7 – 33.0 
CL unbound (L/h/m2) 300 315 ± 71.4 188 – 446 
fu(pre) (%) 5.38 5.49 ± 1.01 3.93 – 7.93 
fu(Cmax) (%) 6.18 6.37 ± 1.50 ** 3.91 – 10.3 
fu(AUC) (%) 6.05 6.00 ± 1.03 *** 4.12 – 8.06 
 
Abbreviations: n, total number of patients studied; CL, apparent clearance; fu(pre), fraction 
unbound docetaxel in pre-treatment plasma samples; fu(Cmax), fraction unbound docetaxel at 
the peak concentration; fu(AUC), fraction unbound docetaxel based on the unbound drug to 
total drug AUC ratio; AUC, area under the plasma concentration-time curve. 
* Based on non-compartmental analysis; ** P = 0.012 versus fu(pre); *** P = 0.038 versus fu(pre) 
(paired T-test). 
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Figure 1. (A) Pattern of the fraction unbound docetaxel over time in all studied patients 
(mean ± SD), and (B) a scatterplot of the fraction unbound docetaxel in pre-treatment plasma 
samples [fu(pre-treatment)] and at docetaxel peak concentration [fu(Cmax)] in those 
patients. The solid line represents the line of identity. 
 
 
The fu docetaxel in pretreatment plasma samples (i.e. the in vitro assessment of 
binding capacity) was also moderately variable, and ranged from 3.93% to 7.93% 
(coefficient of variation, 18.4%). This fraction was time-dependent and increased 
during the infusion (Figure 1A), resulting in a 12% higher fu on the basis of the AUC 
ratio of unbound to total drug, as compared with that obtained in individual pre-
treatment plasma samples (6.00 ± 1.03% versus 5.49 ± 1.01%, P = 0.038) (Table 3). 
The estimate of the highest fu in vivo (i.e., the fraction observed at peak polysorbate 80 
concentrations) was on average 16% higher as compared with the pretreatment values 
(6.37 ± 1.50% versus 5.49 ± 1.01%, P = 0.012) (Table 3 and Figure 1B). Of the 
various serum proteins analyzed in pretreatment samples, only AAG concentration 
was significantly correlated with the observed fu docetaxel at pretreatment both in 
univariate (P = 0.0015) and multivariate regression analyses (P = 0.0018), with higher 
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fu values in the presence of lower AAG concentrations (Table 4 and Figure 2). 
Relationships were also observed between AAG concentrations and clearance of total 
docetaxel (R2 = 0.13, P = 0.058), the fu docetaxel in pretreatment samples (R2 = 0.15; P 
= 0.039), and the fu docetaxel determined based on the AUC ratio of unbound to total 
drug (R2 = 0.29; P = 0.0048) (Figure 3). 
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Figure 2. Relationship between AAG and the fraction unbound docetaxel in pre-treatment 
plasma samples [fu(pre)]. Open symbols indicate individual patient data, and the closed 
symbol represents the quality-control sample without docetaxel. The solid line is the fit from 
linear regression analysis. 
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Table 4. Relationships between patient characteristics and docetaxel pharmaco-
kinetics 
Characteristics   R2* P** 
AAG (g/L) vs fu(pre) (%) 0.36 0.0015 
Albumin (g/L) vs fu(pre) (%) <0.01 0.73 
High density lipoprotein (mM) vs fu(pre) (%) <0.01 0.30 
Low density lipoprotein (mM) vs fu(pre) (%) <0.01 0.41 
     
AAG (g/L) vs CL total (L/h/m2) 0.13 0.058 
fu(pre) (%) vs CL total (L/h/m2) 0.15 0.039 
fu(AUC) (%) vs CL total (L/h/m2) 0.29 0.0048 
 
Abbreviations: AAG, α1-acid glycoprotein; fu(pre), fraction unbound docetaxel in pre-
treatment plasma samples; fu(AUC), fraction unbound docetaxel based on the unbound drug to 
total drug AUC ratio; AUC, area under the concentration-time curve; CL, apparent clearance. 
* Regression coefficient for a least-squares linear-regression analysis; ** Probability value for 
a least-squares linear-regression analysis. 
 
 
Discussion 
 
 The standard analytical methods for measuring concentrations of drugs (including 
docetaxel) in plasma determine concentrations of drug bound to plasma proteins or 
other macromolecules (e.g., formulation vehicles), as well as free drug dissolved in 
plasma water [3]. For this reason, the relationship between total drug concentration in 
plasma and treatment outcome (i.e., toxicity and efficacy) will only be good if the 
degree of binding of the agent is constant over time and in the clinically relevant 
concentration range,or if so little drug is protein-bound that changes in binding result 
in insignificant changes in unbound concentration. Previous in vitro studies 
demonstrated that docetaxel is mainly bound to albumin and AAG, an acute-phase 
reactant, the concentration of which is highly variable in cancer patients [16], and that 
this latter protein is the main determinant of variability in docetaxel plasma binding 
[7]. Because only the unbound drug fraction is directly available for cellular 
partitioning and disposition processes, AAG concentrations might be a predictor of 
docetaxel pharmacokinetics. Indeed, Bruno et al. [8] have shown that AAG was a 
significant covariate on total docetaxel clearance in a population pharmacokinetic 
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model, in which high AAG levels were related to low docetaxel clearance. Likewise, 
AAG was shown previously to be a predictor of the severity of drug-induced 
neutropenia, in which low AAG levels were related to increased severity of 
neutropenia [10], as well as efficacy and survival in patients with non-small-cell lung 
cancer, in whom high AAG levels were related to worse outcome [11]. 
 To further study the clinical pharmacological behavior of docetaxel, a reliable 
method for the determination of unbound docetaxel fractions in human plasma 
samples was developed and validated, based on experience with a previous 
equilibrium dialysis assay for measurement of the fu paclitaxel in patient samples [13]. 
Despite the longer period of incubation needed to reach equilibrium when the 
radiolabeled docetaxel tracer is added to the buffer compartment, this method is less 
laborious and time-consuming because of the simultaneous addition of [3H]docetaxel-
containing PBS to all samples. Moreover, by estimating the recovery of the total 
amount of radioactivity added, the accuracy of the procedure can be evaluated. For 
example, in cases in which hemolytic plasma samples are to be analyzed, these can be 
diluted in blank plasma prior to the liquid-scintillation counting after dialysis, because 
slightly discolored samples will result in lower counts and, thus, an overestimation of 
the fu docetaxel. 
 The in vitro binding of docetaxel to human plasma in the absence of polysorbate 
80 was approximately 93% (unbound drug fraction, 6.95 ± 0.0678%), which is similar 
to the 92 – 94% reported previously with ultrafiltration techniques [7]. This degree of 
binding to serum proteins appears to be higher than that of the related agent paclitaxel, 
which is 87% bound in vitro [13] and 85% in vivo [17] in the absence of its 
formulation vehicle Cremophor EL. In contrast to earlier observations [7], we found 
that polysorbate 80 at clinically relevant concentrations increases the fu docetaxel from 
6.95% to 7.84% in vitro and on average from 5.49% to 6.37% at docetaxel peak 
concentration in vivo. This increase in vitro was observed at concentrations above 
those used by Urien et al. in a previous study (i.e. 0.20 µL/mL) [7]. 
 Recent investigations into the pharmacokinetic behavior of polysorbate 80 after 
docetaxel administration have shown peak levels of 0.30 mg/mL (i.e. ~0.28 µL/mL) at 
a dose of 35 mg/m2 administered as a 30-min intravenous infusion, as measured using 
liquid chromatography coupled with tandem mass-spectrometric detection [18]. The 
decline in polysorbate 80 levels after the end of infusion was rapid, with 
concentrations falling below 0.10 µL/mL within 30 minutes and below 0.010 µL/mL 
within 3 hours after the end of infusion. Overall, these results suggest that 
concentrations of polysorbate 80 during drug infusion in the current study, in which 
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docetaxel was administered at doses of 75 and 85 mg/m2, might be high enough to 
have an impact on the unbound fraction of docetaxel in patients. This is in keeping 
with recent observations that for docetaxel a minor deviation from linear distribution 
pathways exists that may be related to the presence of the nonionic surfactant [19]. 
 The mechanistic basis for the altered binding of docetaxel in the presence of high 
polysorbate 80 concentrations is as yet unclear. It is possible, however, that with time 
polysorbate 80 is able to form complexes with proteins so that the binding of docetaxel 
to plasma proteins becomes saturable on single sites [20]. Alternatively, it cannot be 
excluded that this effect is the result of a displacement interaction caused by some 
(degradation) components of polysorbate 80. Similar observations have been reported 
for the binding of several other drugs that bind with high affinity but low capacity to 
AAG in the presence of structurally-related mixed-micellar systems [21]. Interestingly, 
the effect of polysorbate 80 appears to be biphasic both in vitro and in vivo, with a 
slight decrease in the fu at low concentrations of the vehicle. The mechanism 
underlying this phenomenon is unknown. However, it is possible that two competing 
polysorbate 80-mediated mechanisms affect the fu docetaxel in opposite directions; 
that is, micellar encapsulation of docetaxel (resulting in a reduced f=u docetaxel) and 
binding-displacement by polysorbate 80 degradation products (resulting in an 
increased fu docetaxel). The former process might be predominating at low polysorbate 
80 concentrations, whereas the latter may become increasingly important as a result of 
a proportionally increased release of polysorbate 80 degradation products, which 
interfere with the normal binding of docetaxel to plasma proteins. Most important is 
that the net effect over the entire sampling interval in vivo was a moderate increase in 
the fu docetaxel (from 5.49% to 6.00%). This overall increase is consistent with 
clinical data from a dose-finding study with a new submicronic polysorbate 80-free 
dispersion formulation of docetaxel (XRP6976L; Aventis), which suggests a lower 
incidence and severity of the dose-limiting hematologic toxicity at equimolar doses 
compared with the current polysorbate 80-containing formulation of docetaxel [22]. 
 Given that docetaxel is bound in plasma to albumin, AAG and high-density 
lipoproteins [7], we investigated the impact of the pretreatment levels of these proteins 
on drug disposition. A significant inverse relationship was observed between AAG 
concentration and fu docetaxel in pretreatment samples, with higher fractions in the 
presence of lower AAG concentrations, as has also been found in previous in vitro 
experiments [7]. No correlations were observed with other investigated proteins in 
both univariate and multivariate analyses. Similar to data from a population model for 
docetaxel pharmacokinetics [8], AAG concentration was related to clearance of total 
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docetaxel. Furthermore, the fu docetaxel in pretreatment samples was correlated with 
total clearance, and the correlation improved when the AUC ratio of unbound to total 
drug was related to the total clearance. This suggests that AAG concentration is not the 
sole predictor of the fu during docetaxel treatment. Interestingly, the fu docetaxel did 
not alter during the infusion in all patients, which might be explained by the high 
degree of interindividual variability in the rate of serum esterase-mediated metabolic 
breakdown of polysorbate 80 [23,24].  
 In conclusion, this study confirms previous observations regarding the 
involvement of AAG in the binding of docetaxel, and demonstrates that the fu 
docetaxel in human plasma is also influenced by the presence of its formulation 
vehicle, polysorbate 80, in a concentration-dependent, biphasic manner. Future studies 
will focus on the potential clinical significance of this latter observation in addition to 
the mechanisms underlying the altered docetaxel plasma binding in the presence of 
polysorbate 80. 
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Abstract 
 
 An analytical procedure is described for the simultaneous determination of the 
anticancer agent docetaxel (Taxotere) and its formulation vehicle polysorbate 80 
(Tween 80) in human plasma samples. Sample pretreatment involved a double liquid-
liquid extraction step with a mixture of CEGVQPKVTKNGPDWV[N EJNQTKFG 
 XX. 
Separation of the compounds of interest, including the internal standard paclitaxel, was 
achieved on a reversed-phase 9CVGTU :6GTTC /5 EQNWOP 
 ×  OO KPVGTPCN
FKCOGVGT RCEMGF YKVJ C zO QEVCFGE[N UVCVKQPCT[ RJCUG, using isocratic elution. 
Detection of docetaxel and polysorbate 80 was performed using tandem MS detection 
with electrospray ionization. Validation results indicated that the method is accurate 
and precise, and has lower limits of quantitation of 0.500 nM (~0.4 ng/ml) and 
µION HQTFQEGVCZGN CPFRQN[UQTDCVG TGURGEVKXGN[. The method was subsequently 
used to measure concentrations of docetaxel and polysorbate 80 in plasma samples in 
support of a project to assess the influence of polysorbate 80 concentrations on the 
disposition and toxicity profile of docetaxel in cancer patients receiving Taxotere.  
 
Introduction 
 
 Docetaxel (Taxotere) is an antineoplastic agent that acts by disrupting the 
microtubular network, and is one of the most active agents in the treatment of locally 
advanced or metastatic breast and non-small cell lung cancer [1,2]. Elimination routes 
of docetaxel are mediated by the cytochrome P450 (CYP) 3A isoforms, notably 
CYP3A4 and CYP3A5 [3], and the membrane transporter P-glycoprotein (ABCB1) 
[4]. It has been suggested that variability in expression of these proteins accounts for 
the substantial interindividual differences in drug clearance [5], and the severity of 
drug-induced neutropenia as well as efficacy and survival in patients treated with 
standard doses of docetaxel [6]. For clinical use, docetaxel is formulated in the 
nonionic surfactant polyoxyethylene-20-sorbitan monooleate (polysorbate 80; Tween 
80). In recent years, substantial evidence has been generated that polysorbate 80 is a 
biologically and pharmacologically active compound [7]. It has been shown that 
polysorbate 80 has intrinsic antitumor activity [8], and its use has been implicated in 
the occurrence of severe anaphylactoid hypersensitivity reactions and cumulative fluid 
retention associated with docetaxel therapy [9]. More recently, it was demonstrated 
that polysorbate 80 interferes with the normal binding of docetaxel to serum proteins 
in a concentration-dependent manner, and can modulate the pharmacokinetics of 
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docetaxel in vivo [10]. As part of a project to further assess the importance of 
polysorbate 80 with respect to the disposition and toxicity profile of docetaxel, we 
report here on the development and validation of an analytical method that allows the 
simultaneous determination of docetaxel and polysorbate 80 in human plasma 
samples. 
 
Materials and methods 
 
Chemicals 
 Docetaxel (lot #9915420; purity, 99.5%; Figure 1A) was obtained from Aventis 
Pharma (Vitry-sur-Seine Cedex, France). Polysorbate 80 (lot #99H01002; Fig. 1B) and 
the internal standard paclitaxel (lot #061K1158) were supplied by Sigma Chemical Co. 
(St. Louis, MO, USA). Formic acid (98%, v/v in water) was obtained from J. T. Baker 
(Phillipsburg, NJ, USA), acetonitrile (HPLC grade) and methanol (HPLC Grade) from 
EM Science (Gibbstown, NJ, USA), and n-butyl chloride from Burdick & Jackson 
(Muskegon, MI, USA). Deionized water was obtained from a Milli-Q-UF system 
(Millipore, Milford, MA, USA) and used throughout in all aqueous solutions. Drug-
free (blank) human plasma originated from Pittsburgh Blood Plasma, Inc. (Pittsburgh, 
PA, USA). 
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Figure 1. Chemical structures of (A) docetaxel and (B) polysorbate 80 (w + x + y + z ~ 20). 
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Drug solutions 
 Stock solutions of docetaxel (Mr 807) at a concentration of 1 mM were prepared in 
duplicate by dissolving 8.07 mg in 1.0 mL of 50% methanol/water (50/50, v/v). Stock 
solutions of polysorbate 80 (Mr 1309) at a concentration of 10 mg/ml were prepared in 
duplicate by diluting 100 mg in 10 ml of methanol/water (50/50, v/v). Stock solutions 
of docetaxel and polysorbate 80 were stored in glass vials at –20ºC, and found to be 
stable under these conditions for at least 246 and 62 days, respectively. Likewise, 
dilutions of the stock solutions in 50% methanol did not demonstrate significant loss 
of docetaxel or polysorbate 80 when stored for up to 6 h at room temperature (data not 
shown). The stock solutions were diluted further in blank human plasma on each day 
of analysis to prepare 10 calibration samples containing docetaxel and polysorbate 80, 
respectively, at the following combinations of analyte concentrations: 0.500 nM and 
1.00 µg/ml (duplicate), 0.500 nM and 2.00 µg/ml, 1.00 nM and 2.00 µg/ml, 5.00 nM 
and 10.0 µg/ml, 10.0 nM and 30.0 µg/ml, 50.0 nM and 50.0 µg/ml, 75.0 nM and 75.0 
µg/ml, and 100 nM and 100 µg/ml (duplicate). Quality control (QC) samples were 
prepared independently in blank plasma at 5 different concentrations for docetaxel and 
polysorbate 80, respectively: 0.500 nM and 1.00 µg/ml, 2.00 nM and 3.00 µg/ml, 20.0 
nM and 20.0 µg/ml, 80.0 nM and 80.0 µg/ml, and 8000 nM and 1000 µg/ml. 
 
Sample preparation 
 Prior to extraction, frozen plasma samples were thawed in a water bath at ambient 
temperature. A 1-ml aliquot of plasma was extracted in a screw-cap glass tube (16 × 
125 mm) with 4 ml of a mixture of acetonitrile/n-butyl chloride (1/4, v/v) and 
paclitaxel (20 nM), the internal standard. The tube was capped and mixed vigorously 
for 10 s on a vortex-mixer, and for 5 min on automated multi-tube shaker, followed by 
centrifugation at 2,000 g for 10 min at ambient temperature. The top organic layer was 
transferred to a disposable borosilicate glass culture tube (13 × 100 mm). After a 
repeat of the solvent extraction, the combined organic extracts were combined and 
evaporated to dryness at 40°C under a gentle stream of nitrogen. The residue was 
reconstituted in 100 µl of acetonitrile/water (50:50, v/v) by vortex mixing (30 s) and 
ultrasonication (5 min). The sample was transferred to a 250-µl polypropylene 
autosampler vial, sealed with a Teflon crimp cap, and a volume of 50 µl was injected 
onto the HPLC instrument for quantitative analysis using a temperature-controlled 
autosampling device operating at 10°C.  
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Equipment and conditions 
 Chromatographic analysis was performed using a Waters Model 2690 
chromatographic system (Milford, MA, USA). Separation of the analytes from 
potentially interfering material was achieved at ambient temperature using a Waters X-
Terra MS column (50 × 2.1 mm internal diameter) packed with a 3.5-µm octadecyl 
stationary phase, protected by a stainless steel guard column packed with 3.5-µm 
RP18 material (20 × 2.1 mm internal diameter; Waters). The mobile phase used for the 
chromatographic separation was composed of acetonitrile/water (80/20, v/v) 
containing 0.1% of formic acid, and was delivered isocratically at a flow rate of 0.15 
ml/min. The column effluent was monitored using a Micromass Quattro LC triple-
quadrupole MS detector (Beverly, MA, USA). The instrument was equipped with an 
electrospray interface, and controlled by the Masslynx version 3.4 software 
(Micromass), running under Microsoft Windows NT on a Compaq AP200 computer 
with a Pentium III processor. The samples were analyzed using an electrospray probe 
in the positive ionization mode operating at cone voltages of 15 V, 38 V, and 20V for 
docetaxel, polysorbate 80, and paclitaxel, respectively. Samples were introduced into 
the interface through a heated nebulizer probe (350°C). The spectrometer was 
programmed to allow the [MH]+ ions of docetaxel at m/z 808.5, polysorbate 80 at m/z 
1309.6, and paclitaxel at m/z 854.5 to pass through the first quadrupole (Q1) and into 
the collision cell (Q2). The collision energy was set at 10 eV for docetaxel, at 35eV for 
polysorbate 80, and at 8.0 eV for paclitaxel. The product ions for docetaxel (m/z 
527.2), polysorbate 80 (m/z 419.4), and paclitaxel (m/z 509.4) were monitored through 
the third quadrupole (Q3). Argon was used as collision gas at a pressure of 0.0027 
mBar, and the dwell time per channel was between 0.3 and 0.5 s. 
 
Calibration 
 Calibration curves for docetaxel and polysorbate 80 were computed using the ratio 
of the peak area of the analyte and internal standard by using a least-squares linear 
regression analysis with uniform weighting for docetaxel or using a non-linear power-
regression analysis for polysorbate 80. Selection of the weighting option was based on 
assessment of the correlation coefficient and accuracy of the standards at the lower and 
upper end of the calibration curve. The parameters of each calibration curve were used 
to compute back-calculated concentrations and to obtain values for the QC samples 
and unknown samples by interpolation. 
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Method validation 
 Method validation runs were performed under Good Laboratory Practice 
according to the Food and Drug Administration guidance (see: 
http://www.fda.gov/cvm/guidance/published.htm; accessed July 13, 2004) on five 
consecutive days using freshly prepared samples. Each of the runs included a 
calibration curve processed in duplicate, and QC samples at five different 
concentrations in quintuplicate. The lower limit of quantitation (LLOQ) of the assay 
was assessed by determining the concentration of docetaxel and polysorbate 80 at 
which the signal to noise ratio was greater than 5, and the values for precision and 
accuracy were less than 20%.  
 The accuracy and precision of the assay were assessed by the mean relative 
percentage deviation (DEV) from the nominal concentrations and the within-run and 
between-run precision, respectively. The accuracy for each tested concentration was 
calculated as: 
  DEV = 100 × {([analyte]mean – [analyte]nominal)/[analyte]nominal}  
 Estimates of the between-run precision were obtained by one-way analysis of 
variance (ANOVA) using the run day as the classification variable. The between-
groups mean square (MSbet), the within-groups mean square (MSwit), and the grand 
mean (GM) of the observed concentrations across runs were calculated using the 
software package JMP version 4 (SAS Institute, Cary, NC, USA). The between-run 
precision (BRP), expressed as a percentage relative standard deviation, was defined as: 
)/)/)(((100 witbet GMnMSMSBRP −×=  
where n represents the number of replicate observations within each run. For each 
concentration, the estimate of the within-run precision (WRP) was calculated as: 
)/)((100 GMMSWRP wit×=  
 The specificity of the method was tested by visual inspection of chromatograms of 
extracted human plasma samples from 6 different donors for the presence of 
interfering peaks. The extraction efficiency of the assay was measured by comparison 
of extracted plasma samples and aqueous samples at concentrations of 2.00, 20.0, and 
80.0 nM, and 3.00, 20.0, and 80.0 µg/ml for docetaxel and polysorbate 80, 
respectively. The extraction efficiency of the internal standard, paclitaxel, was tested at 
a concentration of 20 nM. 
 The stability of docetaxel and polysorbate 80 in plasma was tested at the 
concentrations of the low and high QC samples following 3 freeze-thaw cycles at –
80ºC. The long-term (up to 91 days at -20°C) and short-term storage stability (6 h at 
room temperature) of both agents in plasma, and autosampler stability (24 h at room 
___________________________________  Analysis of Docetaxel and Polysorbate 80  
 123 
temperature) of both agents extracted from plasma and reconstituted with 50 % 
acetonitrile was assessed in triplicate. Results are expressed as the percent recovery 
relative to the initial (nominal) concentration at time zero. Stability was defined as less 
than 10% loss of the initial concentration. 
 
Analysis of patient samples 
 Blood samples were obtained from two patients with cancer who were treated with 
docetaxel administered as a 1-h intravenous infusion at a dose of 30 or 75 mg/m2. 
Docetaxel was formulated in vials containing 20 mg (0.5 ml) or 80 mg (2.0 ml) of the 
active ingredient and 570 mg and 2080 mg of polysorbate 80, respectively. The 
protocol was approved by the Institutional Review Board of The Sidney Kimmel 
Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD, USA), and the 
patients provided written informed consent. 
 The samples were collected in heparin-containing tubes before drug 
administration, at 30 min after start of infusion, at 4 min before the end of infusion, 
and at 10 and 30 min, 1, 3, 7, 24, 48, and approximately 168 (day 8), 336 (day 15), and 
504 h (day 22) after the end of infusion. Samples were processed immediately by 
centrifugation for 10 min at 3,000 g at ambient temperature. The plasma supernatant 
was collected and stored frozen at –70ºC until analysis. 
 For quantitation of docetaxel and polysorbate 80 in patient plasma, QC samples at 
low, medium, and high concentrations were assayed in duplicate and were distributed 
among the calibrators and unknown samples in the analytical run; no more than 33% of 
the QC samples were greater than ± 15% of the nominal concentration. Samples with 
docetaxel or polysorbate 80 concentrations greater than the assay upper limits of 
quantitation of 100 nM and 100 µg/ml were diluted with blank human plasma prior to 
extraction and quantitation. Depending on the docetaxel dose level and the time point 
of blood collection relative to the end of infusion, plasma samples were pre-diluted 
with blank human plasma at volume ratios between 1:10 and 1:100.
 
Results and discussion 
 
 In recent years, several analytical methods based on reversed-phase HPLC have 
been reported for the quantitative determination of docetaxel in human plasma either 
based on UV detection [11-17] or MS detection [18-20]. So far, most have relied on 
laborious solid-phase extraction techniques and lack in sensitivity, precluding drug 
measurement at sub nanogram-per-milliliter levels associated with drug doses used in 
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weekly regimens. The present paper describes an alternative procedure, which is based 
on a previous assay for polysorbate 80 and uses a double liquid-liquid extraction step 
followed by reversed-phase HPLC and tandem MS detection [21]. The method is 
sufficiently sensitive to be applied to samples from patients receiving low doses of 
docetaxel (e.g., 25 to 35 mg/m2), simultaneously detects polysorbate 80, and yet 
avoids the use of solid-phase extraction for sample clean-up. 
 
Detection and chromatography 
 The mass spectra of docetaxel and polysorbate 80 showed protonated molecules 
([MH+]) at m/z 808.5 and m/z 1309.6, respectively (Figures 2 and 3). The prominent 
ions observed at m/z 527.2 and m/z 419.4 were selected for subsequent monitoring in 
the third quadrupole. The mass spectrum of the internal standard paclitaxel showed a 
[MH+] at m/z 854.5, and the high collision energy gave one major product at m/z 
509.4, consistent with previous observations [22].  
 Representative chromatograms of blank and spiked human plasma samples are 
shown in Figures 4 and 5. The mean (± standard deviation) retention times for 
docetaxel, polysorbate 80, and paclitaxel under the optimal conditions were 1.90 ± 
0.03 min, 3.88 ± 0.03 min, and 1.90 ± 0.03 min, respectively, with an overall 
chromatographic run time of 7 min. The selectivity for the analysis is shown by 
symmetrical resolution of the peaks, with no significant chromatographic interference 
around the retention times of docetaxel, polysorbate 80, and the internal standard in 
drug-free specimens, obtained from a total of six different individuals. 
 
Linearity of detector responses 
 The calculated peak-area ratios of docetaxel to paclitaxel versus the nominal 
concentration of the analyte displayed a linear relationship in the tested range (i.e., 
0.500 nM to 100 nM). The measurement variance over this range increased 
proportionally with the docetaxel concentration, as detected by a one-sided F-test at an 
α-value of 5%. Because of this heteroscedasticity a weighting factor was used, which 
is inversely proportional to the variance at the given concentration level (x). After 
applying the peak area ratio in combination with a weighting factor of 1/x, a mean 
least-squares linear-regression correlation coefficient of greater than 0.995 was 
obtained in all analytical runs. The statistical evaluation of the coefficients of the 
ordinary least-squares line indicated small bias in the slope and in the intercept further 
indicating minor matrix effects and blank problems, respectively.  
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Figure 2. Mass spectrum of docetaxel with monitoring at m/z 808.5 → 527.2. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mass spectrum of polysorbate 80 with monitoring at m/z 1309.6 → 419.4. 
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Figure 4. Mass chromatograms of pre-treatment plasma from three different individuals. Polysorbate 
80, paclitaxel, and docetaxel were monitored at m/z 1309.6 → 419.4, 854.5 → 509.4, and 808.5 → 
527.2, respectively. The retention times of polysorbate 80, paclitaxel, and docetaxel where 
approximately 1.90 ± 0.03 min, 3.88 ± 0.03 min, and 1.90 ± 0.03 min, respectively. 


 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mass chromatograms of plasma spiked with polysorbate 80 (1.00 µg/ml; top panel), the 
internal standard paclitaxel (20.0 nM; middle panel), and docetaxel (0.500 nM; bottom panel). 
Polysorbate 80, paclitaxel, and docetaxel were monitored at m/z 1309.6 → 419.4, 854.5 → 509.4, and 
808.5 → 527.2, respectively. The retention times of polysorbate 80, paclitaxel, and docetaxel where 
approximately 1.90 ± 0.03 min, 3.88 ± 0.03 min, and 1.90 ± 0.03 min, respectively. 
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 The lack-of-fit test indicated that the detector response factors for polysorbate 80 
in the range of 1.00 µg/ml to 100 µg/ml deviated significantly from linearity, which is 
related to a concentration-dependence of the extraction efficiency (see below). Hence, 
for polysorbate 80, calibration curves were fit using a nonlinear power regression 
analysis, as described previously [21]. 
 For each point on the calibration curves for docetaxel and polysorbate 80, the 
concentrations back-calculated from the equation of the regression analysis were 
always within acceptable limits for accuracy and precision (Table 1). A linear 
regression of the back-calculated concentrations versus the nominal values provided a 
unit slope and an intercept not significantly different from zero. The distribution of the 
residuals showed random variation, was normally distributed and centered around 
zero. The bias was not statistically different from zero, and the 95% confidence 
intervals included zero (not shown).  
 
Table 1. Back-calculated concentrations from calibration curves 
Nominal 
concentrationa 
Accuracy (%) Precision (%) 
Within-run 
Between-run 
Docetaxel    
0.500 
1.00 
5.00 
10.0 
50.0 
75.0 
100 
99.20 
97.60 
100.7 
103.8 
100.4 
100.3 
99.22 
14.1 
6.18 
4.87 
5.05 
4.37 
7.67 
5.44 
b 
2.42 
3.78 
b 
5.75 
b 
b 
Polysorbate 80    
1.00 
2.00 
5.00 
10.0 
30.0 
50.0 
75.0 
100 
107.6 
98.05 
93.30 
101.7 
101.6 
99.63 
99.54 
100.6 
4.32 
16.0 
17.1 
5.19 
5.93 
6.50 
8.53 
3.59 
9.77 
b 
b 
6.96 
3.95 
b 
b 
0.53 
 
a In units of nM for docetaxel and µg/ml for polysorbate 80; b No significant additional 
variation was observed as a result of performing the assay in different runs. 
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 The lower limit of quantitation (LLOQ) for docetaxel and polysorbate 80 was 
established at 0.500 nM (~0.4 ng/ml) and 1.00 µg/ml, which concentrations were 
associated with a mean (± standard deviation) signal-to-noise ratio of 5.37 ± 1.60 and 
13.2 ± 4.14, respectively. At these concentrations, the values for precision did not 
exceed 15%, and the accuracy was less 104% for both analytes (Table 2). This 
quantitation limit for docetaxel represents a 25 to 50-fold increase in sensitivity 
compared to analytical assays based on HPLC with UV detection [11-17], and is 
similar to a recent procedure based on solid-phase extraction followed by HPLC with 
single-quadrupole MS detection using positive mode electrospray ionization [19]. The 
present LC/MS/MS assay based on liquid-liquid extraction provides the advantage of 
being less labor intensive and expensive relative to methods using solid phase 
extraction, without compromising assay sensitivity.  
 
Table 2. Assessment of accuracy, precision and recovery 
Nominal 
concentrationa 
Accuracy (%) Precision (%) 
Within-run 
Between-run Recovery 
(%) 
Docetaxel     
0.500 
2.00 
20.0 
80.0 
8000c 
104.0 
97.20 
96.70 
97.83 
101.1 
19.8 
14.1 
6.86 
4.47 
4.02 
3.22 
8.38 
2.30 
5.20 
8.06 
b 
92.50 
90.48 
95.66 
Polysorbate 80     
1.00 
3.00 
20.0 
80.0 
1000c 
103.2 
99.07 
94.20 
104.4 
104.7 
15.9 
8.80 
8.68 
5.00 
14.8 
12.8 
0.71 
6.10 
5.74 
19.3 
b 
102.4 
81.56 
81.16 
b 
 
a In units of nM for docetaxel and µg/ml for polysorbate 80; b Not done; E5CORNG FKNWVGF
YKVJRNCUOCRTKQTVQGZVTCEVKQP
 
 
Accuracy, precision and recovery 
 For non LLOQ QC samples spiked with docetaxel, the within-run and between-
run variability (precision), expressed as the percentage relative standard deviations, 
were always less than 10%, whereas the mean predicted concentration (accuracy) was 
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within 5% of the nominal value at the various concentrations analyzed in quintuplicate 
on five separate occasions (Table 2); for polysorbate 80, precision was less than 18% 
and accuracy was less than 7%. The extraction efficiency of docetaxel was 
concentration-independent and averaged 92.9%, whereas for paclitaxel the overall 
recovery was 94.8%. For polysorbate 80, the extraction efficiency slightly decreased 
with an increase in the spiked concentration (Table 3). As compared to a previous 
procedure for polysorbate 80 [21], the recovery was substantially improved over the 
range studied from 50-60% to 80-100% as a result of the use of a double extraction 
procedure with acetonitrile/n-butyl chloride.  
 
Table 3. Assessment of stabilitya 
Condition Docetaxel (nM) Polysorbate 80 (µg/ml) 
 2.00 80.0 3.00 80.0 
Freeze-thaw stability 
Cycle 1 
Cycle 2 
Cycle 3 
 
101.0 
81.14 
83.98 
 
101.8 
102.4 
102.4 
 
128.3 
131.9 
131.9 
 
108.0 
106.6 
104.3 
Long-term stability 
T = 91 days 
 
118.4 
 
107.4 
 
97.0 
 
116.5 
Short-term stability 
T = 1 h 
T = 2 h 
T = 4 h 
T = 6 h 
 
94.48 
95.64 
92.44 
93.31 
 
105.4 
102.1 
102.6 
98.63 
 
99.89 
91.66 
76.89 
71.03 
 
100.9 
98.47 
90.62 
79.40 
Autosampler stability 
T = 2 h 
T = 4 h 
T = 6 h 
T = 24 h 
 
102.8 
107.8 
93.66 
94.57 
 
97.82 
97.16 
94.62 
96.78 
 
96.63 
115.4 
96.39 
95.90 
 
90.93 
99.35 
102.6 
92.32 
 
a Expressed as mean percentage change from time zero (nominal concentration). 
 
Analyte stability 
 QC samples undergoing 3 freeze-thaw cycles showed a concentration-dependent 
degradation for docetaxel, with a loss of approximately 20% at the lowest 
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concentration (Table 3). This needs to be taken into consideration when multiple 
analytical measurements or re-analyses are required on the same frozen material. In 
frozen plasma samples, stability was assessed over a three month period, and no 
significant degradation was observed for either docetaxel or polysorbate 80. Plasma 
spiked with docetaxel or polysorbate 80 allowed to stand at room temperature for up to 
6 hours indicated that docetaxel was stable during this time period. However, a 
concentration-dependent instability of polysorbate 80 was noted at 4 and 6 hours for 
polysorbate 80 (Table 3). This is most likely related to enzyme-mediated breakdown 
of the surfactant, as has been noted previously [23], and suggests that rapid freezing of 
clinical samples is indicated in order to obtain reliable pharmacokinetic data. In acidic 
extracts, both analytes could last at least 24 hours on the autosampler without any 
significant degradation, allowing for more than 200 samples to be analyzed 
simultaneously within a single chromatographic run.  
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Figure 6. Plasma concentration-time profiles of (A) docetaxel and (B) polysorbate 80 in a cancer 
patients treated with docetaxel formulated in polysorbate 80 at a dose of 30 mg/m2 (docetaxel, 68 mg; 
polysorbate 80, 1768 mg; closed symbols) or at a dose of 75 mg/m2 (docetaxel, 129 mg; polysorbate 
80, 3354 mg; open symbols). 
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Plasma concentration-time profiles 
 The suitability of the developed method for clinical use was demonstrated by the 
determination of docetaxel and polysorbate 80 in plasma samples from two patients 
with cancer treated with docetaxel at a dose level of 30 or 75 mg/m2 (Figure 6). The 
assay allowed plasma concentrations of docetaxel to be detected for more prolonged 
time periods (up to 3 weeks after treatment) compared with less sensitive methods 
based on HPLC with UV detection, which typically only allow detection of circulating 
levels up to 24 h at a lower limit of quantitation of 5-10 ng/ml. In contrast to 
docetaxel, polysorbate 80 concentrations in plasma of both patients declined in an 
apparent mono-exponential fashion, and remained undetectable beyond 4 h after the 
start of drug administration.  
 
 In conclusion, a novel assay for simultaneous measurement of docetaxel and its 
formulation vehicle polysorbate 80 in human plasma samples was developed. The 
method was validated according to the Food and Drug Administration bioanalytical 
guidance, and met the pre-defined acceptance criteria for precision and accuracy [24]. 
The described method permits the analysis of patient samples to concentrations of 
0.500 nM and 1.00 µg/ml for docetaxel and polysorbate 80, respectively, which is 
sufficiently sensitive to allow pharmacokinetic monitoring after intravenous 
administration of docetaxel at low doses used in weekly dosing regimens. The method 
is currently being used to further study the influence of circulating polysorbate 80 
levels on the clinical pharmacology of docetaxel in patients with cancer. 
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 Docetaxel is a semisynthetic taxane derived from needles of the European yew 
(Taxus baccata), and is currently approved for the treatment of breast cancer and non-
small-cell lung cancer [1,2]. The drug has been shown to bind extensively to plasma 
proteins, including α1-acid glycoprotein (AAG), albumin, and lipoproteins [3]. 
Interindividual variability in AAG concentrations has been associated with altered 
docetaxel clearance, severity of neutropenia, and overall survival in patients with non-
small-cell lung cancer [4,5]. Recent data also indicate that the plasma binding of 
docetaxel is further influenced by the presence of its formulation vehicle polysorbate 
80 in a concentration-dependent biphasic manner [6], although the clinical significance 
of this observation in addition to that of AAG is currently unknown. Regardless, these 
findings indicate that unbound docetaxel concentrations may better correlate with 
treatment outcome (i.e., toxicity and efficacy) than with total drug. In an effort to 
better understand the clinical pharmacology of docetaxel, a rapid and reproducible 
assay based on microequilibrium dialysis was developed for measuring the fraction 
unbound (fu) docetaxel in patient plasma samples.  
 Equilibrium dialysis was performed on a plate rotator (Model 74-2334; Harvard 
Apparatus, Holliston, MA) at 37°C in a humidified atmosphere of 5% CO2 using 96-
well microdialysis plates (Harvard Apparatus; Holliston, MA; 
www.harvardapparatus.com). The dialysis compartments in each well are separated by 
membrane. In preliminary experiments, both regenerated cellulose membranes and 
polyethylsulfone membranes with a 5- or 10-kDa cutoff were evaluated. Eventually, a 
cellulose membrane with a 5-kDa cutoff was used for further experiments, because it 
provided the most consistent results and minimal accidental leaking. Experiments were 
carried out with 250-µl aliquots of plasma containing a tracer amount of [G-
3H]docetaxel (specific activity, 7.2 Ci/mmol; Moravek Biochemicals, Brea, CA) 
against an equal volume of phosphate-buffered saline (PBS; pH 7.4). Next, the 
individual chambers in the dialysis plate were physically separated and aliquotted. 
Drug concentrations in 125 µl-aliquots of both compartments were measured by liquid 
scintillation counting for 1 minute following the addition of 5 ml Bio-Safe II 
scintillation fluid (Research Products International, Mount Prospect, IL) on a Model 
LS6000IC counter (Beckman Instruments, Inc., Columbia, MD). The time to 
equilibrium was assessed in triplicate at 2, 3, 4, 6, 8, 16, 24, 48, and 72 hours after start 
of the experiment. As fu measurements were to be made on patient samples that 
contained variable amounts of drug and excipient, fu was also determined in plasma 
samples over the entire anticipated concentration range of docetaxel (i.e., 0, 1, 10, 100, 
1,000, and 10,000 ng/ml; Aventis Pharma, Vitry-sur-Seine Cedex, France) [7] and 
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polysorbate 80 (i.e., 0, and 0.5 mg/ml; Sigma Co., St. Louis, MO) [8]. Unlabeled 
docetaxel or polysorbate 80 were added to the plasma-containing compartment to 
mimic the composition of samples obtained from patients treated with docetaxel (i.e., 
with varying concentrations of docetaxel and polysorbate 80). 
 During the establishment of the method, quadruplicate plasma samples with 
differing docetaxel fu values, depending on the spiked polysorbate 80 concentrations, 
were subject to repeated analysis on 6 consecutive days to assess reproducibility. 
Preliminary experiments indicated that volume shifts during the dialysis period were 
negligible (< 10%); hence the results were used directly without applying a correction 
factor. 
 It was confirmed in all equilibrium dialysis experiments that the total drug 
recovery from the fractions was equal to the amount of [G-3H]docetaxel added to the 
plasma samples (mean recovery, 95%; P > 0.05 versus hypothesized mean of initial 
value). This recovery was assessed for each paired PBS and plasma sample taken after 
dialysis by calculating the ratio of the measured radioactivity and the amount of 
radioactivity added to each plasma sample prior to dialysis. Equilibrium for docetaxel 
transport across the membrane was established within 4 hours, which is considerably 
faster than the 48-hour period required in our previous method [6]. In the absence of 
polysorbate 80, the mean (± SD) docetaxel fu was 8.6% ± 0.5%, which is comparable 
to previous data obtained using conventional equilibrium dialysis or ultrafiltration 
[3,6]. In the presence of polysorbate 80 at a concentration of 0.5 mg/ml, the mean 
docetaxel fu was increased to 9.4% ± 0.80% (relative increase, 8.5%). As predicted 
based on previously published data on docetaxel binding to plasma proteins [3], 
docetaxel concentration had no influence on fu as determined by one-way analysis of 
variance (P = 0.88; N = 16), with an overall coefficient of variation of 7.93%. This 
suggests that the overall binding of docetaxel to plasma proteins is concentration-
independent and nonsaturable in the clinically achievable range. 
 The mean relative SD of all samples was less than 4.18%, assuring high 
discriminatory power in the detection of changes in docetaxel fu in the presence of 
variable AAG and/or polysorbate 80 levels in patient samples. With the final method, 
the within-run and between-run variability were always less than 15%. 
 The assay was next applied to a prospective analysis to define concentration-time 
profiles of unbound docetaxel in 5 patients with cancer receiving single-agent 
docetaxel (Taxotere; Aventis Pharma), which was administered as a 1-hour continuous 
intravenous infusion at a dose of 75 mg/m2. The unbound concentration was calculated 
as the product of fu and the total plasma concentration, determined using a validated 
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Table 1. Fraction unbound docetaxel in plasma of 5 patients with cancer (docetaxel 
dose, 75 mg/m2 
Time (h)* (Mean) SD (%) Range (%) 
0 3.93 0.496 3.34 - 4.50 
0.50 4.85 1.06 3.66 - 6.25 
1.0 5.38 1.64 3.10 - 7.54 
1.2 4.48 1.11 3.67 - 6.11 
1.5 4.54 0.491 3.98 - 5.03 
2.0 4.77 1.13 3.55 - 6.23 
4.0 4.52 0.964 3.46 - 5.84 
8.0 4.77 1.35 3.19 - 6.78 
25 4.56 2.02 2.47 - 7.61 
 
*Denotes time after the start of a 1-hour continuous intravenous infusion 
 
0 5 10 15 20 25 30
Time (h)
0.1
1
10
100
1000
10000
C
on
ce
nt
ra
tio
n 
(n
g/
m
l)
 
Figure 1. Concentration-time profiles of total docetaxel (ng/ml) (squares) and unbound 
docetaxel (ng/ml) (circles) in plasma of 5 patients with cancer (docetaxel dose, 75 mg/m2).
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liquid-chromatographic assay with tandem mass-spectrometric detection [9]. The 
mean docetaxel fu increased from 3.93% to 5.35% at the end of infusion, and then 
gradually declined to values similar to those in samples obtained immediately before 
drug administration (Table 1). Semilogarithmic concentration-time profiles of total and 
unbound docetaxel in plasma in the 5 patients are shown in Figure 1. 
 In conclusion, the presented data indicate that docetaxel fu in plasma samples of 
patients treated with the drug can be reliably determined using this assay. The 
procedure is more cost-efficient and less time consuming than other currently available 
assays, and likely introduces less bias and random error. This is because the use of 
standardized equilibrium dialysis plates such as those used here will improve 
reproducibility of the method, along with minimal volume shift and minor occurrence 
of leakage. The developed procedure is currently used to prospectively evaluate 
relationships between pharmacokinetic characteristics of unbound drug- and 
docetaxel-mediated toxicity in a large cohort of patients with cancer.  
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Abstract 
 
 Purpose: Weekly administration of docetaxel has demonstrated comparable 
efficacy together with a distinct toxicity profile with reduced myelosuppression, 
although pharmacokinetic data with weekly regimens are lacking. The comparative 
pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) 
administration schedules was evaluated. 
 Experimental Design: Forty-six patients received weekly docetaxel 35 mg/m2 as a 
30 min infusion alone (n=8) or in combination with irinotecan (n=12), or in 3-weekly 
regimens, as a 1 h infusion at 60 mg/m2 with doxorubicin (n=10), 75 mg/m2 alone 
(n=9) or 100 mg/m2 alone (n=7). Serial blood samples were obtained immediately 
before and up to 21 days after the infusion. Plasma concentrations were measured by 
liquid chromatography-mass spectrometry and analyzed using compartmental 
modeling. 
 Results: Mean±SD docetaxel clearance values were similar with weekly and 3-
weekly schedules (25.2±7.7 versus 23.7 ± 7.9 L/h/m2); values for half-life were also 
similar with both schedules of administration (16.5±11.2 and 17.6±7.4 h). With 
extended plasma sampling beyond 24h post-infusion, docetaxel clearance is 18% 
lower and the terminal half-life is 5-fold longer. At 35 mg/m2, the mean±SD docetaxel 
concentration on day 8 was 0.00088±0.00041 µg/mL (1.08±0.51 nM); at 75 mg/m2, 
concentrations on day 8, 15, and 22 were 0.0014±0.00043 µg/mL (1.79±0.53), 
0.00067±0.00025 µg/mL (0.83±0.31 nM), and 0.00047±0.00008 µg/mL (0.58±0.099 
nM), respectively. 
 Conclusion: Docetaxel pharmacokinetics are similar with weekly and 3-weekly 
regimens. Prolonged circulation of low nanomolar concentrations of docetaxel may 
contribute to the mechanism of action of docetaxel through suppression of microtubule 
dynamics and tumor angiogenesis and enhanced cell radiosensitivity in combined 
modality therapy. 
 
Introduction 
 
 The antineoplastic agent docetaxel acts by disrupting the microtubular network, 
and is one of the most active agents in the treatment of locally advanced or metastatic 
breast, non-small cell lung, and ovarian cancer [1-4]. The docetaxel dose used for 
treating cancer patients has ranged from 60 to 100 mg/m2 as a 1-hour intravenous 
infusion given once every 3 weeks (hereafter referred to as "3-weekly"). In this 
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regimen, neutropenia occurs in virtually all patients, and grade 4 neutropenia occurs in 
75% of patients given 100 mg/m2 (N = 2045; febrile neutropenia incidence, 12%); 
grade 3/4 neutropenia occurs in 65% of patients given 75 mg/m2 (N = 176; febrile 
neutropenia incidence, 6.3%), and grade 4 neutropenia occurs in 75% of patients given 
60 mg/m2 (N = 174; febrile neutropenia incidence, 0%) (see: http://www.taxotere.com/ 
- last accessed july 13, 2004). Other side effects include alopecia, asthenia, 
dermatologic reactions, fluid retention, hypersensitivity reactions, and stomatitis. Drug 
exposure-toxicity relationships are clearly defined for docetaxel administered as 
monotherapy at doses of 75 to 100 mg/m2 in 3-weekly regimens where the AUC of 
total plasma concentrations during the first cycle of treatment is related to incidence of 
grade 4 neutropenia and febrile neutropenia [5]. 
 Recent clinical trials have examined single-agent docetaxel administered at doses 
of 35 to 40 mg/m2 given weekly for six consecutive weeks followed by two weeks 
without treatment [6-14], or on other weekly schedules such as 3 consecutive weeks 
with one week of rest [15-17] (hereafter “weekly”). Administration of weekly 
schedules significantly changed the toxicity profile of docetaxel with a reduction in 
acute toxicity and only mild myelosuppression. Fatigue and asthenia appeared as the 
dose-limiting side effects and nail changes and excessive lacrimation became more 
common. The response rates observed with weekly administration of single-agent 
docetaxel in phase II studies in metastatic breast cancer and advanced non-small cell 
lung cancer are within the range reported in other studies of 3-weekly docetaxel [18-
21], and in general, the planned dose intensity is equivalent to that used in 3-weekly 
regimens. 
 At present, the pharmacokinetic profile of docetaxel administered in weekly 
treatment regimens has not been previously reported. The objectives of the study were 
to compare the pharmacokinetics of docetaxel during weekly and 3-weekly 
administrations and to describe plasma drug concentrations during extended periods 
with both schedules. 
 
Patients and Methods 
 
Chemicals and Reagents  
 Docetaxel powder (batch, #990720; purity, 99.5%) was supplied by Aventis 
Pharma (Vitry-sur-Seine Cedex, France). The internal standard, paclitaxel (Lot, 
#061K1158; purity, 100%) was obtained from Sigma Chemical Co. (St. Louis, MO). 
Methanol and acetonitrile were purchased from EM Science (Gibbstown, NJ), n-butyl 
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chloride from AlliedSignal, Inc. (Muskegon, MI), and formic acid (88%, v/v in water) 
from J.T. Baker (Phillipsburg, NJ). All chemicals were of HPLC grade or better. 
Purified water was obtained by filtration and deionization using a Milli-Q-UF system 
(Millipore, Milford, MA), and was used throughout. Drug-free plasma originated from 
Pittsburgh Blood Plasma, Inc (Pittsburgh, PA). 
 
Patients and Treatment 
 Docetaxel was administered as part of several clinical study protocols and 
pharmacokinetic data were gathered into this study. The clinical docetaxel preparation 
(Taxotere; Aventis) contained 20 or 80 mg of the drug formulated in 0.5 mL and 2.0 
mL, respectively, of polysorbate 80, and was diluted in ethanol – water (13:87, v/v) to 
a 10-mg/mL concentrate. This solution was diluted in 250-mL infusion bags with 0.9% 
(w/v) sodium chloride in water to a concentration of 0.30 – 0.74 mg/mL. Individual 
drug doses were normalized to body-surface area and administered as part of a clinical 
study protocol once every week at a dose of 35 mg/m2 alone (n=8) or 30 minutes 
before irinotecan 50 mg/m2 (n=12), or once every-3-weeks (3-weekly) at a dose of 60 
mg/m2 1 hour after doxorubicin 60 mg/m2 (n=10), 75 mg/m2 alone (n=9), or 100 
mg/m2 alone (n=7). The drug was given as a 0.5-hour (35 mg/m2) or 1-hour (60, 75, 
and 100 mg/m2) continuous intravenous infusion using an infusion system with an in-
line 0.22-µm filter. The clinical protocols were approved by the local institutional 
review boards (Baltimore, MD, and Rotterdam, the Netherlands), and all patients 
provided written informed consent before enrollment. Patients had adequate renal and 
hepatic function defined as: (i) serum creatinine ≤ 2.0 × the institutional upper limit of 
normal (ULN); (ii) total bilirubin ≤ ULN; and (iii) if alkaline phosphatase was ≤ ULN, 
any elevations in AST/ALT; or if AST/ALT were ≤ ULN, any elevation in alkaline 
phosphatase; patients with ALT and/or AST > 1.5 × ULN with concomitant alkaline 
phosphate > 2.5 × ULN were not eligible for treatment with docetaxel on the 
administrations schedules described in the present manuscript. 
 
Pharmacokinetic Sampling  
 Pharmacokinetic studies were part of each study protocol and were performed 
during the first week of therapy for the weekly regimens, and during the first cycle of 
treatment for the 3-weekly regimens; pharmacokinetic studies were performed during 
the second cycle of treatment in three of seven patients receiving docetaxel 100 
mg/m2. Blood samples were collected in vacutainer tubes containing heparin as 
anticoagulant from a peripheral site contralateral to the infusion site. Blood samples 
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were immediately placed in an ice-water bath, centrifuged within 30 minutes of 
collection at 1000 × g for 10 minutes at 4°C, and were stored at or below –20 °C until 
analysis. The following sampling schemes were used: (i) docetaxel 35 mg/m2 given 
alone or followed by irinotecan: pre-treatment, 29 minutes (immediately before the 
end of the infusion), and post-infusion at 10 and 30 minutes and at 1, 3, 7.5, 24, and 48 
hours and pre-treatment on day 8; (ii) docetaxel 60 mg/m2 with doxorubicin: pre-
treatment, 30 minutes during the infusion, 59 minutes (immediately before the end of 
infusion), and post-infusion at 10 and 30 minutes, and at 1, 2.5, 5, 22, and 46 hours, 
and prior to cycle 2 on day 22; (iii) docetaxel 75 mg/m2 alone: pre-treatment, 30 
minutes during the infusion, 59 minutes (immediately before the end of infusion), and 
post-infusion at 10 and 30 minutes, and at 1, 3, 7, 24, and 48 hours and on days 8, 15, 
and 22; and (iv) docetaxel 100 mg/m2 alone: pre-treatment, 30 and 55 minutes during 
the infusion, end of infusion, and post-infusion at 10, 20, and 30 minutes, and at 1, 1.3, 
2, 4, 8.5, 24, 48, and 72 h and on days 8, 15, and 22. 
 
Analytical Assay  
 Docetaxel was quantitated in plasma using high-performance liquid 
chromatography (HPLC) with tandem mass-spectrometric detection. The method was 
validated according to the recommendations provided by the FDA 
(http://www.fda.gov/cvm/guidance/published.htm - last accessed July 13, 2004). 
Briefly, drug was extracted from 1.0 mL of plasma by liquid-liquid extraction with a 
mixture of acetonitrile – n-butyl chloride (1:4, v/v). The eluent was evaporated under a 
stream of nitrogen and reconstituted with 200 µL of methanol – water (50:50, v/v). 
The analytical system consisted of a Model 2690 chromatograph (Waters, Milford, 
MA) equipped with a model 996 photodiode-array detector. Chromatographic 
separations were achieved on a Waters X-Terra MS column (50 × 2.1 mm internal 
diameter) packed with a ODS stationary phase with a 3.5-µm particle size, protected 
by a Phenomenex C18 (4.0 × 3.0 mm internal diameter) guard column (Torrance, CA). 
The mobile phase was composed of a mixture of acetonitrile – water (80:20, v/v) 
containing 0.1% (w/v) formic acid, and was delivered isocratically at a flow rate of 0.2 
mL/min. Detection was performed with a MicroMass Quattro LC triple-quadrupole 
mass spectrometer (Cary, NC) in the positive ion mode. The electrospray ionization 
operated at 3.6 kV and the cone voltage of 20 V. The detector was programmed to 
allow the [MH]+ ions of docetaxel (m/z 808.49) and that of the internal standard, 
paclitaxel (m/z 854.99), to pass through the first quadrupole and into the collision cell. 
The collision energy for collision-induced dissociation was set at 8.0 eV, with argon 
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used as collision gas at a pressure of 0.0027 mbar. The daughter ions of docetaxel (m/z 
527.52) and paclitaxel (m/z 509.44) were monitored through the third quadrupole. The 
dwell time per channel for data collection was set at 0.5 seconds. 
 Docetaxel plasma concentrations were quantitated over the range of 0.50 to 100 
nM. The accuracy and precision of quality control (QC) samples, which included 
docetaxel concentrations of 2.0, 20.0, 80.0 nM, and an 80-nM QC that was diluted 
100-fold prior to processing, were < 15%. At the assay lower limit of quantitation 
(LLOQ) of 0.50 nM (400 pg/mL), accuracy was 103% and between-run precision was 
17.5%. This represents a 25 to 50-fold increase in sensitivity as compared to analytical 
assays based on HPLC with UV detection [22-28], although an analytical assay based 
on HPLC with mass spectrometric detection with an LLOQ of 0.30 nM has recently 
been described [29]. For quantitation of docetaxel in unknown samples, QC samples at 
low, medium, and high concentrations were assayed in duplicate and were distributed 
among the calibrators and unknown samples in the analytical run; no more than 33% of 
the quality assurance samples were greater than ± 15% of the nominal concentration. 
Samples with docetaxel concentrations greater than the assay upper limit of 
quantitation of 100 nM were diluted with analyte free human plasma prior to 
extraction and quantitation. Depending on the docetaxel dose level, plasma samples 
were pre-diluted at volume ratios of 1:10, 1:50, or 1:100. 
 
Pharmacokinetic Data Analysis  
 Individual docetaxel pharmacokinetic parameters were estimated using model-
dependent methods as implemented in Adapt II release 4 (Biomedical Simulations 
Resource, Los Angeles, CA) [30]. Pharmacokinetic parameters were estimated twice 
for each patients using: (i) data from time zero to 24 hours post-treatment 
(conventional plasma sampling scheme) for comparison to previously published 
pharmacokinetic data; and (ii) from time zero to the last measurable concentration on 
8, 15, or 22 (extended plasma sampling scheme). This latter analysis was performed 
only if patients had measurable docetaxel concentrations on day 8 or later. Data were 
fit with either a two- or three-compartment model using weighted least-squares as the 
estimation procedure, and inverse variance of the output error (linear) as the weighting 
option. Model discrimination was guided by inspection of the weighted sum of squares 
and the coefficient of variation of the fitted pharmacokinetic parameters and by the 
Akaike information criterion [31]. Maximum plasma concentration (Cmax) values were 
obtained from the model-estimated plasma concentration at the end of the docetaxel 
infusion. Calculated secondary pharmacokinetic parameters included half-life during 
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the terminal phase of the disposition curve (t1/2,λz) and systemic clearance (CL). The 
area under the plasma concentration-time curve (AUC) was calculated as dose divided 
by CL. For weekly regimens, the cumulative AUC during a 3-week treatment period 
was calculated by multiplying the AUC during week 1 of treatment by 3 with the 
assumption that docetaxel clearance did not change during weeks 2 and 3 of treatment.  
 
Statistical Considerations 
 Pharmacokinetic parameters are presented as mean values ± SD, and for all tests 
the a priori cut-off for statistical significance was taken at P < .05. Analysis of 
variance was used to compare Cmax values and cumulative AUC during a 3-week 
treatment period at the different dose levels. The method of Tukey-Kramer HSD was 
used to adjust for multiple comparisons of mean values. Differences between 
pharmacokinetic parameter values, which were calculated using data from sampling to 
24 h or extended sampling, were compared by a paired Student’s t-test. Statistical 
calculations were performed using the software package JMP version 3.2.6 (SAS 
Institute, Carey, NC). 
 Group sample sizes of 20 were calculated to achieve approximately 70% power to 
detect a ratio of 1.50 between the clearance of docetaxel in the respective treatment 
groups, using a double-sided test with a significance level (α) of 0.05 and assuming 
equal variances for both groups. This statistical calculation was performed in the SISA 
Binomial program (D.G. Uitenbroek, Hilversum, the Netherland, 1997; available at 
hhtp://home.clara.net/sisa/samsize.htm [accessed July 13, 2004]). 
 
Results 
 
 Data from twenty-three female and 23 male patients were included this 
pharmacokinetic study and patient demographic data are summarized in Table 1. 
Docetaxel pharmacokinetic parameters determined from plasma concentrations 
measured from time zero to 24 hours post-treatment are displayed in Table 2. 
Docetaxel pharmacokinetic parameters were similar when docetaxel 35 mg/m2 was 
given alone or with irinotecan (P > 0.50), similar to earlier findings of this 
combination given in a 3-weekly regimen [32, 33]; therefore, data from both schedules 
were combined and summary statistics are presented in Table 2. Mean ± SD docetaxel 
clearance values were similar with weekly and 3-weekly schedules (overall means, 
25.2 ± 7.7 versus 23.7 ± 7.9 L/h/m2; P < 0.5467); values for half-life were also similar 
with both schedules of administration (overall means, 16.5 ± 11.2 and 17.6 ± 7.4 h, P = 
Chapter 9_____________________________________________________________ 
 148
0.6990). Docetaxel Cmax and AUC values at the different dose levels are shown in 
Figure 1. Mean ± SD Cmax values with docetaxel administered at a dose of 35 mg/m2 
over 30 min (1.93 ± 0.60 µg/mL) were similar to those observed at doses of 60 mg/m2 
(1.55 ± 0.41 µg/mL) and 75 mg/m2 (2.18 ± 0.71 µg/mL) administered over 1 h, but 
significantly lower (P < 0.0001) than at 100 mg/m2 (4.15 ± 1.35 µg/mL) over 1 h. The 
difference in Cmax observed between the weekly and 3-weekly schedules is not related 
to a pharmacokinetic difference but to the shorter infusion duration in the weekly 
schedule (30 min versus 1 h) and the different doses administered in the 3-weekly 
regimens (60, 75, and 100 mg/m2).  
 
Table 1. Patient demographic dataa 
 Schedule of administration 
Characteristic Weekly Every-3-week 
Number of patients 20 26 
Sex, female/male 5/15 18/8 
Age, years 65 (47 – 77) 47 (26 – 71) 
BSA, m2 1.96 (1.57 – 2.55) 1.83 (1.54 – 2.29) 
Tumor Type   
Breast  12 
Melanoma  4 
NSCLC 12  
Prostate 8 1 
Unknown primary  4 
Other2  5 
Docetaxel dose, mg/m2   
35 20  
60  10 
75  9 
100  7 
 
aContinuous data are given as median with range in parenthesis, and categorical data as 
number of patients; bOther tumor types include one each of cervix, head and neck, melanoma, 
rectum, sarcoma, unknown primary. 
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Figure 1. Docetaxel peak plasma concentration [Cmax (panel A)] and area under the plasma 
concentration-time curve [AUC (panel B)] values as a function of dose (mg/m2). The 
difference in Cmax observed between the weekly and 3-weekly schedules is not related to a 
pharmacokinetic difference but to the shorter infusion duration in the weekly schedule (30 
min versus 1 h) and the different doses administered in the 3-weekly regimens (60, 75, and 
100 mg/m2). 
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Table 2. Docetaxel pharmacokinetic parameters: sampling to 24 hours post-treatmenta 
Parameter 
Schedule 
Concurrent 
Drug 
No. of 
Patients 
Infusion 
Time (h) 
Cmax 
(µg/mL) 
AUC 
(µg×h/mL) 
CL 
(L/h/m2) 
t1/2,λz 
(h) 
Weekly        
35 mg/m2 None 8 0.50 ± 0.035 
1.85 
± 0.73 
1.32 
± 0.42 
29.1 
± 10.2 
15.6 
± 12.0 
35 mg/m2 Irinotecan 12 0.54 ± 0.053 
1.99 
± 0.52 
1.59 
± 0.40 
22.5 
± 4.2 
17.1 
± 12.7 
 ALL DATA 20 0.52 ± 0.044 
1.93 
± 0.60 
1.48 
± 0.41 
25.2 
± 7.7 
16.5 
± 11.2 
3-Weekly       
60 mg/m2 Doxorubicin 10 1.01 ± 0.031 
1.55 
± 0.41 
2.85 
± 1.40 
25.0 
± 9.7 
18.0 
± 9.29 
75 mg/m2 None 9 1.04 ± 0.036 
2.18 
± 0.71 
3.05 
± 0.85 
25.8 
± 6.3 
17.5 
± 7.3 
100 mg/m2 None 7 1.03 ± 0.047 
4.15 
± 1.35 
5.62 
± 2.12 
19.6 
± 5.60 
17.2 
± 6.2 
 
aData represent mean ± SD. Docetaxel plasma concentration-time data from time zero to 24 hours post 
infusion were used for calculation of pharmacokinetic parameters.  
 
 
Since docetaxel clearance is not schedule dependent, exposure-intensity (AUC) 
comparisons between weekly and 3-weekly schedules are equivalent to dose-intensity 
comparisons. The AUC during 3 weeks of treatment is larger following the 35 mg/m2 
weekly dose (4.44 ± 1.24 µg/mL) (cumulative 3-week dose of 105 mg/m2) compared 
to 60 mg/m2 (2.85 ± 1.40 µg/mL) and 75 mg/m2 (3.05 ± 0.85 µg/mL) given 3-weekly 
but is similar to 100 mg/m2 (5.62 ± 2.12 µg/mL) given 3-weekly. 
  
 Docetaxel pharmacokinetic parameters calculated from data that included 
extended plasma sampling to days 8 to 22 post-treatment are listed in Table 3. 
Observed and model-simulated docetaxel concentration-time profiles from 
representative patients receiving docetaxel 35 mg/m2 as a 30 min infusion and 75 
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mg/m2 as a 1 h infusion are shown in Figure 2 and mean observed docetaxel 
concentration-time profiles following single agent administration at 35 mg/m2 (30 min 
infusion) (n=9), 75 mg/m2 (1 h infusion) (n=9), and 100 mg/m2 (1 h infusion) (n=7) 
are illustrated in Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Plasma concentration-time profiles from extended plasma sampling following 
administration of docetaxel 35 mg/m2 administered as a 30 min infusion (panel A) and 75 
mg/m2 administered as a 1 h infusion (panel B). Dashed lines are simulated concentrations 
from fitting a 3-compartment model to the observed concentration-time data. The following 
equation converts docetaxel concen-trations in units of µg/mL to nM: concentration (nM) = 
concentration (µg/mL) × 1237.79. 
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Figure 3. Observed mean docetaxel plasma concentrations following administration of 
docetaxel 35 mg/m2 administered as a 30 min infusion (solid line), 75 mg/m2 administered as 
a 1 h infusion (dashed line), and 100 mg/m2 administered as a 1 h infusion (dotted line). 
Panel A includes concentrations to 24 hours post infusion and panel B includes 
concentrations to day 22 (approximately 500 hours). The following equation converts 
docetaxel concentrations in units of µg/mL to nM: concentration (nM) = concentration 
(µg/mL) × 1237.79. 
 
 
 With the weekly schedules, clearance values were 19% lower when calculated 
from concentration-time data from extended sampling to day 8 than versus 24-hour 
data; with the 3-weekly schedules, docetaxel clearance values were 10 to 34% lower 
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with extended sampling to day 22 (overall paired means, 19.7 ± 5.1 L/h/m2 versus 24.0 
± 6.6; P < 0.0001). These differences reflect the fact that samples were obtained for 
longer time periods thus allowing for a more accurate estimate of the terminal 
disposition half-life. By measuring docetaxel concentrations over an extended 
sampling time period of 3 weeks, the calculated terminal disposition half-life of 
docetaxel was found to be about 5-fold longer than that estimated on the basis of the 
standard 24-hour sampling interval (overall paired means, 86.4 ± 44.9 versus 16.6 ± 
8.2 h; P < 0.0001). At 35 mg/m2, the mean ± SD docetaxel concentration on day 8 was 
0.00088 ± 0.00041 µg/mL (1.08 ± 0.51 nM); at 75 mg/m2, concentrations on day 8, 15, 
and 22 were 0.0014 ± 0.00043 µg/mL (1.79 ± 0.53 nM), 0.00067 ± 0.00025 µg/mL 
(0.83 ± 0.31 nM), and 0.00047 ± 0.00008 µg/mL (0.58 ± 0.099 nM), respectively. 
 
Discussion 
 
 In the present study, we describe the comparative pharmacokinetics of docetaxel 
in plasma following weekly and 3-weekly administration schedules. The data 
complement previous knowledge on the clinical pharmacology of docetaxel, and may 
have practical implications for its clinical use. Previous published studies of docetaxel 
pharmacokinetics have only focused on 3-weekly schedules in which the drug is 
administered as a 1-hour intravenous infusion [34,35]. There is great current interest in 
evaluating the administration of docetaxel on weekly schedules. Weekly regimens 
appear to have comparable antitumor efficacy as 3-weekly schedules, together with a 
distinct toxicity profile with reduced myelosuppression [18-21]. Given the known 
exposure-toxicity relationship that has been defined for 3-weekly regimens with 
docetaxel monotherapy (AUC during cycle 1 and neutropenia) [5], we attempted to 
understand the differences in the toxicity profile between weekly and 3-weekly 
docetaxel by evaluating the comparative pharmacokinetics for both schedules. The use 
of a sensitive analytical method based on liquid chromatography with tandem mass-
spectrometric detection allowed the determination of docetaxel exposure during the 
entire week or cycle of therapy. 
 At doses of 35 mg/m2 given weekly and 100 mg/m2 given 3-weekly, the predicted 
AUC over a 3-week period for weekly administration (4.44 µg×h/mL) was similar to 
that during cycle 1 of the 3-weekly regimen (5.62 µg×h/mL in the present study; 
4.81µg×h/mL in reference 5). Given the difference in the incidence of severe 
myelosuppression between the two schedules, the pharmacokinetic data suggests that 
the same exposure-toxicity relationship defined previously for 3-weekly regimens with 
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docetaxel monotherapy [5], may not apply to weekly regimens. It is possible, however, 
that measurement of unbound drug concentrations is required to understand exposure-
toxicity relationships that apply to both regimens. Indeed, it has recently been shown 
that the plasma protein binding of docetaxel is decreased in the presence of the 
docetaxel vehicle polysorbate 80 at concentrations that may be achieved at the end of 
the docetaxel infusion when given at doses used in 3-weekly regimens [36,37]. The 
influence of polysorbate 80 on docetaxel protein binding is presumably the result of a 
complex formation of polysorbate 80 with serum proteins and/or a displacement 
interaction on the main docetaxel binding protein, alpha-1-acid glycoprotein [38], 
caused by a polysorbate 80 degradation product(s) [39]. Regardless of the exact 
mechanistic basis for this phenomenon, this finding indicates that exposure to the 
(pharmacologically active) fraction of unbound docetaxel may increase with an 
increase in dose (from 35 mg/m2 to 75 or 100 mg/m2), which would be expected to 
result in more severe hematological toxicity. However, docetaxel is often administered 
as a 30-minute infusion with weekly regimens and as a 1-hour infusion with 3-weekly 
regimens, which may achieve similar polysorbate 80 concentrations at the end of the 
docetaxel infusion. Measurement of polysorbate 80 plasma concentrations with weekly 
and 3-weekly regimens is in progress.  
 The similar exposure-intensity and dose-intensity [6] for docetaxel is consistent 
with observations of comparable efficacy of weekly and 3-weekly regimens in phase II 
trials in patients with metastatic breast cancer and advanced non-small cell lung cancer 
[18-21], and with preclinical studies suggesting that the antitumor activity of docetaxel 
is independent of the dose/schedule of administration [40]. Weekly and 3-weekly 
docetaxel regimens are being directly compared in breast cancer in the adjuvant 
setting. Similar to docetaxel, paclitaxel appears to have comparable efficacy when 
administered in high-dose or low-dose regimens in patients with metastatic breast 
cancer [41-43]. 
 By measuring docetaxel concentrations over an extended sampling time period of 
3 weeks, docetaxel clearance values were on average 10 to 35% lower than those 
determined from the 24-hour data. Because a 25% decrease in docetaxel clearance has 
been shown to be associated with a significant increase (150%) in the odds of 
developing febrile neutropenia [5], when combining data from different studies for 
pharmacokinetic, pharmacodynamic, and/or pharmacogenetic analysis, it will be 
important to include data utilizing similar sampling schemes and equally sensitive 
analytical methods if extended sampling strategies are used. 
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 With the use of prolonged plasma sampling schemes, the calculated terminal 
disposition half life of docetaxel was approximately 86 h, which is about 5-fold longer 
than that estimated on the basis of conventional 24-hour sampling intervals, and 
almost 9-fold longer than published values [35]. Consequently, docetaxel concen-
trations are maintained above 0.0008 µg/mL (1.0 nM) for 7 days with weekly 
schedules and above 0.0004 µg/mL (0.5 nM) for 21 days with 3-weekly regimens 
(Table 3, Figure 3). This observation is of particular relevance with regard to potential 
mechanisms of action of the taxanes where low nanomolar concentrations have been 
shown to inhibit cell proliferation without arresting cells at mitosis [44,45], suppress 
microtubule dynamics [46], inhibit tumor angiogenesis [47-49], and enhance cell 
radiosensitization [50].   
 There is current preclinical and clinical interest in the potential antiangiogenic 
properties of the taxanes. Indeed, docetaxel and paclitaxel have recently been shown to 
be potent and specific inhibitors of endothelial cell migration in vitro [51], vascular 
endothelial cell growth factor secretion [52], and angiogenesis in vitro and in vivo at 
IC50 values of approximately ≤ 1 nM (47-49). It has been suggested that weekly 
schedules of taxanes possess antiangiogenic properties relative to 3-weekly schedules 
because a weekly schedule of paclitaxel has been shown to induce responses in some 
patients with tumors refractory to paclitaxel administered every 21 days [53,54]. 
However, this has not been demonstrated unequivocally in in vivo preclinical models. 
Moreover, if maintaining low nanomolar concentrations for prolonged periods 
contributes to the antiangiogenic properties of docetaxel, than this mechanism of 
action should apply to both schedules of administration given the similarity in 
circulating concentrations. 
 Collectively, these data show that the altered toxicity profiles observed with 
weekly docetaxel administrations may not be explained by a change in plasma 
pharmacokinetics of total drug, and that previously defined exposure-toxicity 
relationships for 3-weekly regimens do not apply to weekly regimens. In addition, we 
have shown by applying an extended sampling time period of 21 days that until now 
the circulation time of docetaxel in cancer patients has been greatly underestimated. 
The presently observed prolonged terminal disposition phase of docetaxel should be 
taken into consideration when designing future clinical trials of docetaxel administered 
in novel drug combinations and combined modality therapy, and when evaluating 
alternative schedules of administration. 
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Abstract 
 
 Purpose: To prospectively study the pharmacokinetics and toxicity profile of 
docetaxel as well as cytochrome P450 3A (CYP3A) phenotype in elderly patients with 
cancer.  
 Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 once every 
3 weeks to 25 elderly cancer patients aged ≥ 65 years and 26 cancer patients aged < 65 
years. CYP3A was phenotyped using the erythromycin breath test (ERMBT) prior to 
drug administration. Pharmacokinetic studies were performed during the first cycle of 
therapy. 
 Results: Of 51 patients treated, 20 aged ≥ 65 years (median [range], 71 years [65-
80]) and 20 aged < 65 years (53 years [26-64]) were evaluable for pharmacokinetic 
and CYP3A studies, and 39 were evaluable for toxicity. Patient characteristics were 
similar (P ≥ .15) between the 2 cohorts. The ERMBT parameter, percentage 14C-
exhaled/h, was not altered in elderly patients (mean, 2.38% vs 2.74%; P = .23), 
suggesting similar CYP3A4 activity. Mean (SD) docetaxel clearance was also similar 
between the 2 cohorts: 30.1 (18.3) L/h versus 30.0 (14.8) L/h (P = .98). The 
development of febrile neutropenia was associated with higher AUC values (P = .02). 
The percentage of patients with grade 4/febrile neutropenia was 63%/16% versus 
30%/0% (P ≥ .06) in the older and younger cohort, respectively; febrile neutropenia in 
the elderly cohort may be related to drug exposure and not age. 
 Conclusion: CYP3A activity and docetaxel pharmacokinetics are unaltered in 
elderly patients. It is concluded that docetaxel 75 mg/m2 in a 3-weekly regimen is 
feasible in the elderly.  
  
Introduction 
 
 Docetaxel is a semi-synthetic taxane derived from an extract of the needles of the 
European yew tree (Taxus baccata), and acts by disrupting the microtubule network 
[1]. The drug has significant antitumor activity against numerous tumors and is 
approved for treatment of locally advanced or metastatic breast and non-small cell 
lung cancers. In patients with advanced breast cancer receiving docetaxel 100 mg/m2 
as a 1 hour infusion every 3 weeks (3-weekly), grade 4 and febrile neutropenia occur 
in 84% and 11.8% of patients, respectively (see: http://www.taxotere.com/ - last 
accessed July 13, 2004); in patients with non-small cell lung cancer receiving 75 
mg/m2, grade 3/4 and febrile neutropenia occur in 65% and 6.3% of patients, 
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respectively. Other side effects include alopecia, asthenia, dermatologic reactions, 
fluid retention, hypersensitivity reactions, and stomatitis. Drug exposure-toxicity 
relationships have been extensively studied for docetaxel monotherapy administered 3-
weekly and indicate that the area under the curve (AUC) of total plasma 
concentrations during the first cycle of treatment is related to incidence of grade 4 
neutropenia and febrile neutropenia [2]. 
 As the population in Western countries ages and life expectancy increases [3], 
there is an increasing number of cancer patients 65 years of age or older that might 
benefit from chemotherapeutic treatment. There is often hesitation to treat elderly 
patients with chemotherapy due, in part, to the older patient being more susceptible to 
therapy-related toxicity [4-6]. However, studies have demonstrated that elderly 
patients with good performance status and lacking comorbidities are not at increased 
risk for treatment-related toxicities [4-7]. Studies also indicate that undertreatment is 
associated with inferior outcome in older patients [8-10]. Little is known about the 
clinical pharmacokinetics and pharmacodynamics of anticancer agents, including 
docetaxel, and their relation to drug tolerance and outcome in the elderly [4-6]. 
Docetaxel administered in weekly schedules at lower doses has been found to be both 
efficacious and generally well tolerated in elderly patients [11-13], and a study 
evaluating the population pharmacokinetics of weekly docetaxel showed no effect of 
age on drug clearance [14]. There is general reluctance to administer docetaxel 3-
weekly to elderly patients due to the prevalence of neutropenia with docetaxel therapy 
[15], although this has not been adequately evaluated in a clinical trial. 
 The objective of the present study was to prospectively characterize the 
pharmacokinetic and toxicity profile of docetaxel during one cycle of treatment when 
administered at a dose of 75 mg/m2 once every 3 weeks to patients aged less or older 
than 65 years. Because docetaxel undergoes extensive metabolism by cytochrome 
P450 3A (CYP3A) [16], CYP3A activity was assessed prior to treatment to determine 
if the function and/or expression of enzyme is altered with increasing age.  
 
Patients and methods 
 
Patient eligibility  
 Patients were eligible when they had histologically or cytologically confirmed 
solid tumor malignancies, for which docetaxel was a viable treatment option. Other 
criteria for patient enrollment were: 1) age ≥ 18 years; 2) performance score (PS) < 3 
according to the Eastern Cooperative Oncology Group criteria; 3) adequate bone 
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marrow function as defined by pre-therapy values of hemoglobin ≥ 8.0 g/dL, ANC 
≥1,500/µL, and platelet count ≥ 100,000/µL; 4) creatinine ≤ 2.0 × the institutional 
upper limit of normal (ULN); 5) total bilirubin < 1.5 × ULN; 6) if alkaline phosphatase 
was <2.5 × ULN, any elevations in AST/ALT; or if AST/ALT were <1.5 × ULN, any 
elevation in alkaline phosphatase; patients with ALT and/or AST ≥ 1.5 × ULN with 
concomitant alkaline phosphate ≥ 2.5 × ULN were not eligible for treatment; 7) 
peripheral neuropathy ≤ grade 1 and no symptomatic brain metastasis; 8) no previous 
treatment with docetaxel; and 9) no concomitant use of phenytoin, carbamazepene, 
barbiturates, rifampicin, phenobarbital, St. John’s wort, and ketoconazole. All 
concomitant drugs and the use of herbal medicines were recorded. The clinical 
protocols were approved by the local institutional review boards (Baltimore, MD, 
Rotterdam, the Netherlands, and Washington, DC), and all patients provided written 
informed consent before enrollment. Before treatment, a complete registration form 
was received by the coordinating center (Baltimore, MD), and a study number was 
assigned. Patients who did not have complete pharmacokinetic and CYP3A 
phenotyping studies during cycle 1 were replaced. 
 
Drug Treatment 
 Two groups of patients were studied based on age. The control group consisted of 
patients aged 18 to 64 years, and the elderly group consisted of patients aged 65 years 
or older. The clinical docetaxel preparation (Taxotere; Aventis Pharmaceuticals) 
containing 20 or 80 mg of the drug formulated in 0.5 mL and 2.0 mL of polysorbate 
80, respectively, was diluted with a solution of 13% ethanol in water to a 10 mg 
docetaxel/mL concentration. This solution was diluted further in a 250-mL infusion 
bag or bottle of either 0.9% sodium chloride solution or 5% dextrose solution to 
produce a final concentration of 0.30 – 0.74 mg/mL. Individual drug doses were 
normalized to body-surface area and administered intravenously over 1 h at a dose of 
75 mg/m2 every 3 weeks in both treatment groups. Dexamethasone, 8 mg orally every 
12 hours for 5 doses (3 days), was administered starting 24 h before drug treatment. 
Patients did not routinely receive anti-emetic prophylaxis. After 1 cycle of therapy, 
treatment continued at the discretion of the treating physician until tumor progression, 
development of unacceptable toxicity, or patient withdrawal.  
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Patient Evaluation  
 The extent of prior treatment was assessed two-fold: 1) the number of prior 
treatment regimens; and 2) patients were considered heavily pretreated if they received 
≥ 2 cycles of mitomycin C, ≥ 4 cycles of carboplatin, ≥ 6 cycles with cisplatin or an 
alkylating cytostatic drug. Pretreatment evaluations included assessment of PS, height, 
weight, toxicity assessment, a complete blood count with differential (CBC), and the 
following serum chemistries: creatinine, alkaline phosphatase, AST, ALT, total 
bilirubin, α1-acid glycoprotein (AAG), and albumin. 
 Toxicity assessment and a CBC with differential were performed weekly for a 
total of 3 weeks (1 cycle). Toxicity assessments were performed according the 
National Cancer Institute Common Toxicity Criteria version 2.0. Management of 
toxicity was at the discretion of the treating physician per institutional guidelines. 
 
Erythromycin Breath Test (ERMBT) 
 Within one week prior to docetaxel administration during cycle 1, CYP3A activity 
was determined using the ERMBT. The ERMBT dose consisted of 0.04 mg [14C-N-
methyl]-erythromycin, containing 3 µCi of radioactivity, dissolved in 4.5 mL of 5% 
dextrose solution. The dose was administered as an intravenous bolus injection over 
approximately 1 min. Breath samples were collected in balloons post-injection at 5, 
10, 15, 20, 25, 30 and 40 minutes. Samples were shipped to Metabolic Solutions 
(Nashua, NH) for measurement of breath carbon dioxide. The data was reported as 
percentage 14C metabolized per min (% 14C exhaled/min) at each time point. The 
conventional ERMBT parameter, percentage 14C metabolized per hour (% 14C 
exhaled/h), was calculated using the equation y = -65.988·x2 + 54.645·x + 0.0377, 
where x is the value for % 14C exhaled/min at the 20 min time point [17]. The area 
under the % 14C exhaled/min-time curve from time zero to 40 min (AUC0-40) was 
determined using the linear trapezoidal method. The ERMBT parameter, 1/Tmax, was 
determined as described previously [18]. A mono-exponential equation was also fitted 
to the % 14C exhaled/min-time data and the time of the maximum % 14C/min (Tmax) 
was the estimated value. 
 
Pharmacokinetic Sampling and Assay 
 Blood samples were collected for docetaxel pharmacokinetic studies during the 
first cycle of treatment cycle at the following time points: pre-treatment, 30 min during 
the infusion, 59 min (immediately before the end of the infusion), and post-infusion at 
10 and 30 min, 1, 3, 7, 24, and 48 h, and on day 8. Samples were collected in a 10 mL 
Chapter 10____________________________________________________________ 
 168
heparinized tube and placed on ice until further processing within 30 minutes of 
collection. Plasma was isolated by centrifugation at 4 oC, at 1000 g for 10 minutes and 
frozen at or below –20 °C until the time of analysis. 
 Docetaxel was quantitated in plasma over the range of 0.50 nM to 100 nM using a 
validated liquid chromatographic method with tandem mass-spectrometric detection, 
as previously described [19]. The bias and precision of quality control (QC) samples, 
which included docetaxel concentrations of 2.0, 20.0, 80.0 nM, and an 80-nM QC that 
was diluted 100-fold prior to processing, were < 15%. At the assay lower limit of 
quantitation of 0.50 nM (~400 pg/mL), bias and precision were < 20%. 
 Individual docetaxel pharmacokinetic parameters were estimated using model-
dependent methods as implemented in Adapt II release 4 (Biomedical Simulations 
Resource, Los Angeles, CA) [20]. Concentration-time data were fit with a three-
compartment model using weighted least-squares as the estimation procedure, and 
inverse variance of the output error (linear) as the weighting option. Calculated 
secondary pharmacokinetic parameters included half-life during the terminal phase of 
the disposition curve (t1/2,λz) and systemic clearance (CL). The AUC was calculated as 
dose divided by CL. Maximum plasma concentration (Cmax) values were the observed 
values. 
 
Statistical Analysis 
 Group sample sizes of 20 in both age groups (< 65 years and ≥ 65 years) were 
calculated to achieve 88% power to detect a ratio of 1.50 between clearance variances 
in the respective groups, using a two-sided F test with a significance level (α) of .05. 
Sample size calculations were performed using the computer program SISA-binomial 
(Uitenbroek DG, 1997, Available http://home.clara.net/sisa/binomial.htm, accessed july 
13, 2004). 
 Docetaxel and ERMBT pharmacokinetic parameters were summarized as the 
mean, standard deviation, and range. For continuous variables, nonparametric tests 
were used to compare mean values between the two age groups. The method of 
Tukey-Kramer was used to adjust for multiple comparisons of mean values. 
Categorical variables were compared using 2-tailed Fisher’s Exact Test for 2-by-2 
tables. Statistical calculations were performed using the software package JMP version 
3.2.6 (SAS Institute, Carey, NC).  
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Table 1. Patient demographics 
 Age < 65 years (n = 20) Age ≥ 65 years (n = 20)
 Median (Range) Median Range 
Age (years) 53 (26 – 64) 71 (65 – 80) 
Body surface area (m2) 1.93 (1.49 – 2.45) 1.85 (1.45 – 2.25) 
Sexa     
Female 10  9  
Male 10  11  
AAG (mg/dL)a 159 (86 – 257) 126 (60 – 201) 
Liver Function Tests     
AST (× ULN) 0.95 (0.30 – 3.9) 0.80 (0.40 – 4.7) 
ALT (× ULN) 0.70 (0.20 – 6.6) 0.50 (0.10 – 1.5) 
Alkphos (×ULN) 0.85 (0.50 – 2.0) 0.80 (0.40 – 6.2) 
Total bilirubin 0.50 (0.30 – 1.1) 0.40 (0.20 – 0.60) 
CYP3A Activity (% 14C exhaled/h)a 2.38 (0.83 – 4.35) 2.74 (0.78 – 5.79) 
ECOG performance statusa,b     
0 4  4  
1 15  12  
2 1  3  
Primary tumor typea     
Breast 5  3  
Head and neck 3  1  
Lung 5  3  
Melanoma 3  0  
Prostate 0  5  
Angiosarcoma 0  3  
Unknown 1  4  
Other 3  1  
Prior treatmenta     
None 1  8  
1-2 cytotoxic regimens 14  11  
 ≥ 3 cytotoxic regimens  5  1  
Light 12  13  
Heavy 8  7  
 
aData are mean (range) values; bData is number of patients; cBaseline performance status was 
not performed in one patient aged ≥ 65 years. 
 
Results 
 
 Between August 2002 and September 2003, 51 patients (26 were aged < 65 and 25 
were ≥ 65 years) were enrolled on this study. Of these patients, 40 (20 in each age 
group) were evaluable for pharmacokinetic and ERMBT studies. Patients were not 
evaluable for pharmacokinetic studies for the following reasons: 1) severe 
hypersensitivity reaction with discontinuation of drug treatment (1 patient); 2) inability 
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to perform pharmacokinetic studies due to poor venous access (2 patients); 3) plasma 
samples became thawed during shipment for analytical analysis (7 patients); and 4) 
erroneous administration of a lower docetaxel dose of 50 mg/m2 (1 patient). Patient 
characteristics for the 40 evaluable patients are listed in Table 1. Body surface area, 
liver function, performance status, and prior treatment were similar between the 2 
cohorts (P ≥ .15), although pre-treatment serum α1-acid glycoprotein concentrations 
were 20% lower in the elderly (mean, 126 mg/dL [≥ 65 years] vs 159mg/dL [< 65 
years]; P = .04). 
 
Table 2. Docetaxel pharmacokinetic parameters 
 < 65 years ≥ 65 years 
Parameter Mean SD Range Mean SD Range 
Cmax 
(µg/mL) 
4.06 1.38 1.65 – 6.36 3.44 1.58 0.88 – 6.52 
AUC 
(µg/mL×h) 
5.69 2.27 2.47 – 10.2 6.01 3.23 1.54 – 13.7 
Cl (L/h) 30.0 14.8 13.7 – 68.8 30.1 18.3 9.5 – 91.6 
Cl (L/h/m2) 15.4 6.94 7.30 – 30.1 16.6 10.0 5.20 – 49.2 
Vc (L) 5.24 2.63 2.16 – 10.1 6.24 3.45 2.76 – 16.3 
Vc (L/m2) 2.70 1.28 1.29 – 5.25 3.45 1.94 1.44 – 8.78 
Vss (L) 803 370 399 – 1479 923 435 382 – 2408 
Vss (L/m2) 413 170 185 – 788 513 249 193 – 1301 
t1/2,α (h) 0.078 0.031 0.046 – 0.15 0.087 0.024 0.051 – 0.013 
T1/2,β (h) 1.78 1.34 0.84 – 6.91 1.65 0.51 0.66 – 2.60 
T1/2,γ (h) 64.6 19.2 45.9 – 117 72.8 32.8 32.2 – 164 
 
 
Plasma Pharmacokinetics 
 Docetaxel pharmacokinetic parameters were similar in the elderly and younger 
patient cohorts (P ≥ .15; Table 2). Mean (SD) docetaxel clearance was 30.1 (18.3) L/h 
in patients aged ≥ 65 years and 30.0 (14.8) L/h in patients < 65 years (P = .98). 
Interpatient variability in clearance was larger in the elderly (9.6-fold) versus the 
younger patients (5.0-fold) (Figure 1B). One patient aged 70 years had the highest 
clearance of 91.6 L/h. Removal of this outlier clearance value (> 3 standard 
deviations) from the elderly group resulted in a mean (range) clearance of 27 (9.5 to 
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48.3) L/h and interpatient variation (5.1-fold) similar to the younger patients. It is 
possible that the patient with an outlier value for clearance was in the elderly group by 
chance, and hence, there appears to be no age-related interpatient variation in 
docetaxel clearance. 
 
CYP3A Phenotyping 
 The ERMBT was performed 24 hours before docetaxel treatment in 82% of 
patients and immediately before the docetaxel infusion in 18% of patients. The 
ERMBT parameter, percentage 14C-exhaled/h, was not altered in elderly patients 
(mean, 2.74 %; range, 0.78 to 5.79) compared to patients < 65 years (mean, 2.38%; 
range, 0.83 to 4.35; P = .23) suggesting similar CYP3A4 activity between the 2 age 
groups. The other ERMBT parameters (% 14C exhaled/min, AUC0-40, and 1/Tmax) were 
also similar between the 2 groups (P ≥ .42). Interpatient variation in CYP3A activity 
was 7.4-fold and 5.2-fold in patients ≥ 65 years and < 65 years, respectively (Figure 
1A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. [A] CYP3A activity (%14Cexhaled/h) and [B] docetaxel clearance as a function of 
age group. Lines represent the mean values.  
0
20
40
60
80
100
Age (years)
< 65 >/= 65
B
P = .9790
Chapter 10____________________________________________________________ 
 172
Toxicity 
 Twenty patients aged < 65 years and 19 patients aged ≥ 65 years, respectively, 
were evaluable for hematological toxicity. The incidence of grade 3 and 4 neutropenia 
and febrile neutropenia, the ANC nadir, and percentage decrements in ANC are 
summarized in Table 3. The absolute neutrophil count nadir occurred on day 8 in 85% 
and 80% of patients in the younger and elderly groups, respectively, and no patient had 
grade 4 neutropenia for > 7 days. Grade 4 neutropenia occurred more frequently in the 
elderly (63% versus 30%), but the difference was not statistically significant (P = .06); 
however, because the sample size was not calculated to detect statistical differences in 
docetaxel-mediated neutropenia between the 2 groups, the possibility of such a 
difference cannot be fully excluded. Three elderly patients developed febrile 
neutropenia. One patient had metastatic pancreatic cancer with a performance status of 
2, and her disease progressed rapidly 3 weeks after docetaxel treatment at cycle 1. One 
patient had metastatic prostate cancer, having received prior treatment with 
bicalutamide, and one patient had adenocarcinoma of unkown primary without any 
prior chemotherapy. All three patients were treated with broad-spectrum antibiotic 
therapy without administration of growth factors, and ANC values returned to 
pretreatment values on day 15. 
 
Table 3. Hematological toxicity 
Neutropeniaa Treatment 
Group Grade 3 Grade 4 Febrile 
ANC nadir 
(× 109/L)b 
% Decrease in 
 ANCb 
< 65 years 7 (35%) 6 (30%) 0 (0) 1.1 (0.08 – 5.5) 83 (42 – 98) 
≥ 65 years 1 (5%) 12 (63%) 3 (16%) 0.61 (0.05 – 1.8) 92 (46 – 99) 
 
aData is number of patients (% of patients); bData is mean (range) 
 
 
 The association between docetaxel AUC and neutropenia was assessed (Figure 2). 
Patients with febrile neutropenia had significantly higher AUC values (mean, 10.2 
µg/mL×h) than patients with grade 0 to 3 (mean AUC, 5.6 µg/mL×h) or 
uncomplicated grade 4 neutropenia (mean, 5.6 µg/mL×h; P = .02) (Figure 2A). It is 
likely that development of febrile neutropenia in the 3 elderly patients versus no 
patients in the younger cohort was related to higher drug exposure in these individual 
patients rather than age.  
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Percentage decrements in ANC were greater in those patients with AUC values in the 
upper quartile (mean decrement, 93%) compared to those with AUC values in the 
interquartile range (mean, 77%; P = .02) (Figure 2B). 
 Nineteen patients in both age groups were evaluable for non-hematological 
toxicity. Non-hematological toxicities that were monitored are listed in Table 4. The 
most frequent toxicities occurring in > 20% of patients were grade 1 or 2 alopecia, 
asthenia, nausea, oral mucositis, cutaneous toxicity, and neuropathy. The frequency of 
non-hematological toxicities appeared similar between the 2 age groups, although the 
small number of patients and low incidence precluded statistical evaluation. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. [A] Worst grade of neutropenia (grade 0–3 versus grade 4 versus febrile 
neutropenia) and [B] percentage decrease in ANC as a function of docetaxel AUC. Dotted 
lines are the 25% quantile and dashed lines are the 75% quantile.  
 
 
Discussion 
 
 Despite the widespread clinical use of docetaxel, only few data are available on 
the effect of aging on the pharmacokinetic and pharmacodynamic behavior of this 
drug. Recent investigations have emphasized the disappointingly low participation of 
elderly patients in cancer treatment trials and the barriers associated with patient 
accrual [3]. Several of the factors identified include the lack of information on age-
related changes in organ function and on the pharmacokinetics and pharmacodynamics 
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of anticancer agents. Indeed, while some studies have examined the efficacy and 
feasibility of chemotherapy in elderly patients, including several studies with weekly 
docetaxel in breast and nonsmall cell lung cancers [11-13], little is known about the 
pharmacokinetic behavior of the anticancer agents under evaluation. A few exceptions 
include studies that evaluated the pharmacokinetics of anthracyclines, cisplatin, 
ifosfamide, methotrexate and paclitaxel in elderly patients, although most of these 
studies provide data for a limited number of patients (< 10 patients aged greater than 
65 years) and did not include a comparative cohort of younger patients [4-21]. In an 
attempt to fill this gap of knowledge, we have prospectively evaluated the 
pharmacokinetics of docetaxel administered once every 3 weeks as well as the 
phenotypic activity of the major enzyme involved in its elimination, CYP3A, in 
elderly cancer patients in comparison to younger patients. Overall, the results indicate 
that there is no statistically significant change in the pharmacokinetics of docetaxel or 
in CYP3A activity, as measured by the ERMBT, between the two studied age groups. 
These data complement previous knowledge on the clinical pharmacology of 
docetaxel, and may have important practical implications for its optimal use in the 
elderly.  
 The influence of age on the expression and activity of drug-metabolizing enzymes 
remains controversial with reports describing either a decline in activity or no change 
in activity in elderly patients [22-24]. In the current study, docetaxel clearance and the 
associated interpatient variability (approximately 5-fold) were found to be similar in 
both treatment groups. Likewise, CYP3A activity and its interpatient variation was not 
significantly altered with age in this study. Prior in vitro studies have suggested an age 
related decline in CYP3A activity [25]. However, our results are consistent with in 
vivo studies applying the ERMBT as a phenotyping probe of CYP3A-mediated drug 
clearance where no decrease in CYP3A activity was observed as a function of age 
[22,24]. 
 The incidence of grade 3/4 neutropenia in the elderly group (68%) was consistent 
with other studies evaluating docetaxel monotherapy at 75 mg/m2 once every 3 weeks 
(65%). Neutropenia resolved within 7 days in all patients without administration of 
growth factors. It is noteworthy that incidences of neutropenic fever were observed in 
3 patients (16%) in the elderly group, which might seem more prevalent than that 
observed in other studies (6.3%). These 3 patients, however, all had docetaxel 
clearance values in the lower quartile, which was shown to be associated with the 
severity of neutropenia. The apparent inconsistencies between unaltered docetaxel 
clearance in both age groups and a slightly increased incidence of neutropenic fever in 
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the elderly needs to be interpreted with caution, as our trial was not designed to detect 
statistical differences in variability in docetaxel-mediated neutropenia between the 
tested groups with sufficient power. Therefore, the provided information on 
neutropenia, which was based on a sparse set of hematological toxicity data (e.g., 
blood cells measured on a once a week basis), should not be taken as evidence for a 
meaningful clinical difference in toxicity between the two age groups and/or as an 
argument for the use of standard reductions in docetaxel dose administered to the 
elderly. In line with this contemplation, previous studies with weekly docetaxel 
schedules in heavily pretreated elderly patients indeed appeared to be both effective 
and very well tolerated [11,12]. 
 The incidence of non-hematological toxicities was also similar between both age 
groups. It is important to note, however, that docetaxel-mediated non-hematological 
toxicity was not assessed over multiple cycles of treatment as has been done with 
weekly docetaxel schedules [11-13], where the development of non-hematological 
toxicities often occur at later cycles. Further investigation is clearly required to shed 
light on this aspect as well as on efficacy of the once every 3 weeks treatment schedule 
in elderly cancer patients. 
 The current pharmacokinetic findings with docetaxel are in contrast with recent 
data obtained for the related drug, paclitaxel, where drug clearance was found to be 
inversely correlated with patient age. In addition, exposure to the pharmacologically 
active fraction unbound paclitaxel was approximately 25% increased in the elderly as 
compared to younger patients [21]. The mechanisms underlying the discrepant 
findings observed with paclitaxel and docetaxel are not clear, but may involve age-
dependent differences in elimination pathways involved with each agent as well as a 
differential influence of pharmacokinetic interference by their respective formulation 
vehicles (ie, polysorbate 80 vs Cremophor EL). Regardless, it further underscores the 
importance of conducting appropriately designed prospective clinical trials to 
recognize potential alterations in the pharmacokinetic profile of anticancer drugs with 
advancing age. 
 In conclusion, this study indicates that docetaxel pharmacokinetics are not altered 
in the elderly and that age appears to be an unimportant consideration in drug dosing 
when considering the potential for age-related changes in drug clearance. The overall 
incidence of grade 3/4 neutropenia in the elderly cohort was similar to historical data 
with single-agent docetaxel 75 mg/m2, and the incidence of febrile neutropenia in the 
cohort of elderly patients studied may likely be related to drug exposure and not to 
age. Therefore, on the basis of these results it is concluded that the administration of 
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docetaxel in a 3-weekly regimen at a dose of 75 mg/m2 is feasible in the elderly. In 
view of the wide degree of interindividual variability in drug clearance in both age 
groups, further evaluations of alternative dosing strategies for individual patients to 
decrease this variability and improve therapy are still urgently needed. 
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Abstract 
 
 Objective: To evaluate the association between exposure to unbound docetaxel 
and neutropenia in cancer patients and to identify factors influencing unbound 
docetaxel clearance.  
 Methods: Docetaxel was administered once every 3 weeks at a dose of 75 mg/m2 
to 49 patients with normal liver function (n=40) or mild elevations in liver function 
tests (n=9), or at 50 mg/m2 to patients with moderate elevations in liver function tests 
(n=6). Pharmacokinetic studies and toxicity assessments were performed during the 
first cycle of therapy. Total docetaxel concentrations were determined by HPLC and 
tandem mass spectrometry and unbound docetaxel fraction was determined by 
equilibrium dialysis. 
 Results: In patients with normal liver function, unbound docetaxel disposition was 
characterized by mean (± SD) Cmax, AUC, and clearance values of 233 ± 101 ng/mL, 
321 ± 143 ng/mL×h, and 565 ± 329 L/h, respectively, and unbound clearance varied 
8.5-fold; polysorbate 80 exhibited mean (± SD) Cmax, AUC, and clearance values of 
451 ± 221 µg/mL, 528 ± 217 µg/mL×h, and 8.18 ± 3.66 L/h, respectively, and 
clearance varied 6.7-fold. Unbound docetaxel clearance (P=.020) and polysorbate 80 
clearance (P=.092) were reduced in patients with liver impairment. From multiple 
linear regression analysis, only polysorbate 80 AUC and liver impairment were 
significantly associated with unbound docetaxel clearance. Unbound docetaxel AUC 
was better correlated than total AUC with both percentage decrements in absolute 
neutrophil count (P=.002 versus P=.029) and worst grade of neutropenia (P=.013 
versus P=.220), where higher exposure was associated with worse hematological 
toxicity.  
 Conclusions: Exposure to unbound docetaxel is more closely related to drug-
induced hematologic toxicity than total drug and should be considered for future 
pharmacologic investigations. 
 
Introduction 
 
 Docetaxel is a semi-synthetic taxane derived from an extract of the needles of the 
European yew tree (Taxus baccata), and acts by disrupting the microtubule network 
[1]. The drug has significant antitumor activity against numerous tumors and is 
approved for treatment of locally advanced or metastatic breast and non-small cell 
lung cancers at doses ranging from 60 to 100 mg/m2 administered as a 1 hour infusion 
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every 3 weeks (3-weekly). Neutropenia is the dose-limiting toxicity of docetaxel 
administered on 3-weekly schedules. In patients with normal liver function receiving 
docetaxel at 75 mg/m2, grade 3/4 and febrile neutropenia occur in 65% and 6.3% of 
patients, respectively [2]. Other side effects include alopecia, asthenia, dermatologic 
reactions, fluid retention, hypersensitivity reactions, and stomatitis. 
 Docetaxel’s pharmacokinetic profile is characterized by substantial interpatient 
variability in total clearance (>10-fold), which has important clinical consequences. In 
a population pharmacokinetic-pharmacodynamic study of more than 600 patients 
receiving docetaxel monotherapy at doses ranging from 75 to 100 mg/m2 administered 
3-weekly, a reduction in total docetaxel clearance by 50% was associated with an 
increase in the odds of developing grade 4 neutropenia and febrile neutropenia by 
430% and 300%, respectively [3]. Even a 25% decrease in docetaxel clearance is 
associated with a 150% increase in the odds of developing febrile neutropenia [3]. In 
addition, docetaxel exposure has also been related to treatment efficacy. The area 
under the curve (AUC) was a significant predictor of time to tumor progression in non-
small cell lung cancer [3], and underdosing (e.g., lower docetaxel AUC due to 
increased clearance) was associated with a worse time to progression and time to death 
[4].  
 Elimination routes of docetaxel are mediated principally by the hepatic 
cytochrome P450 3A (CYP) isoforms CYP3A4 and CYP3A5 [5]. The major docetaxel 
metabolites and less than 10% of the parent drug are excreted into the feces, whereas 
total urinary excretion is less than 10% [1]. The metabolites demonstrate substantially 
reduced cytotoxic activity as compared to the parent drug, making biotransformation 
by CYP3A a major route of inactivation [6]. Liver impairment presenting with 
concurrent elevations in serum transaminases in the presence of normal total bilirubin 
is associated with reduced total clearance by 25% [3] and elevated total bilirubin 
greater or equal to 1.5 times the upper limit of institutional normal is associated 
reduced total docetaxel clearance by greater than 50% [7,8].  
 Docetaxel is extensively bound to albumin and alpha1-acid glycoprotein (AAG), 
and the latter is the main determinant of variability in docetaxel serum binding [9]. In 
cancer patients, AAG concentrations vary approximately 5-fold between patients [10], 
which may contribute to differences in protein binding and systemic drug clearance. 
From a population pharmacokinetic modeling analyses, AAG has been identified as a 
significant predictor of total docetaxel clearance, with high AAG levels being 
associated with reduced docetaxel clearance [11]. Recently, it has been shown that the 
plasma binding of docetaxel is further influenced by the presence of its formulation 
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vehicle polysorbate 80, such that the unbound fraction of docetaxel increases during 
the docetaxel infusion [12]. This time-dependent change in unbound fraction resulted, 
on average, in a 12% higher unbound fraction on the basis of the AUC ratio of 
unbound to total drug, as compared with that obtained from pretreatment plasma 
concentrations. 
 The clinical significance of increasing unbound fraction of docetaxel during the 
infusion is unknown. The purpose of this study was to investigate the association 
between unbound docetaxel exposure and the principal toxicity, neutropenia. In 
addition, an analysis was undertaken to identify factors influencing unbound docetaxel 
clearance. 
 
Patients and methods 
 
Patient eligibility 
 Patients were eligible when they had histologically or cytologically confirmed 
solid tumors, for which docetaxel was a viable treatment option. Other criteria for 
patient enrollment were: 1) age ≥ 18 years; 2) performance score (PS) < 3 according to 
the Eastern Cooperative Oncology Group criteria; 3) adequate bone marrow function 
as defined by pre-therapy values of hemoglobin ≥ 8.0 g/dL, ANC ≥ 1,500/µL, and 
platelet count ≥ 100,000/µL; 4) creatinine ≤ 2.0 × the institutional upper limit of 
normal (ULN); 5) total bilirubin < 1.5 × ULN; 6) if alkaline phosphatase was < 2.5 × 
ULN, any elevations in AST/ALT; or if AST/ALT were < 1.5 × ULN, any elevation in 
alkaline phosphatase; patients with ALT and/or AST ≥ 1.5 × ULN with concomitant 
alkaline phosphate ≥ 2.5 × ULN, considered mild liver impairment, were eligible for 
treatment and received a reduced dose of docetaxel; 7) peripheral neuropathy ≤ grade 
1 and no symptomatic brain metastasis; 8) no previous treatment with docetaxel; and 
9) no concomitant use of phenytoin, carbamazepine, barbiturates, rifampin, 
phenobarbital, St. John’s wort, and ketoconazole. All concomitant drugs and the use of 
herbal medicines were recorded. The clinical protocols were approved by the local 
institutional review boards (Rotterdam, The Netherlands, Baltimore, MD, and 
Washington, DC), and all patients provided written informed consent before 
enrollment. Before treatment, a complete registration form was received by the 
coordinating center (Baltimore, MD), and a study number was assigned. 
 Retrospectively, patients were grouped according to baseline liver function to 
determine the association between elevations in liver transaminases and/or alkaline 
phosphatase and unbound docetaxel clearance. Patients in liver function group 1 had 
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no elevations in AST/ALT or alkaline phosphatase as described for liver function 
groups 2 and 3. Patients in liver function group 2 had concurrent elevations in 
transaminases and alkaline phosphatase as follows: AST/ALT >1 .0 × ULN concurrent 
with alkaline phosphatase ≥ 2.5 × ULN, or AST/ALT ≥ 1.5 × ULN concurrent with 
alkaline phosphatiase > 1.0 × ULN, or isolated elevations of AST/ALT or alkaline 
phosphatase ≥ 5.0 × ULN. Patients in liver function group 3 had concurrent elevations 
in transaminases as previously described [3]: AST/ALT ≥ 1.5 × ULN concurrent with 
alkaline phosphatase ≥ 2.5 × ULN. 
 
Drug treatment 
  The clinical docetaxel preparation (Taxotere; Aventis Pharmaceuticals, 
Bridgewater, NJ) containing 20 or 80 mg of the drug formulated in 0.5 mL and 2.0 mL 
of polysorbate 80, respectively, was diluted with a solution of 13% ethanol in water to 
a 10 mg docetaxel/mL concentration. This solution was diluted further in a 250-mL 
infusion bag or bottle of either 0.9% sodium chloride solution or 5% dextrose solution 
to produce a final concentration of 0.30 – 0.74 mg/mL. Individual drug doses were 
normalized to body-surface area and administered intravenously over 1 h at a dose of 
75 mg/m2 every 3 weeks. Patients with ALT and/or AST ≥ 1.5 × ULN with 
concomitant alkaline phosphate ≥ 2.5 × ULN received a reduced docetaxel dose of 50 
mg/m2, which has been shown to be tolerated in patients with similar degrees of liver 
impairment [7,8]. Dexamethasone, 8 mg orally every 12 hours for 5 doses (3 days), 
was administered starting 24 h before drug treatment. Patients did not routinely receive 
anti-emetic prophylaxis. After 1 cycle of therapy, treatment continued at the discretion 
of the treating physician until tumor progression, development of unacceptable 
toxicity, or patient withdrawal.  
 
Patient evaluation  
 The extent of prior cytotoxic treatment was assessed two-fold: 1) the number of 
prior treatment regimens; and 2) patients were considered heavily pretreated if they 
received ≥ 2 cycles of mitomycin C, ≥ 4 cycles of carboplatin, or ≥ 6 cycles with 
cisplatin or an alkylating agent. Pretreatment evaluations included assessment of PS, 
height, weight, toxicity assessment, a complete blood count with differential (CBC), 
and the following serum chemistries: creatinine, alkaline phosphatase, AST, ALT, 
total bilirubin, AAG, and albumin. 
 Toxicity assessment and a CBC were performed weekly for a total of 3 weeks (1 
cycle). Toxicity assessments were performed according the National Cancer Institute 
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Common Toxicity Criteria version 2.0. Management of toxicity was at the discretion 
of the treating physician per institutional guidelines. 
 
Pharmacokinetic sampling and assay  
 Blood samples were collected for docetaxel and polysorbate 80 pharmacokinetic 
studies during the first cycle of treatment cycle at the following time points: pre-
treatment, 30 min during the infusion, 59 min (immediately before the end of the 
infusion), and post-infusion at 10 and 30 min, 1, 3, 7, 24, and 48 h, and on day 8. 
Samples were collected in a 10 mL heparinized tube and placed on ice until further 
processing within 30 minutes of collection. Plasma was isolated by centrifugation at 4 
oC, at 1000 g for 10 minutes and frozen at or below –20 °C until the time of analysis. 
 Total docetaxel concentrations and polysorbate 80 concentrations were quantitated 
in plasma over the range of 0.50 nM to 100 nM and 1 to 100 µg/mL, respectively, 
using a validated liquid chromatographic method with tandem mass-spectrometric 
detection, as previously described [13]. The bias and precision of quality control (QC) 
samples were < 15%. At the assay lower limit of quantitation, bias and precision were 
< 20%. 
 The fraction unbound docetaxel in plasma (fu) was determined using a validated 
method based on equilibrium dialysis as previously described [14]. Briefly, 
equilibrium dialysis was conducted on a rotator at 37°C in a humidified atmosphere of 
5% CO2 using 96-wells microdialysis plates (Harvard Apparatus, Holliston, Mass). 
The dialysis compartments in each well were separated by a regenerated cellulose 
membrane with a 5-kDa molecular weight cut-off (Harvard Apparatus). Experiments 
were carried out with 250-µl aliquots of plasma containing a tracer amount of [G-
3H]docetaxel (Moravek Biochemicals, Brea, Calif) against an equal volume of 0.01 M 
phosphate buffer (pH 7.4). Following a 4-hour reaction time, measurement of total 
radioactivity in both compartments was measured by liquid scintillation counting for 1 
minute. The tritium-label is relatively stable and the volume shift during dialysis is 
negligible, hence the results were used directly without applying a correction factor. 
The concentration of unbound docetaxel (Cu) was calculated from the concentration of 
total docetaxel in plasma (Cp) as: Cu = Cp × fu. The within-run and between-run 
variability (reproducibility) and bias (accuracy) of the method were less than 15% on 
the basis of repeat analyses of quadruplicate samples with differing docetaxel fu values 
(depending on the spiked polysorbate 80 concentration) on 6 consecutive days. The 
mean relative standard deviation was less than 10%, assuring high discriminatory 
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power in the detection of changes in the fraction unbound docetaxel in patient samples 
with different AAG and polysorbate 80 concentrations. 
 With the pharmacokinetic sampling scheme used, total docetaxel concentrations 
are best described by a 3-compartment model [15]. Because docetaxel unbound 
fraction increased during the infusion, which contributed to increasing docetaxel 
concentrations unrelated to the dosing rate over a 1 hour infusion, standard 
noncompartmental methods were used for calculation of pharmacokinetic parameters, 
including those for total docetaxel and polysorbate 80. To determine the contribution 
of increasing unbound fraction to overall unbound docetaxel exposure, unbound 
docetaxel concentrations were calculated for estimation of pharmacokinetic parameters 
twice as follows: 1) unbound fraction measured at each sampling time point was 
multiplied by the corresponding total concentration (Cu = Cp × fu), or 2) unbound 
fraction measured at pre-treatment was calculated by the total concentration at each 
time point after the start of the docetaxel infusion (Cu = Cp × fupre-treatment). Values for 
Cmax and Cmaxpre-treatment fu and AUC and AUCpre-treatment fu values were then compared. 
Noncompartmental analysis was performed using the software program Winnonlin 
version 3.0 (Pharsight Inc., Mountain View, Calif). 
 
Statistical analysis  
 Docetaxel and polysorbate 80 pharmacokinetic parameters were summarized as 
the mean, standard deviation, and range. For continuous variables, nonparametric tests 
were used to compare mean values between different groups. When 3 or more groups 
were compaired, a trend test was used [16]. Categorical variables were compared using 
2-tailed Fisher’s Exact Test for 2-by-2 tables. Multiple linear regression models were 
used to assess the influence of polysorbate 80 exposure (Cmax, AUC), AAG, age and 
liver function group (2 or 3) (predictor variables) on unbound docetaxel clearance 
(outcome variable). Predictor variables were evaluated for colinearity; if several 
variables were correlated, only one was maintained in the model. Regression 
coefficients, standard errors of the coefficients, and the associated P-values were 
determined from the multiple linear regression modeling. Stepwise backward 
elimination was performed to systematically exclude the least significant factors until 
the P-value was < .05. Multiple linear regression modeling was performed using the 
software program Stata version 8.2 (Stata Corp., College Station, TX). The a priori 
level of significance was set at P < .05. 
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Table 1. Patient demographics 
 Liver function group 
 Group 1 (n = 40) Group 2 (n = 9) Group 3 (n = 6) 
 Median (Range) Median (Range) Median (Range) 
Docetaxel dose (mg/m2) 75 75 50 
Age (years) 62 (27 – 80) 60 (26 – 70) 53 (36 – 64) 
Body surface area (m2) 1.88 (1.45 – 2.50) 1.80 (1.50 – 2.12) 1.73 (1.63 – 2.08) 
Sexa    
Female 19 6 4 
Male 21 3 2 
AAG (mg/dL) 129 (60 – 257) 176 (81 – 254) 159 (116 – 271) 
Liver function tests    
AST (× ULN) 0.75 (0.30 – 3.2) 2.6 (0.80 – 4.7) 2.9 (1.7 – 10.6) 
ALT (× ULN) 0.50 (0.10 – 2.2) 1.0 (0.40 – 6.6) 2.1 (0.6 – 3.1) 
Alkphos (× ULN) 0.80 (0.40 – 2.0) 1.4 (1.1 – 6.2) 3.5 (2.5 – 15.4) 
Total bilirubin (× ULN) 0.40 (0.20 –1.1) 0.40 (0.20 – 0.70) 0.80 (0.40 – 1.0) 
ECOG performance status a,b    
0 7 1 1 
1 28 5 5 
2 4 3  
Primary tumor typea    
Breast 8 5  
Head and neck 4  4 
Lung 7 2 2 
Melanoma 5   
Prostate 3 2  
Angiosarcoma 3   
Unknown 5   
Other 5   
Prior treatmenta    
None 8 1 2 
1-2 cytotoxic regimens 30 4 2 
 ≥ 3 cytotoxic regimens  2 4 2 
Light 26 4 3 
Heavy 14 5 3 
aValues are number of patients; bBaseline performance status was not performed in one 
patient in liver function group 1. 
 
Results 
 
 Pharmacokinetic studies were performed in 55 cancer patients receiving docetaxel 
therapy. Forty-eight patients received docetaxel 75 mg/m2 and 7 patients received 50 
mg/m2. One patient receiving 50 mg/m2 erroneously received a lower docetaxel dose, 
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where the intended dose was 75 mg/m2. Patient characteristics as a function of liver 
function group are summarized in Table 1. 
 
Docetaxel pharmacokinetics  
 Concentration-time curves for unbound and total docetaxel from a representative 
patient are shown in Figures 1A and 1B; this patient, representing liver function group 
1, had average values for unbound and total docetaxel pharmacokinetic parameters and 
change in fraction unbound during the docetaxel infusion. Unbound docetaxel 
pharmacokinetic parameters are summarized in Table 2. In 40 patients receiving 
docetaxel 75 mg/m2 with normal liver function tests (liver function group 1), unbound 
docetaxel disposition was characterized by mean (± SD) Cmax, AUC, and clearance 
values of 233 ± 101 ng/mL, 321 ± 143 ng/mL×h, and 565 ± 329 L/h, respectively, and 
unbound clearance varied 8.5-fold. Patients in liver function group 2 did not have 
reduced unbound clearance as compared to patients with normal liver function 
parameters (Table 2; Figure 3A); unbound clearance varied 13.0-fold, which was more 
variable than those in liver function group 2, most likely due to the inclusion of 1 
patient with an outlier value for unbound clearance (2770 L/h). A trend for reduced 
unbound docetaxel clearance in patients with moderate elevations in liver function 
tests (liver function group 3) was observed (P = .020) 
 In 40 patients with normal liver function parameters, the mean (± SD) pre-
treatment fu expressed as a percentage was 4.72 ± 1.79% and protein binding as 
determined by the ratio of AUCunbound/AUCtotal expressed as a percentage was 5.66 ± 
1.40% (Table 2); overall, protein binding varied 2.5-fold and was independent of liver 
function. Although statistically associated, a strong linear correlation was not observed 
between pre-treatment fu and AUCunbound/AUCtotal (R2=0.4593, P=.459), demonstrating 
that accurate assessment of unbound docetaxel exposure can not be determined from a 
pre-treatment fu only. The discordance between pre-treatment fu and 
AUCunbound/AUCtotal is most likely due to increasing unbound fraction after the start of 
the infusion. Compared to pretreatment values, the unbound fraction was significantly 
increased at 30 min during the infusion and at the end of the infusion (P = .0012), with 
a decline in fu after the end of the infusion and return to values close to baseline fu at 3 
to 7 hours post-infusion (data not shown). The maximum increase in fraction unbound 
docetaxel occurred at the end of the infusion, where the mean (± SD) fu value was 
5.68 ± 1.56% (range, 2.78 to 9.56%) (N = 55); this represents an average increase in 
the fu of 24% compared to the pretreatment fu (mean ± SD, 4.60 ± 1.63%; range, 1.19 
to 8.63%; N = 55).  
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Table 2. Pharmacokinetic parameters 
 Liver Function Group 
Parameter 
Group 1 
75 mg/m2* 
n = 40 
Group 2 
75 mg/m2 
n = 9 
Group 3 
50 mg/m2 
nN = 6 
    
Unbound docetaxel    
Cmax (ng/mL) 233 ± 101 
(57.4 – 489) 
213 ± 92.4 
(43.8 – 329) 
190 ± 40.3 
(137 – 228) 
AUC (ng/mL*h) 321 ± 143 
(96.4 – 584) 
296 ± 176 
(50.9 – 654) 
361 ± 132 
(217 – 533) 
Clearance (L/h) 565 ± 329 
(207 – 1763) 
715 ± 790 
(199 – 2770) 
269 ± 94.9 
(161 – 414) 
Pre-treatment fu (%) 4.72 ± 1.79 
(1.19 – 8.63) 
4.42 ± 1.32 
(2.71 – 6.58) 
4.00 ± 0.56 
(3.34 – 4.75) 
AUCunbound/AUCtotal (%) 5.66 ± 1.40 
(3.41 – 8.59) 
4.92 ± 0.98 
(3.24 – 6.33) 
4.93 ± 0.84 
(3.68 – 5.80) 
Cmaxpre-treatment fu (ng/mL) 181 ± 92.1 
(42.4 – 390) 
164.8 ± 71.3 
(40.8 – 247) 
151 ± 55.3 
(83.5 – 241) 
AUCpre-treatment fu (ng/mL*h) 268 ± 147 
(59.1 – 667) 
233 ± 140 
(42.5 – 496) 
323 ± 141 
(178 – 565) 
    
Total docetaxel    
Cmax (µg/mL) 3.89 ± 1.49 
(0.88 – 6.44) 
4.14 ± 1.60 
(1.51 ± 6.52) 
3.56 ± 1.27 
(1.82 – 5.35) 
AUC (µg/mL×h) 5.75 ± 2.51 
(2.30 – 12.1) 
5.95 ± 3.55 
(1.57 – 13.4) 
7.54 ± 3.06 
(3.75 – 12.6) 
Clearance (L/h) 30.0 ± 14.2 
(12.4 – 74.0) 
30.7 ± 23.8 
(9.69 – 89.8) 
13.4 ± 6.02 
(7.17 – 24.0) 
    
Polysorbate 80    
Cmax (µg/mL) 451 ± 221 
(210 – 1199) 
379 ± 163 
(28.9 – 593) 
344 ± 88.5 
(244 – 458) 
AUC (µg/mL×h) 528 ± 217 
(244 – 1212) 
466 ± 190 
(56.2 – 725) 
484 ± 173 
(208 – 708) 
Clearance (L/h) 8.18 ± 3.66 
(3.00 – 20.2) 
13.1 ± 19.6 
(4.30 – 65.2) 
5.62 ± 2.50 
(3.11 – 9.95) 
    
 
Data are presented as mean ± SD (range) 
* One patient erroneously received 50 mg/m2 and Cmax and AUC values for this patient were 
not included in the summary statistics. 
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To determine the contribution of time-dependent changes in fu on the exposure to 
unbound docetaxel, Cmax and AUC values were calculated using the pre-treatment fu 
and the observed fu at each time point (Table 2). On average, unbound Cmax and 
AUC values were 28% and 19% higher, respectively, when the observed fu was used 
versus the pre-treatment unbound fraction. 
 Total docetaxel pharmacokinetic parameters (Table 2) are similar to those reported 
previously following administration of docetaxel 75 mg/m2 as a 1-hour infusion [15].  
 
Table 3. Multiple regression model for docetaxel unbound clearance* 
 Coefficient 
Standard 
error 
P value 
Intercept 5.94 .0998 < .0001 
1/polysorbate 80 AUC 112 29.3 <.0001 
Liver function (group 3) -.663 .209 .003 
Overall model R2 = .3224, P < .0001 
 
*Unbound clearance is lower with a negative coefficient value. 
 
 
Polysorbate 80 pharmacokinetics   
 A concentration-time curve for polysorbate 80 from a representative patient is 
shown in Fig 1C, and polysorbate 80 pharmacokinetic parameters are summarized in 
Table 2. As described previously [13,17], polysorbate 80 concentrations were 
undetectable after 4 hours (3 hours post infusion) in all but a few patients. In patients 
receiving docetaxel 75 mg/m2 in liver function group 1, polysorbate 80 exhibited mean 
(± SD) Cmax, AUC, and clearance values of 451 ± 221 ug/mL, 528 ± 217 ug/mL×h, 
and 8.18 ± 3.66 L/h, respectively; in this population, polysorbate 80 clearance varied 
6.7-fold. Similar to unbound docetaxel, polysorbate 80 clearance was not reduced in 
patients in liver function group 2, but a trend for reduced clearance was observed in 
patients with moderate elevations in liver function tests (liver function group 3), 
although this did not reach a level of statistical significance (P = .092). 
 
Predictors of unbound docetaxel clearance  
 AAG concentration was significantly correlated with pre-treatment unbound 
fraction (R2=0.3863; P<.0001) (Fig 2A). However, no association was noted between 
AAG concentration and unbound docetaxel clearance (Fig 2B).  
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This is presumed to be due to the effect of polysorbate 80 exposure on unbound 
docetaxel clearance [12]. Considering what is known regarding predictors of total 
docetaxel clearance, specifically AAG concentration, age and liver function, a multiple 
linear regression analysis was performed to determine if these variables in addition to 
polysorbate 80 exposure were associated with unbound docetaxel clearance. Although 
polysorbate Cmax and AUC were associated with unbound docetaxel clearance, 
polysorbate 80 AUC was a better predictor. And since Cmax and AUC were highly 
correlated, only polysorbate AUC was included in the multivariate model. However, 
the reciprocal of polysorbate 80 AUC gave a better prediction than un-transformed 
AUC, and thus 1/polysorbate AUC was included in the model. Furthermore, because 
unbound clearance had a skewed distribution, unbound clearance was log-transformed. 
After stepwise backward deletion, only 1/polysorbate AUC and liver function group 3 
were retained in the final model (R2 = .3402; P < .00001) (Table III), which explained 
32% of the total variability. Fig 3B illustrates the relationship between polysorbate 80 
AUC and unbound docetaxel clearance, where higher AUC values are associated with 
lower unbound clearance values; polysorbate 80 alone accounted for 19% of the 
variability in unbound docetaxel clearance. 
 
Relation between unbound docetaxel exposure and neutropenia  
 Fifty-two of 55 patients were evaluable for hematological toxicity. The incidence 
of grade 3 and 4 neutropenia and febrile neutropenia, and percentage decrements in 
ANC are summarized in Table 4. Overall, 26 of 52 patients experienced grade 4 
neutropenia and four of 26 patients with grade 4 neutropenia experienced febrile 
neutropenia. The development of grade 0 – 3 versus grade 4 neutropenia was not 
related to extent of prior cytoxic therapy, which was categorized as lightly- or heavily-
pretreated (P = .776). 
 
Table 4. Hematological toxicity 
Neutropeniaa Liver function 
group 
No. of 
patients Grade 3 Grade 4 Febrile 
% Decrease ANCb 
1 40 6 23 4 90 (46 – 100) 
2 7 3 1 0 87 (42 – 96) 
3 5 0 2 0 81 (0 – 94) 
aData are presented as number of patients (% of patients); bData are presented as median 
(range)
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 The association between unbound docetaxel AUC and neutropenia was assessed, 
as was the relation between total docetaxel AUC and neutropenia for the purpose of 
comparison. Patients in liver function group 3 received a reduced dose of docetaxel to 
achieve AUC values similar to those in liver function groups 1 and 2 [3,7]. Unbound 
and total AUC values were similar in the former and latter groups (P = .395); 
therefore, AUC values at the different dose levels were combined to assess the relation 
between docetaxel exposure and neutropenia. Unbound docetaxel AUC was better 
correlated with both percentage decrements in absolute neutrophil count (ANC) (Fig 4; 
P = .002 versus P = .029) and worst grade of neutropenia (Fig 5; P = .013 versus P = 
.220). The percentage decrements in ANC was greater in those patients with unbound 
AUC values in the upper quartile (mean decrement, 95.4%) compared to those with 
AUC values in the interquartile range (mean decrement, 76.9%) (P = .020) (Fig 4A). 
Likewise, patients who developed grade 4 neutropenia had significantly higher 
unbound AUC values (mean, 374 ng/mL×h) than patients with grade 0 to 3 
neutropenia (mean, 275 ng/mL×h) (P = .013) (Fig 5A). In addition, all patients who 
developed neutropenic fever had unbound AUC values above the overall mean value, 
whereas only 3 of 4 patients had total AUC values above the overall mean value.  
 
Discussion 
 
 Previous studies examining relationships between the pharmacokinetics of the 
anticancer drug docetaxel and treatment outcome have consistently focused on 
measurement of total docetaxel concentrations in plasma [3,18], disregarding effects of 
variable levels of systemic binding on the fraction unbound drug. The present study 
demonstrates that the hematologic toxicity induced by docetaxel is significantly better 
correlated with the systemic exposure to unbound drug than total drug. 
 Variability in systemic drug binding has frequently been demonstrated in humans 
[19]. However, the clinical significance of this variability to drug disposition and 
pharmacodynamics depends largely upon intrinsic pharmacokinetic characteristics of 
the drug. For most anticancer drugs, the interindividual variation in plasma protein 
binding is quite small in patients with normal liver function and drug-metabolizing 
capability. Therefore, vascular binding is usually not an important consideration in 
therapeutic drug monitoring and in the evaluation of pharmacokinetic-
pharmacodynamic relationships. However, in rare instances, the total concentration is 
not reflective of the unbound drug level [20]. For some anticancer agents, this situation 
arises if the drug demonstrates protein concentration-dependent binding (e.g., imatinib 
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[21] and 7-hydroxystaurosporine (UCN-01) [22]), or when irreversible or near-
covalent binding occurs after therapeutic doses of an anticancer drug (e.g., platinum-
containing agents). Indeed, cisplatin, carboplatin, and oxaliplatin are currently the only 
agents for which unbound concentrations are routinely measured and for which the 
relation between unbound drug and therapeutic effects has been demonstrated [23].  
 The significant relationship between exposure to total docetaxel and the 
percentage decrease in neutrophil count at nadir, as described previously in a study 
involving more than 600 patients receiving docetaxel in similar regimens [3], was not 
observed in the current investigation. It is likely that this apparent inconsistency is a 
direct consequence of the differences in sample size, which might become an 
important consideration when the pharmacodynamic evaluation is based on a sparse 
set of hematological toxicity data (i.e., with blood cells measured on a once a week 
basis). Experimental evidence has also suggested that information on the entire time 
course of changes in blood cell counts might be more physiologically-relevant 
endpoint than the nadir count [24]. In order to further resolve this issue with respect to 
the current data set, a population analysis for docetaxel-mediated neutropenia is 
currently being planned by taking into account the entire time course of neutrophils. 
 The current data on docetaxel describe a previously unrecognized type of time-
dependence for the fraction unbound drug, which was recently shown in vitro to be 
associated with its formulation vehicle, polysorbate 80 [12]. In the present study, 
although the fraction unbound docetaxel in pretreatment samples was correlated with 
individual levels of AAG, only exposure to polysorbate 80 (and not AAG) was 
significantly associated with the clearance of unbound docetaxel in both univariate and 
multivariate analyses, thus demonstrating in vivo the influence of polysorbate 80 
exposure on fraction unbound docetaxel. In this regard, it is of particular interest to 
note that for etoposide (VePesid; Bristol-Myers Squibb Co., Princeton, NJ), the only 
other registered anticancer drug formulated in polysorbate 80, the systemic exposure to 
unbound drug is also more precisely correlated with measures of hematologic toxicity 
than total drug levels [25]. Since the rate of administration and total dose of 
polysorbate 80 are similar between docetaxel and etoposide, this raises the possibility 
of a common mechanism being involved in pharmacokinetic-pharmacodynamic 
relationships for these drugs. 
 The mechanistic basis for the influence of polysorbate 80 on docetaxel fraction 
unbound during the infusion is as yet unknown. It is possible that polysorbate 80 or its 
metabolites (e.g., oleic acid) interfere with the binding of docetaxel to albumin and 
AAG(9) and lead to temporary increase in the fraction unbound drug. However, other 
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possible mechanisms, including inhibition of CYP3A [26,27] and/or P-glycoprotein 
[28] mediated elimination of docetaxel by polysorbate 80 early after drug 
administration, can not be excluded. These and several other possible mechanisms are 
currently under further investigation. 
Collectively, this study demonstrates that the exposure to unbound docetaxel is more 
closely related to drug-induced hematologic toxicity than total drug. Since an increase 
in systemic exposure to unbound drug was associated with more severe neutropenia, 
these findings suggest that determination of unbound docetaxel concentrations is 
indicated for future pharmacologic investigations.  
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  From the early nineties onward, the anticancer drug docetaxel has obtained a 
prominent position in the treatment of various human malignancies, including 
advanced breast cancer and non-small cell lung cancer. Many publications have since 
discussed the drug’s clinical pharmacological properties, although many aspects still 
remain to be elucidated, in particular the factors contributing to the extensive degree of 
interindividual variability in the pharmacokinetic profile of docetaxel that is observed 
with commonly applied dosing regimens.  
 
 Chapter 2 provides a literature overview of recent developments into the 
understanding of factors involved in the pharmacokinetics of docetaxel. 
 
 In chapter 3 an evaluation of the usefullness of body-surface area (BSA) is 
presented as an independent variable to explain interpatient variability in the exposure 
to docetaxel as well as 32 investigational agents, which were tested in phase I trials 
between 1991 and 2001, in 1650 adult cancer patients. It was noted that BSA-based 
dosing was statistically significantly associated with a reduction in interpatient 
variability in drug clearance for only five of the agents evaluated. This suggests that 
BSA should not be considered as the prime factor to be used in future studies, and 
evaluation of alternate dosing strategies for docetaxel are needed.  
 
 In chapter 4 the influence of age, body size, concomitant drugs, dose, infusion 
duration, and sex on the clearance of docetaxel is explored in a retrospective analysis 
involving 152 individual patients. The upper extremes of body size were found to be 
associated with increased docetaxel clearance, whereas no consistent effect of age was 
discerned. Concomitant treatment of docetaxel with doxorubicin and capecitabine was 
associated with approximately 20% decreased and increased docetaxel clearance, 
respectively, in a multiple linear regression analysis. These findings further suggest 
that variables other than BSA should be incorporated in routine dosing strategies for 
docetaxel. 
 
 Variable response to cancer chemotherapy with docetaxel is presumed to be 
related, in part, to interindividual variation in expression of the enzyme cytochrome P-
450 3A (CYP3A). In chapter 5, a study is described aimed at identifying the 
demographic, physiologic, and inheritable factors that influence CYP3A activity in 
134 patients with cancer that underwent the erythromycin breath test as a CYP3A 
phenotyping probe. CYP3A activity varied up to 14-fold in this population, and was 
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not significantly influenced by age, sex, body size measures, and genetic 
polymorphisms in the CYP3A4 and CYP3A5 genes. However, in a multivariate 
analysis, liver function combined with the concentration of the acute-phase reactant, 
alpha-1 acid glycoprotein, explained approximately 18% of overall variation in 
CYP3A activity. This indicates that additional factors, including the inflammation 
marker C-reactive protein as well as concomitant use of other drugs, food constituents, 
and complementary and alternative medicine with inhibitory and inducible effects on 
CYP3A, are needed to reduce variation in CYP3A and the variable response to 
chemotherapeutic treatment with docetaxel. 
 
 In chapter 6 the extent of docetaxel binding to plasma in the presence and absence 
of its excipient polysorbate 80 (Tween 80) was studied in relation to the 
pharmacokinetics of unbound docetaxel. Polysorbate 80, added at clinically relevant 
concentrations (up to 1.0 µL/mL), was found to increase the fraction unbound docetaxel 
(fu) by 12% (6.00 ± 1.03% versus 5.49 ± 1.01%, P = 0.038). Furthermore, the serum 
protein α1-acid glycoprotein was significantly related to fu (P < 0.0018), with higher 
fu in the presence of lower protein levels, indicating that the plasma binding of 
docetaxel is influenced by both alpha1-acid glycoprotein and its formulation vehicle. 
This study was made possible by the availability of validated analytical methods for 
the analysis of the fraction unbound docetaxel as determined using equilibrium 
dialysis (chapter 8). 
 
 Weekly administration of docetaxel has demonstrated comparable efficacy, 
together with a distinct toxicity profile with reduced myelosuppression, although 
pharmacokinetic data with weekly regimens are lacking. In chapter 9, the comparative 
pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) 
administration schedules was evaluated in 46 cancer patients. The mean (± SD) 
docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 ± 
7.7 versus 23.7 ± 7.9 L/h/m2); values for half-life were also similar with both 
schedules of administration (16.5 ± 11.2 and 17.6 ± 7.4 hours). With the use of 
prolonged plasma sampling schemes, the calculated terminal disposition half life of 
docetaxel was found to be approximately 86 hours, which is about 5-fold longer than 
that estimated on the basis of conventional 24-hour sampling intervals, and almost 9-
fold longer than published values. Consequently, docetaxel concentrations are 
maintained above 1.0 nM for 7 days with weekly schedules and above 0.5 nM for as 
long as 21 days with 3-weekly regimens. Measurement of low docetaxel 
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concentrations with extended sampling schemes was made possible by the availability 
of validated analytical methods for the determination of total docetaxel concentrations 
in human plasma based on liquid chromatography coupled with tandem mass 
spectrometric detection (chapter 7). This previously unrecognized prolonged 
circulation of low nanomolar concentrations of docetaxel may contribute to the 
mechanism of action of docetaxel through suppression of microtubule dynamics and 
tumor angiogenesis and enhanced cell radiosensitivity in combined modality therapy. 
 
 Despite the increasing numbers of elderly patients presenting with cancer, only 
few pharmacological studies have been conducted in this subgroup of patients. The 
pharmacokinetics of anticancer drugs may be altered with aging due to several factors, 
including differences in end organ function and body composition. In chapter 10, the 
pharmacokinetics of docetaxel in elderly patients (≥ 65 years) and patients < 65 years, 
revealed an unchanged mean (± SD) docetaxel clearance of 30.1 ± 18.3 vs 30.0 ± 14.8 
L/h, respectively. In support of this lack of age-dependence, it was shown that 
phenotypic activity of CYP3A, as assessed using the erythromycin breath test, was not 
changing with advancing age. Although there was no significant difference observed 
in treatment-related side effects between the two age groups, the incidence of 
neutropenic fever seemed to be slightly increased in the elderly, but was attributed to 
drug exposure differences unrelated to age. 
 
 A multiple linear regression analysis, described in chapter 11, revealed that only 
exposure to polysorbate 80 and degree of liver impairment are significantly associated 
with the clearance of unbound docetaxel in a group of 55 patients treated with 
docetaxel. Furthermore, the unbound docetaxel AUC was better correlated than total 
AUC with both the percentage decrements in absolute neutrophil count (P=.002 versus 
P=.029) and worst grade of neutropenia (P=.013 versus P = .220), where higher 
exposure was associated with worse hematological toxicity. This suggests that 
exposure to unbound docetaxel is more closely related to drug-induced hematologic 
toxicity than total drug and should be considered for future pharmacologic 
investigations. 
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Future perspectives 
 
 The work presented in this thesis aimed at identifying factors involved in 
pharmacokinetic variability observed with docetaxel, and included an evaluation of 
common patient demographic characteristics, liver dysfunction, use of concomitant 
chemotherapy, protein binding, and interference by the vehicle polysorbate 80. 
However, a substantial degree of interpatient variation in the pharmacokinetics of 
docetaxel is still unaccounted for, and likely contributes to unpredictable treatment 
outcome (ie, toxicity and efficacy). The residual pharmacokinetic variability that 
cannot be explained by the factors evaluated in this thesis likely involve individual 
variation in hepatic metabolism by members of the cytochrome P-450 family and 
expression and function of transporters involved in docetaxel elimination such as P-
glycoprotein. 
 
 Currently ongoing studies will focus on the role of inherited factors regulating the 
expression and function of these proteins, and will hopefully lead to the development 
of a more predictable pharmacokinetic behavior for docetaxel in individual patients 
through the use of dosing formulae on the basis on population pharmacokinetic-
pharmacodynamic models. However, it is possible that in addition to genetic 
components, other environmental and physiological factors not studied here may 
influence the clinical pharmacology of this drug. Hence, it will be imperative to design 
additional prospective studies in the future employing both genotyping and 
phenotyping approaches to predict docetaxel elimination in order to eventually 
individualize and improve chemotherapeutic therapy. 
 
 Finally, the drawback presented by the presence of polysorbate 80 as an integral 
component of the pharmaceutical formulation of docetaxel has already instigated 
extensive research to develop alternative delivery systems. These alternative 
formulations might eventually enable a safer administration with less likelihood of 
interactions between the formulation vehicle and the active drug, and a reduced 
incidence and severity of vehicle-mediated side-effects. Such alternative formulations 
also should enable the drug to be administered without premedication and lead to a 
more predictable and sustained exposure of the tumor to the drugs, and to a more 
favorable treatment outcome. 
  
   
Chapter 13 
 
Samenvatting, Conclusies en Perspectieven 
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 Sinds het begin van de jaren 1990 heeft het anti-kankermiddel docetaxel een 
belangrijke plaats verworven in de behandeling van diverse vormen van kanker, in het 
bijzonder van het mammacarcionoom en het niet-kleincellig bronchuscarcinoom. In tal 
van publicaties zijn de klinisch farmacologische eigenschappen van dit middel 
besproken; echter, vele aspecten zijn nog steeds onopgehelderd, met name de factoren 
die bijdragen aan de mate van variabiliteit tussen patiënten onderling in het 
farmacokinetisch gedrag van docetaxel dat wordt waargenomen bij de huidig 
toegepaste doseerstrategieën. 
 
 Hoofdstuk 2 geeft een literatuuroverzicht van recente ontwikkelingen in de 
diverse factoren die van invloed zijn op de farmacokinetiek van docetaxel. 
 
 In hoofdstuk 3 wordt een studie beschreven waarin de mate waarin 
lichaamsoppervlak (BSA) bijdraagt aan het verklaren van de interpatiënt variabiliteit is 
onderzocht in de blootstelling aan docetaxel en 32 experimentele medicamenten die 
het onderwerp vormden van fase I onderzoek in de jaren 1991-2001, in een groep van 
1650 volwassen kankerpatiënten. Er werd gevonden dat doseerstrategieën gebaseerd 
op BSA leiden tot een statistisch significante vermindering in de interpatiënt 
variabiliteit in de klaring van slechts 5 van de onderzochte medicamenten. Dit 
suggereert dat BSA niet gebruikt zou moeten worden als de primaire factor in 
toekomstig onderzoek, en dat vervolgonderzoek naar alternatieve doseerstrategieën 
voor docetaxel noodzakelijk is. 
 
 In hoofdstuk 4 is de invloed van leeftijd, BSA, gelijktijdig toegediende medicatie, 
dosis, infusieduur, en geslacht op de klaring van docetaxel retrospectief onderzocht in 
een groep van 152 patiënten. De klaring van docetaxel bleek verhoogd te zijn in 
patiënten met extreme waarden voor BSA; echter, leeftijd had geen eenduidig effect 
op de klaring. Uit een multipele lineaire regressieanalyse bleek dat het gelijktijdig 
toedienen van docetaxel met doxorubicine of capecitabine was geassocieerd met 
respectievelijk een afname of toename van ongeveer 20% in de klaring van docetaxel. 
Deze bevindingen suggereren dat naast BSA andere variabelen geïncorporeerd zouden 
moeten worden in routinematige doseerstrategieën van docetaxel. 
 
 Eerder is verondersteld dat de variatie in mate waarin tumoren gunstig reageren op 
chemotherapeutische behandeling met docetaxel ten dele het gevolg is van interpatiënt 
variabiliteit in de expressie van het enzyme cytochroom P450 3A (CYP3A). 
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Hoofdstuk 5 beschrijft een studie waarin is gepoogd om demografische, fysiologische, 
en genetische factoren te identificeren die de activiteit van CYP3A beïnvloeden. Dit is 
onderzocht in 134 kankerpatiënten die voorafgaand aan behandeling een test 
ondergingen om de fenotypische activiteit van CYP3A vast te stellen, de zogenaamde 
erythromycine-ademtest. Er was een 14-voudige variatie in de activiteit van CYP3A in 
deze populatie, en de variatie was niet gerelateerd aan leeftijd, geslacht, 
lichaamsoppervlaktematen, en polymorfismen in de CYP3A4 en CYP3A5 genen. Met 
behulp van een multivariate-analyse werd echter gevonden dat leverfunctie in 
combinatie met de concentratie van het acute-fase eiwit, α1-zure glycoproteïne, 
ongeveer 18% van de totale variatie in CYP3A activiteit kon verklaren. Dit suggereert 
dat additionele factoren noodzakelijk zijn om de variatie in CYP3A activiteit en de 
variatie in behandelingsuitkomst na behandeling met docetaxel verder te reduceren. 
Tot deze categorie van factoren behoren mogelijk de ontstekingsmarker C-reactive 
proteïne alsmede effecten van gelijktijdig toegediende andere medicamenten, 
voedselbestanddelen, en/of gebruik van alternatieve geneeswijzen die de functie van 
CYP3A kunnen remmen of stimuleren. 
 
 In hoofdstuk 6 is in de aan- of afwezigheid van het oplosmiddel polysorbaat 80 
(Tween 80) de mate van plasmabinding van docetaxel onderzocht in relatie tot de 
farmacokinetiek van het ongebonden docetaxel. Er werd gevonden dat polysorbaat 80, 
bij klinisch relevante concentraties (tot aan 1.0 µL/mL), de ongebonden fractie van 
docetaxel (fu) met 12% verhoogt (6.00 ± 1.03% versus 5.49 ± 1.01%, P = 0.038). Tevens 
bleek het serumeiwit α1-zure glycoproteïne significant gerelateerd aan fu (P < 0.0018), 
zodanig dat fu toenam bij lagere eiwitspiegels, hetgeen suggereert dat de binding van 
docetaxel wordt beïnvloed door zowel α1-zure glycoproteïne als het oplosmiddel. 
Tijdens dit onderzoek is gebruik gemaakt van een gevalideerde analytische methode 
waarin de fractie ongebonden docetaxel is bepaald met behulp van evenwichtsdialyse 
(hoofdstuk 8).  
 
 Eerder onderzoek heeft uitgewezen dat wekelijks toedienen van docetaxel niet ten 
koste gaat van de antitumoractiviteit terwijl het bijwerkingen profiel zodanig verandert 
dat de hematologische toxiciteit minder is in vergelijking met docetaxel toediening 
eenmaal per 3 weken (‘3-wekelijks’). Het farmacokinetisch profiel van docetaxel in de 
wekelijkse schema’s was niet eerder onderzocht. In hoofdstuk 9 wordt een 
vergelijkend onderzoek beschreven naar de farmacokinetiek van docetaxel tijdens 
wekelijkse en 3-wekelijkse behandeling in 46 kankerpatiënten. De gemiddelde (± SD) 
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klaring van docetaxel bleek vergelijkbaar in de 2 onderzochte schema’s (25.2 ± 7.7 
versus 23.7 ± 7.9 L/h/m2); de halfwaardetijd was ook niet verschillend tussen beide 
schema’s (16.5 ± 11.2 and 17.6 ± 7.4 uur). Door toepassing van bloedbemonstering 
over een lange tijdsperiode werd een terminale halfwaardetijd voor docetaxel 
gevonden van ongeveer 86 uur, hetgeen 5-maal zo lang is als de waarde zoals geschat 
op basis van de gebruikelijke 24-uurs bemonstering, en circa 9-maal langer dan 
gepubliceerde waarden. Als gevolg hiervan konden docetaxel concentraties 
gedetecteerd worden van 1.0 nM gedurende 7 dagen in het wekelijkse schema, en van 
0.5 nM gedurende maar liefst 21 dagen gedurende het 3-wekelijkse schema. De 
detectie van deze lage concentraties van docetaxel werd mogelijk gemaakt door de 
beschikbaarheid van een gevalideerde analytische methodiek voor het quantificeren 
van docetaxel concentraties in humaan plasma met behulp van vloeistofchromatografie 
gekoppeld aan massa-spectrometrische detectie (hoofdstuk 7). De eerder on-
opgemerkte en langdurige aanwezigheid van docetaxel concentraties in het laag-
nanomolaire gebied draagt mogelijk bij aan het werkingsmechanisme van docetaxel 
door onderdrukking van het microtubuline netwerk en tumorangiogenese alsmede door 
verbeterde cellulaire gevoeligheid bij combinatiebehandelingen. 
 
 Ondanks de toename in het aantal oudere kankerpatiënten is slechts een zeer 
beperkt aantal studies uitgevoerd in deze subgroep van patiënten. Het 
farmacokinetisch gedrag van antikankermiddelen kan veranderen met de leeftijd ten 
gevolge van verschillende factoren, zoals veranderingen in orgaanfunctie en 
lichaamssamenstelling. In de studie beschreven in hoofdstuk 10 werd gevonden dat de 
farmacokinetiek van docetaxel in oudere (≥ 65 jaar) en jongere (< 65 jaar) patiënten 
niet verschillend is, met een gemiddelde (± SD) klaring van respectievelijk 30.1 ± 18.3 
en 30.0 ± 14.8 L/h. Deze leeftijdsonafhankelijkheid is in overeenstemming met de 
bevinding dat de fenotypische activiteit van CYP3A, gemeten met behulp van de 
erythromycine-ademtest, niet veranderde met een toenemende leeftijd. Alhoewel er 
geen statistisch significant verschil was in docetaxel-gerelateerde bijwerkingen in 
beide leeftijdsgroepen bleek de incidentie van neutropene koorts enigszins 
toegenomen in de ouderen. Dit kon echter toegeschreven worden aan minieme 
verschillen in de blootstelling aan het middel die niet aan leeftijd zijn gerelateerd.  
 
 Met behulp van multipele lineaire regressieanalyse, als beschreven in hoofdstuk 
11, kon aangetoond worden dat naast blootstelling aan polysorbaat 80 ook de mate van 
leverfunctiestoornis significant is geassocieerd met de klaring van het ongebonden 
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docetaxel in een groep van 55 patiënten behandeld met docetaxel. Dit onderzoek liet 
tevens zien dat de AUC van ongebonden docetaxel beter is gerelateerd aan het 
percentage daling in neutrofielen (P=.002 versus P=.029) en de neutropenie graad 
(P=.013 versus P = .220), zodanig dat grotere blootstelling resulteerde in meer 
hematologische toxiciteit. Dit suggereert dat de blootstelling aan ongebonden 
docetaxel beter voorspellend is voor behandelingsgerelateerde beenmergschade dan 
totaal docetaxel, en dat eerstgenoemde parameter prospectief geïmplementeerd zou 
moeten worden in vervolgonderzoek. 
 
Toekomstige ontwikkelingen 
 
 Het beschreven werk in dit proefschrift had tot doel om factoren te identificeren 
die van invloed zijn op de farmacokinetische variabiliteit die wordt waargenomen na 
behandeling met docetaxel, inclusief demografische patiëntkarakteristieken, 
verminderde leverfunctie, gelijktijdig gebruik van andere chemotherapeutica, 
eiwitbinding in plasma, en beïnvloeding door het oplosmiddel polysorbaat 80. Echter, 
een substantiële mate van interpatiënt variabiliteit in de farmacokinetiek van docetaxel 
blijft onverklaard, en dit draagt vermoedelijk bij aan de onvoorspelbaarheid van de 
behandelingsuitkomst met betrekking tot toxiciteit en activiteit. De resterende 
farmacokinetische variabiliteit die niet verklaard kan worden aan de hand van de alhier 
bestudeerde factoren is mogelijk het gevolg van individuele variatie in 
levermetabolisme door cytochroom P-450 iso-vormen alsmede de expressie en functie 
van transporteiwitten die betrokken zijn bij de eliminatie van docetaxel, zoals het P-
glycoproteïne. 
  
 Huidig en toekomstig onderzoek zal de rol van genetisch-bepaalde factoren, die de 
expressie en functie van deze eiwitten reguleren, verder bestuderen, en zal hopelijk 
leiden tot de ontwikkeling van een beter voorspelbaar farmacokinetisch gedrag van 
docetaxel in individuele patiënten door het gebruik van doseerformules afgeleid uit 
farmacologische populatiemodellen. Het is echter niet uitgesloten dat naast de 
genetische componenten ook niet-bestudeerde omgevingsfactoren en fysiologische 
elementen de klinische farmacologie van dit middel beïnvloeden. Derhalve zal het 
noodzakelijk zijn om in de nabije toekomst additioneel prospectief onderzoek uit te 
voeren waarin zowel genotypische als fenotypische testen worden uitgevoerd teneinde 
de blootstelling aan docetaxel te kunnen voorspellen en uiteindelijk daarmee 
chemotherapeutische behandeling te individualiseren en verbeteren.  
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 Tot slot, de nadelen van de aanwezigheid van polysorbaat 80 als een essentieel 
ingrediënt van de huidige farmaceutische formulering van docetaxel heeft nu al geleid 
tot extensief onderzoek naar de ontwikkeling van alternatieve toedieningsvormen. 
Deze nieuwe formuleringen maken het uiteindelijk mogelijk om docetaxel toe te 
dienen met een geringer kans op ongewenste interacties tussen het oplosmiddel en het 
geneesmiddel, tezamen met een lagere incidentie van ernstige, oplosmiddel- 
gerelateerde bijwerkingen. Dergelijke alternatieve formuleringen kunnen theoretisch 
worden toegediend zonder premedicatie, en resulteren mogelijk in een beter 
voorspelbare en verlengde blootstelling van een tumor aan het middel, en in een 
gunstigere behandelingsuitkomst. 
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